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Objectives: To identify the drug treatments currently
available for the management of spasticity and pain in
multiple sclerosis (MS), and to evaluate their clinical and
cost-effectiveness.
Data sources: Electronic bibliographic databases,
National Research Register, MRC Clinical Trials Register
and the US National Institutes of Health Clinical Trials
Register.
Review methods: Systematic searches identified 15
interventions for the treatment of spasticity and 15
interventions for treatment of pain. The quality and
outcomes of the studies were evaluated. Reviews of
the treatment of spasticity and pain when due to other
aetiologies were also sought. 
Results: There is limited evidence of the effectiveness
of four oral drugs for spasticity: baclofen, dantrolene,
diazepam and tizanidine. Tizanidine appears to be no
more effective than comparator drugs such as baclofen
and has a slightly different side-effects profile. Despite
claims that it causes less muscle weakness, there was
very little evidence that tizanidine performed any
better in this respect than other drugs, although it is
more expensive. The findings of this review are
consistent with reviews of the same treatments for
spasticity derived from other aetiologies. There is good
evidence that both botulinum toxin (BT) and intrathecal
baclofen are effective in reducing spasticity, and both
are associated with functional benefit. However, they
are invasive, and substantially more expensive. None of
the studies included in the review of pain were
designed specifically to evaluate the alleviation of pain
in patients with MS and there was no consistency
regarding the use of validated outcome measures. It
was suggested that, although expensive, the use of
intrathecal baclofen may be associated with significant
savings in hospitalisation costs in relation to bed-bound
patients who are at risk of developing pressure sores,
thus enhancing its cost-effectiveness. No studies of
cost-effectiveness were identified in the review 
of pain. There is evidence, albeit limited, of the 
clinical effectiveness of baclofen, dantrolene, 
diazepam, tizanidine, intrathecal baclofen and BT 
and of the potential cost-effectiveness of intrathecal
baclofen in the treatment of spasticity 
in MS. 
Conclusions: Many of the interventions identified are
not licensed for the alleviation of pain or spasticity in
MS and the lack of evidence relating to their
effectiveness may also limit their widespread use.
Indeed, forthcoming information relating to the use of
cannabinoids in MS may result in there being better
evidence of the effectiveness of new treatments than of
any of the currently used drugs. It may therefore be of
value to carry out double-blind randomised controlled
trials of interventions used in current practice, where
outcomes could include functional benefit and impact
on quality of life. Further research into the
development and validation of outcomes measures for
pain and spasticity may also be useful, as perhaps would
cost–utility studies.
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List of abbreviations
All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or 
it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices in which case 
the abbreviation is defined in the figure legend or at the end of the table.
Background
Multiple sclerosis (MS) is one of the commonest
neurological conditions of young adults in the
Western world, with an estimated 58,000–63,000
people with the disease in England and Wales. Pain
and spasticity are two of the commonest symptoms
from which people with MS suffer. A recent survey
of members by the MS Society found that 54%
reported pain as a current symptom and 74%
spasticity. The importance of these symptoms is not
simply because of their frequency, but also because
of the impact they have on daily life. As the disease
progresses, so does the spasticity, resulting in
muscle spasms, immobility, disturbed sleep and
pain. Disability resulting from spasticity can lead to
patients requiring extensive nursing care. 
Pain can be caused by a variety of factors including
spasticity itself, in addition to neuronal damage
due to the disease process. Not uncommonly, it
may be musculoskeletal in origin, arising as a
result of abnormal posture following the disability
caused by MS.
Methods
A systematic review was undertaken to identify
what treatments are available for the management
of pain and spasticity in MS and to evaluate
clinical and cost effectiveness through assessment
of the best available evidence. The scope of the
review was limited to the consideration of drug
treatments. It did not include non-drug therapy or
surgical treatments. It did not consider
cannabinoids, clinical trials of which were ongoing
at the time of the review. Reviews of the treatment
of spasticity and pain when due to other
aetiologies were also sought and their conclusions
were examined for consistency with the
conclusions in the primary studies identified.
Results
Spasticity
Systematic searches for evidence relating to the
treatment of spasticity identified 15 interventions
for inclusion:
 baclofen (Lioresal)
 dantrolene (Dantrium)
 tizanidine (Zanaflex)
 diazepam
 gabapentin (Neurontin)
 botulinum toxin (BT) (Botox, Dysport)
 intrathecal baclofen (Lioresal Intrathecal)
 phenol
 threonine
 vigabatrin
 clonidine
 methylprednisone 
 cyproheptadine
 magnesium
 ketazolam.
Sixty-seven papers, 41 of which were described as
double-blind randomised controlled trials (RCTs),
were included in the review of spasticity. Overall,
the quality of the studies was poor. A wide variety
of outcome measures were used. In cases where
the same outcome measures were used, there were
inconsistencies in the application of instruments
and analysis of results across studies.
There is limited evidence of the effectiveness of
four oral drugs for spasticity: baclofen, dantrolene,
diazepam and tizanidine. All appear to be
approximately equally effective at reducing
spasticity when assessed clinically, although in no
case is there any good evidence of functional
benefit. Tizanidine appears to be no more
effective than comparator drugs such as baclofen.
Tizanidine has a slightly different side-effects
profile in that the main side-effect of tizadine is a
dry mouth. Despite claims that it causes less
muscle weakness, there was very little evidence
that tizanidine performed any better in this
respect than other drugs, although it is more
expensive. The findings of this review are
consistent with reviews of the same treatments for
spasticity derived from other aetiologies.
There is no good evidence of effectiveness for
gapapentin, threonine, vigabatrin,
methylprednisolone, cyprohepladine or
magnesium.
There is good evidence that both BT and
intrathecal baclofen are effective in reducing
Health Technology Assessment 2003; Vol. 7: No. 40
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spasticity, and both are associated with functional
benefit. However, they are invasive, and
substantially more expensive. Their use is most
appropriately restricted to people with severe
disabling spasticity.
Pain
Systematic searches for evidence relating to the
treatment of pain identified 15 interventions:
 carbamazepine
 phenytoin
 gabapentin
 lamotrigine
 tricyclic antidepressants
 steroids
 baclofen
 intrathecal baclofen
 amantadine
 misoprostol
 octreotide
 bupivacaine
 acetazolamide
 lidocaine
 mexiletine.
Thirty-three studies were included in the review of
pain. None of the studies were RCTs designed
specifically to evaluate the alleviation of pain in
patients with MS. The majority of papers were
non-systematic reviews, small case series or
individual case reports. There was no consistency
regarding the use of validated outcome measures.
Most papers recorded only that pain had or had
not been relieved.
Cost-effectiveness and clinical
effectiveness
In the absence of formal research of any quality in
this area, it is not possible to draw conclusions
regarding the effectiveness or otherwise of the
interventions identified.
Evidence relating to the cost-effectiveness of
treatments was extremely limited. In the review of
spasticity, five health economic evaluations of
intrathecal baclofen were identified. No studies
relating to the remaining treatments were
identified. The five studies suggested that
although expensive, the use of intrathecal baclofen
may be associated with significant savings in
hospitalisation costs in relation to bed-bound
patients who are at risk of developing pressure
sores, thus enhancing its cost-effectiveness. No
studies of cost-effectiveness were identified in the
review of pain.
There is evidence, albeit limited, of the clinical
effectiveness of baclofen, dantrolene, diazepam,
tizanidine, intrathecal baclofen and BT and 
of the potential cost-effectiveness of intrathecal
baclofen in the treatment of spasticity in MS.
Owing to the paucity and poor quality of evidence
identified in this review, no further conclusions
regarding the clinical or cost-effectiveness of the
remaining interventions for pain or spasticity can
be drawn.
Conclusions
Many of the interventions identified are not
licensed for the alleviation of pain or spasticity 
in MS. In addition, the lack of evidence relating 
to their effectiveness may militate against them
being used consistently across the NHS. Lastly, 
the licensing and forthcoming availability of 
trial evidence relating to the use of cannabinoids
in the alleviation of symptoms relating to MS may
mean that we are in the ironic position of having
better evidence of the effectiveness of new
treatments than of any of the currently used
drugs. 
Recommendations for research
The following areas are suggested for further
research:
 Double-blind RCTs, with adequate power and
follow-up, of interventions used in current
practice for the alleviation of pain and spasticity
in MS. Outcomes should include functional
benefit and impact on quality of life.
 Development and validation of outcomes
measures for pain and spasticity.
 Cost–utility studies.
Executive summary
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Aim of the report
This report addresses two questions:
 What are the treatments currently available for
the management of spasticity and pain in
multiple sclerosis (MS)?
 What is the clinical and cost-effectiveness of
each of these treatments for spasticity and pain
in MS?
The purpose of this report is to provide a wider
perspective of the needs and potential
interventions in MS. It is not possible to cover
each individual treatment in great depth.
Treatments other than drug therapy are not within
the remit of this report.
Background
The treatment of MS has been identified by the
National Institute for Clinical Excellence (NICE)
as an important area for evaluation. There is no
cure, and treatments currently available are
directed towards slowing the progression of
disease, reducing relapses or alleviating the wide
spectrum of symptoms. This report is part of a
series evaluating the effectiveness and cost-
effectiveness of interventions for MS.
MS is an inflammatory disease, which results in
myelin loss in the central nervous system (CNS).
This in turn leads to the development of sclerotic
patches known as plaques in the brain and spinal
cord. Although the aetiology is unknown, there is
strong evidence that MS is the result of an
autoimmune response.
Epidemiology
MS is one of the most common neurological
conditions affecting young adults in the Western
world. The prevalence of MS in England and
Wales is around 110–120 per 100,000, although
this varies geographically, with a higher prevalence
in the north of England.1 This translates to
between 58,000 and 63,000 cases for England and
Wales, although some estimates have been higher. 
MS is twice as common in women than men.
There is evidence that patients with MS are
starting to live longer1 and this will have
implications for the number of patients
experiencing severe spasticity.
Symptoms
The progression of the disease is extremely
variable. While initially the disease may be
relapsing and remitting, it usually becomes
progressive over time, resulting in chronic
disability. The signs and symptoms of MS are
variable, but generally reflect the degree of
demyelination that has taken place. The main
presenting symptoms of MS are:2
 weakness in one or more limbs
 optic neuritis
 paraesthesiae
 diplopia
 vertigo
 disturbance of micturition.
As the disease progresses, other symptoms become
more significant. A recent survey by the MS
Society of 275 members (all patients with
established MS) reported fatigue, spasticity
(stiffness, spasms or both) and problems with
balance as the most commonly experienced
symptoms (233 responses received – a rate of
80%).3 Results are summarised in Table 1.
Recently, attention has focused on new drugs for
slowing disease progression and reducing relapses.
However, the identification of effective drugs for
the alleviation of symptoms remains very
important. Spasticity and pain are two of the most
important symptoms experienced by suffers of
MS, both because of their frequency, but also
because of the impact on daily life. As the disease
progresses, so does the spasticity, resulting in
muscle spasms, immobility, disturbed sleep and
pain. Disability resulting from spasticity can lead
to patients requiring extensive nursing care. 
Pain can be caused by a variety of factors, including
spasticity itself, in addition to neuronal damage.
Not uncommonly it may be musculoskeletal in
Health Technology Assessment 2003; Vol. 7: No. 40
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Aim and background
origin, arising as a result of abnormal posture
following the disability caused by MS.
Structure of this report
This report contains two separate reviews: one of
the effectiveness and cost-effectiveness of
treatment for spasticity in MS and the other of
treatment for pain. In each case, the problem is
described, followed by what is known of current
treatment, then the methods and findings of the
review are reported. A review, limited by the
amount of available evidence, of the economic
aspects of the treatment of spasticity is included.
There is no economic review of the treatment of
pain, as no literature was identified relating to
this. Overall, there was substantially more primary
literature identified dealing with the treatment of
spasticity than of pain, and this is reflected in the
relative length and in the structure of reporting of
the two reviews.
Aim and background
2
TABLE 1 Results of the MS Society survey
Symptom % currently experiencing symptom % rating symptom as one of 
(top 8) three worst (top 8)
Fatigue 86 65
Bladder or bowel problems 66 50
Balance problems 73 44
Muscle weakness 69 44
Visual problems Not available 20
Pain 54 18
Muscle stiffness 64 17
Muscle spasms 51 14
Spasticity (stiffness or spasm or both) 74 Not available
Numbness/tingling 64 Not available
Nature and aetiology of spasticity
in MS
Spasticity, or increased tone, is a motor disorder
caused by lesions of the CNS involving the upper
motor neurones. It is associated with sprouting of
descending motor pathways to form new 
synaptic connections with spinal neurones and
with denervation hypersensitivity. It is more
common in the lower limbs.
Spasticity is a major contributor to disability in
MS. It can cause pain, inability to walk and, later,
problems with personal hygiene. Indeed, it is
spasticity rather than weakness in the limbs which
accounts for much of the disability affecting lower
limbs.
The severity of spasticity increases as the disease
progresses. Initially increased tone may be
manifest as extensor spasms. These are
particularly likely to occur at night or on 
waking in the morning. They may be so severe 
as to eject the patient from a wheelchair. 
The legs are held rigidly extended for several
minutes. 
However, as the disease progresses, the spasticity
begins to affect the flexor tone, which initially
results in the patient falling over unexpectedly. In
contrast to sudden extension, flexor spasms are
frequently painful. Over time, the flexed posture
can become more frequent and eventually
permanent. The increased muscle tone eventually
leads to difficulties in nursing care and in
maintaining hygiene. In some cases this can lead
to bed sores, which in turn exacerbate the muscle
spasms. It is important to bear in mind that
spasticity can be a useful function in the earlier
stages of the disease, particularly whilst the patient
is still ambulatory, and may assist the patient in
standing. However, the need to treat spasticity
increases as the disease progresses. In non-
ambulatory patients the spasticity can become
painful and problematic, making transfer of the
patient difficult and causing problems for the
carers of patients, particularly in maintaining
hygiene.
Epidemiology of spasticity in MS
Spasticity has been estimated to affect between 40
and 60% of all patients with MS. In the MS Society
survey undertaken in October 1997,3 64% of
respondents reported muscle stiffness and 51%
muscle spasms. Overall, 74% reported stiffness,
spasms or both. However, although the response
rate of 80% was high, it is likely that both the less,
in addition to the more, disabled patients were
excluded. Nevertheless, it does give an indication
as to the scale of the problem. 
Impact and prognosis of
spasticity in MS
It is difficult to be precise about the prognosis of
MS since the evidence is poor. Surveys indicate
that approximately 50% of patients with MS are
independent and still able to walk after 15 years.
A review of survival studies by Compston and
Swinglar indicates that some 75% of patients
survive for 25 years.4 Nevertheless, severe
spasticity can result in complete immobility. It is
not known how many MS patients enter the
helpless bedridden stage.2
Although the authors were not able to identify any
peer-reviewed literature concerning the impact of
spasticity on the quality of life (QoL) of patients
with MS, a poster presented at an MS Society
conference5 reported on the Short Form with 36
Items (SF-36) scores of 174 people with spasticity
related to MS. This suggested a clear reduction,
with increasing spasticity, in SF-36 scores in all
except the ‘role physical’ dimension. Interestingly,
in this sample, 41% of respondents claimed never
to have seen a neurologist, 56% never to have seen
a specialist in a rehabilitation centre and 60% never
to have seen an MS or neurology specialist nurse.
Current service provision
It was not possible to identify any formal review of
current clinical practice regarding the treatment of
spasticity in MS. Anecdotal reports suggest that it
Health Technology Assessment 2003; Vol. 7: No. 40
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Spasticity in MS
may be very variable. The MS Society survey
referred to above reported that 32% of patients
did not see a hospital specialist for treatment.3
Reasons varied from patient unhappiness with
previous experience of hospital specialists to
general practitioners (GPs) telling them ‘that
nothing can be done for MS’. The survey also
found that overall 37% of patients had taken
baclofen, 9% diazepam and 2% dantrolene in the
previous 2 years. No information was available for
any other antispastic drugs. Of those who had
taken baclofen, 42% had had side-effects, most
commonly weakness. 
Current clinical reviews of treatment suggest that
the standard treatment for moderate spasticity is
oral therapy including baclofen, dantrolene,
diazepam and, more recently, tizanidine.
Sometimes, combinations of these therapies are
used. Pharmacological interventions are usually
supported by physiotherapy; however, the
effectiveness of physiotherapy has not been
assessed in this review. MS requires a multi-
disciplinary team approach bringing together
neurologists, physiotherapy and nursing care.
Physiotherapy in particular is used to develop a
programme of stretching and range-of-motion
exercises.
It has been suggested that some GPs may be
reluctant to prescribe the more expensive
antispastic drugs (e.g. tizanidine), though no
evidence has been put forward to substantiate this.
The average daily cost of tizanidine is more than
twice that of baclofen. Access to more invasive
treatment, in particular, continuous intrathecal
baclofen infusion (CIBI), appears to be extremely
variable and depends on the availability of the
service and local clinical practice. Again, there
does not appear to be any systematic information
on this. The use of CIBI appears to be low; for
instance, in 1998 in the whole of Britain, around
200 patients were implanted with a pump for
intrathecal baclofen, of whom only around 60 had
MS.6 This is likely also to be true of the
intramuscular botulinum toxin (BT) injection,
which it should be noted is not licensed for this
indication.
Criteria for treatment
When considering treatments for spasticity, it is
important to recognise that the desired effect may
change over time as the disease progresses. It is
necessary to distinguish between the less severe
spasticity in the early stages of MS when the
patient will still be ambulant and more severe
spasticity in the advanced stages of MS when the
patient may be non-ambulant.
Treatment for spasticity aimed at reducing muscle
tone may achieve this at the expense of increased
weakness. This, in turn, can lead to no
improvement in function or even a deterioration
of function. Spasticity itself can be helpful to an
ambulant patient and treatment is only necessary
when the spasticity becomes a problem.
In the early stages of the disease, patients who are
still ambulant will usually receive oral drugs.
However, in non-ambulant patients, there may be
greater emphasis on increasing comfort and
facilitating nursing care even if this results in
greater muscle weakness and less mobility.
Injectable or intrathecal drugs are more likely to
be given to non-ambulant patients. Once a patient
becomes unresponsive to oral therapy, then the
choices are limited to CIBI or intramuscular
injections of BT. 
Spasticity in MS
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Formal scoping review
The aim of the search was to identify treatments
for inclusion in the review, and to locate relevant
randomised controlled trials (RCTs), reviews and
cost-effectiveness studies.
Initial scoping searches were conducted to identify
references relating to MS and spasticity. The main
aims of the initial searches were twofold: to identify
interventions to contribute to the framework of
treatments considered in the review; and to
identify search terms to inform the development
of further, comprehensive search strategies.
Therefore, search strategies at this stage were
designed to optimise the specificity of the search
results. The searches were undertaken in January
2000 on MEDLINE, EMBASE and the Science
Citation Index. Search results were not limited by
date, language or by study or publication type. 
Comprehensive search strategies were then
constructed to identify papers relating to MS and
the individual treatments for spasticity. Search
results were not restricted by date, but were
restricted to English language. Filters to limit
search results to RCTs, reviews or cost-effectiveness
studies were applied. Searches were undertaken in
June and July 2000 on the following databases:
 MEDLINE
 EMBASE
 Science Citation Index
 CDSR (Cochrane Database of Systematic
Reviews)
 CENTRAL/CCTR (Cochrane Controlled Trials
Register)
 PubMed
 HealthSTAR
 Best Evidence
 CINAHL (Cumulative Index of Nursing and
Allied Health Literature)
 AMED (Allied and Complementary Medicine)
 NHS CRD DARE (Database of Abstracts of
Reviews of Effectiveness)
 NHS CRD NHS EED (NHS Economic
Evaluation Database)
 NHS CRD HTA (Health Technology
Assessment).
Search strategies for MEDLINE are given in
Appendix 3. Search strategies for other databases
are available from the authors.
In addition to searches of electronic bibliographic
databases, sources were consulted to identify
studies not retrieved through database searching,
current research and grey literature. The National
Research Register (NRR), MRC Clinical Trials
Register and the US National Institutes of Health
(NIH) Clinical Trials Register were searched. The
publication lists and current research registers of
health technology assessment and guideline-
producing agencies and funding and regulatory
bodies were consulted. Searches were repeated in
March 2002.
Inclusion criteria
In selecting studies to be included in this review,
the following criteria were used:
 at least 50% of the trial subjects had to be
diagnosed as having MS or
 if less than 50% of subjects had MS, then the
findings for the MS patients had to be
presented separately. 
The inclusion criteria regarding study design were
based on ‘best available’ evidence. Where possible,
the review was restricted to RCTs. However, this
was not always possible owing to lack of RCT
evidence in which case studies of weaker design
were included. Details are given in individual
chapters. 
Quality assessment 
strategy
The Jadad scale was used for assessing the quality
of the papers selected for inclusion in this review.7
Details are given in Appendix 1. 
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Chapter 3
Review of treatments for spasticity: methods
Methods of analysis and 
synthesis
The data were analysed by drug and summarised
in a tabular format. Validity of outcome measures,
validity of design and statistical analysis were
specifically considered. Direction of effect was
summarised. It was not possible to carry out a
meta-analysis of the findings since there was a
wide variety of outcome measures employed and,
even where the same outcome measure was
employed, it was often in incompatible forms.
Review of treatments for spasticity: methods
6
Description of the interventions
considered
This review considers drug treatments for
spasticity and does not include non-drug therapy
or surgical treatments. The drug treatments which
are considered are: 
 baclofen (Lioresal)
 dantrolene (Dantrium)
 tizanidine (Zanaflex)
 diazepam
 gabapentin (Neurontin)
 botulinum toxin (Botox, Dysport)
 intrathecal baclofen (Lioresal Intrathecal)
 phenol
 threonine
 vigabatrin
 clonidine
 methylprednisone 
 cyproheptadine
 magnesium
 ketazolam.
This review excludes cannabinoids, although
anecdotal evidence suggests they may be effective
at treating both spasticity and pain. Clinical trials
are in progress to evaluate their role. 
Existing reviews
In addition to this review, two published systematic
reviews relating to drug treatment for spasticity
were identified. A Cochrane review, last updated
in June 2001, identified 23 placebo-controlled
trials on antispasticity agents for MS8 and Creedon
and colleagues carried out a meta-analysis of
intrathecal baclofen in 1997.9 This took the form
of a meta-analysis of English language trials of
published studies on intrathecal baclofen prior to
June 1996 and covered 27 studies including 162
patients with MS. There were also various reviews
of single antispasticity agents in non-MS
conditions which have been referred to in the
discussion.
Oral baclofen (Lioresal)
Baclofen is a -aminobutyric acid (GABA)
derivative which, unlike the parent compound,
crosses the blood–brain barrier, albeit to a limited
extent. GABA is a major inhibitor of impulse
transmission in the nervous system, and baclofen
is thought to exert an antispastic effect through
inhibiting reflex neurological transmissions in the
spinal cord via its effect on GABA receptors. The
cost of baclofen is £10.84 for 84 5-mg tablets.10
The maximum daily dose is 100 mg. At this
dosage, the average daily cost of oral baclofen
would be £2.58.
Quantity of research available
The search strategy identified 16 papers. Four of
these were excluded, two because they did not
include patients with MS, one because, although it
did include MS patients, they were fewer than half
of all the patients and results were not shown
separately, and one because it was a second
publication of the same study with a different lead
author.
Eleven randomised and one non-randomised
double-blind (DB) controlled trials of the effect of
baclofen on spasticity were identified. Nine
(including the non-randomised study) were
comparisons with placebo, three with diazepam.
One of the latter also reported comparison with
placebo. In this one, the evaluating physician
would not have been blind to the placebo
comparison (and it is not altogether clear that the
patients would have been either). One of these
studies also involved assessing the effect of the
drug on muscle strength, and this was reported
separately. Nine were crossover studies, two
parallel group studies, and in one it was not clear.
Study details are summarised in Tables 2 and 3.
Populations examined
Seven of the studies recruited exclusively patients
with MS, described variously as ‘established’ or
‘clinically definite’. In the others the majority of
patients had MS. The age range where stated was
Health Technology Assessment 2003; Vol. 7: No. 40
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TABLE 2 Baclofen vs placebo
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Jerusalem
(1968),
Germany19
DB parallel
group RCT,
single centre
Baclofen 16 patients,
placebo 14. Baclofen
titrated up to 
80 mg/day. Duration not
explicit (>8 days). 
All had exercise and
hydrotherapy
N = 30.
29 with MS, one with
syringomyelia.
Non-progressive for 
6 months. Majority
housebound, none
bedridden
None Four grades of success
identified (none, slight,
good, very good)
according to change on
an ad hoc five-point
scale
Success reported in 12/16
patients on baclofen, 5/14 on
placebo. Difference reported
to be ‘statistically significant’.
Night spasms helped in 8/9
patients.
Of 25 patients in total who
took baclofen (including
patients transferred from
placebo), 7 reported sedation,
5 weakness (leading to
reduction in dose), 1 nausea, 
1 dry mouth
3/5
Hudgson 
et al. (1971),
UK14,20
DB crossover
RCT, single
centre
Baclofen 30 mg/day for
10 days, placebo 7 days,
washout
N = 23.
18 with MS.
Aged 30–63 y.
16 M, 7 F.
All had spasticity graded
at 3–4/4 on the
Ashworth scale
None Assessment of spasticity
using Ashworth scale, at
the start and finish of
baclofen and placebo
treatment.
Subjective assessment
Degree of improvement in
spasticity greater on baclofen
than placebo in 16 patients,
greater on placebo than
baclofen in 7 patients. Mean
change in score was 1.44 on
baclofen, 0.54 on placebo 
(p < 0.05).
13 patients said stiffness
reduced on baclofen, 5 on
placebo, 5 reported no
difference.
Side-effects (mild nausea) in 
6 patients on baclofen, 3 on
placebo
4/5
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TABLE 2 Baclofen vs placebo (cont’d)
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Basmajian
(1975),
USA21
DB crossover
RCT, single
centre
Baclofen (dose not
specified) for 4 weeks,
placebo for 4 weeks, 
1 week washout
N = 14.
All with MS.
Aged 21–55 y.
MS with spasticity for
>3 months
N = 3, ‘for personal
reasons unrelated to
therapy’
Not stated Baclofen superior in 7/11
patients, placebo superior 
in 3/11.
When 8 additional patients
from an earlier study are
included, baclofen was
superior in a total of 9/19,
placebo superior in 5/19, and
neither drug superior in 5/19.
No information on-side effects
4/5
Levine et al.
(1977),
USA16
DB controlled
trial, possibly
crossover
(does not
appear to
have been
randomised)
Baclofen increasing
15–80 mg/day on
predetermined
schedule.
Placebo.
Treatment for 5 weeks,
washout for 3 weeks
N = 19.
Average age 43 y.
5 F, 12 M.
12 had MS.
Patients were all
severely disabled,
confined either to bed
or wheelchair
N = 1; however, all
patients did not
complete all tests
Muscle hypertonicity
using EMG.
Measurements of
change in MSV
(microvolt seconds)
before and after the test
drug.
Clinical grading score
(CLN)
53% drop in MSV on baclofen,
5% on placebo.
82% of MS patients had
>30% fall in MVS on baclofen,
compared with 21% on
placebo.
No statistical analysis.
No difference to placebo, but
analysis is unclear.
Baclofen was well tolerated
and any side-effects seem to
be dose related
2/5
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TABLE 2 Baclofen vs placebo (cont’d)
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Sachais et al.
(1977),
USA22
DB parallel
group RCT at
16 centres
Baclofen titrated up to 
a maximum of 
70–80 mg/day on a
predetermined
schedule.
Placebo.
Treatment for 5 weeks
N = 166.
Spasticity secondary to
MS receiving inpatient
or outpatient care.
Minimum age 18, 
mean 43 y.
Baclofen 85 patients,
placebo 81
Baclofen N = 31,
placebo N = 29,
excluded from statistical
analysis for protocal
violation, primarily
related to concomitant
use of disallowed
medications,
relationship with side-
effects not specified
Subjective neurological
examination 
Physician assessment of
clinical change.
Patient self-evaluation
Statistically significant
difference in decreases from
baseline values in pain and
frequency of flexor spasms,
resistance to passive joint
movement in the ankle flexion,
knee flexion and extension and
tendon stretch reflexes in the
knee. 
Overall spastic state improved
(p < 0.001).
Muscle spasms and clonus
improved (p < 0.005)
3/5
Feldman 
et al. (1978),
USA18
DB crossover
RCT (long-
term follow-
up not
reported
here)
Baclofen increasing
15–80 mg/day.
Placebo.
4 weeks on each
treatment
N = 33.
Age 38–53 y.
M:F not stated.
Established diagnosis of
MS with spasticity for at
least 3 months.
Duration of MS 3–30 y.
Disability varied
between ambulatory
with spastic gait to
quadriplegic
N = 10, due to non-
compliance, intercurrent
illness, inability to
tolerate worsening
symptoms
Resistance to passive
movement.
Spasm frequency.
Clonus.
Barthel index.
Ambulation.
Transfer activity.
Subjective rating of limb
pain.
Use of spastic limb
15/23 improved on baclofen,
4/23 on placebo (p < 0.05).
9/23 improved on baclofen,
1/23 on placebo (p < 0.05).
12/23 improved on baclofen,
1/23 on placebo (p < 0.001).
No significant difference
No significant difference
No significant difference
No significant difference
No significant difference
Side-effects of baclofen
included drowsiness, dry
mouth, paresthesia and
blurred vision
3/5
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TABLE 2 Baclofen vs placebo (cont’d)
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Sawa and
Paty (1979),
Canada11
DB crossover
RCT
Baclofen increasing
10–60 mg/day.
Placebo.
Treatment for 3 weeks,
washout period of 7
days followed by 2nd
intervention
N = 21.
6 F, 15 M.
Mean ages 36 (F) and 
49 (M) y.
All patients had clinically
definite or presumed
MS.
Mean duration of MS 
9 y (female), 
14 y (male).
Median spasticity 3 on
ad hoc scale of 0–5
N = 3 Spasticity was assessed
using the researchers’
own grading scale,
which ranged from 0 to
5, where 0 represents
‘no spasticity’ and 5
represents ‘ in the
absence of voluntary
contraction, the leg will
stay extended for a
period of 30 s or more’
On baclofen, 13/18 patients
showed an objective
improvement in spasticity 
(p < 0.001).
No change on placebo.
The incidence of side-effects
was high, 71% of those on
baclofen had side-effects
compared with 19% on
placebo. Common side-effects
were sedation, nausea and
vomiting
3/5
Brar et al.
(1991),
USA17
DB crossover
RCT
Baclofen alone 
20 mg/day.
Placebo alone.
Baclofen + stretching.
Placebo + stretching.
2 weeks on each
treatment.
Ten-week study
N = 38.
Aged 24–54 y.
9 M, 29 F.
Clinically definite MS.
Duration of disease not
stated.
Only patients with an
EDSS score of <5.5
included.
13 subjects had minimal
spasticity in both legs.
17 had minimal
spasticity in 1 leg and
moderate in the other.
The more severely
involved leg was used in
the data analysis
N = 8, due to
exacerbation of
symptoms (n = 4),
transportation
difficulties (n = 2), 
side-effects (n = 1) and
other (n = 1)
Quadriceps
hypertonicity based on
Cybex flexion scores.
(Muscle tone.)
Ashworth score.
Self-assessed functional
ability (minimal record
of disability)
Significant improvement 
(p < 0.05) on both baclofen
treatment and combination
therapy when compared with
placebo. Difference between
baclofen and combination
therapy not significant.
9/30 improved on baclofen,
6/30 improved on placebo,
12/30 improved on
combination of stretch +
baclofen (p = 0.105).
No significant improvement
with either intervention
2/5
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TABLE 2 Baclofen vs placebo (cont’d)
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Orsnes et al.
(2000),
Denmark15
DB crossover
RCT
Baclofen increasing
15–45 mg/day.
Placebo.
11 days treatment, 
2 week wash-out
N = 14.
Age 24–57 y.
9 F, 5 M.
All MS, of whom 7 were
‘clinically definite’.
Duration of disease not
stated.
Patients had a median
score of 5 on EDSS at
baseline.
Median score on
Ashworth index of 0.8.
All had moderate
function and were able
to walk unaided for at
least 3 minutes
N = 1, for non-medical
reasons
Gait analysis using
instrumented treadmill
and force plate.
Voluntary power (MRC
scale)
Ashworth scale
EDSS, AMB, NRS, MSISa
Only one of 12 aspects of gait
measured showed
improvement, with p = 0.04.
No significant differences.
No significant differences.
No significant differences
4/5
a EDSS, Expanded Disability Status Scale; AMB, ambulation index; NRS, Neurologic Rating Scale; MSIS, MS Impairment Scale.
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TABLE 3 Baclofen vs diazepam
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Cartlidge 
et al. (1974),
UK13
DB crossover
RCT
Baclofen 30 or 60 mg.
Diazepam 15 or 30 mg.
2 weeks on each dose,
4 weeks total on each
drug
N = 40.
Aged 22–61 y.
19 F, 21 M.
34 had MS ‘in
remission’, 2 ‘probably’
had MS.
4 patients did not have
MS.
All patients had a score
of 3 or 4 on the
Ashworth scale in one
lower limb at least, but
mean Ashworth score
2.87
N = 3, none connected
with the treatment.
There were no
withdrawals during 
low-dose treatment.
During high-dose
treatment there were 
9 patients withdrawn on
baclofen and 10 patients
withdrawn on
diazepam. These
patients were included
in the data analysis
Ashworth scale,
assessed before and
after low- and high-dose
treatment periods.
The assessed limb was
not specified.
Subjective impression of
patients and doctors
No significant difference
between the two treatments
at low dose.
Both drugs produced an
improvement (cf. No
treatment) at both low and
high dose, but this comparison
not blinded.
11 patients were unable to
tolerate high-dose baclofen, 
14 high-dose diazepam.
19/37 patients preferred
baclofen, 15/37 diazepam.
Doctors preferred baclofen for
18/37 patients, cf. diazepam
for 13/37.
Patients on diazepam
experienced more severe side-
effects, especially weakness
and sedation
4/5
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TABLE 3 Baclofen vs diazepam (cont’d)
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
From and
Heltberg
(1975),
Denmark12
DB crossover
RCT
Baclofen 30–120 (mean
61) mg/day.
Diazepam 10–40 (mean
27) mg/day.
4 weeks on each drug
N = 17.
Age 38–68 y.
10 F, 6 M.
All MS.
Duration of disease
3–40 y (mean 17.5).
All inpatients.
All had symptoms of
spasticity, predominantly
in the lower limbs.
Mean Ashworth score in
lower limbs 2.5.
Only 2 patients could
walk, the remaining 14
could either not walk at
all or could only walk
very short distances
N = 1, due to side-
effects, especially
sedation on baclofen
Ashworth scale.
Change in flexor
spasms.
Clonus.
Walking ability.
Side-effects.
Subjective overall rating
No significant difference
between the two drugs.
No difference between the
two drugs.
No significant difference.
Of the 2 patients who could
still walk, both improved on
baclofen, but one of them
deteriorated if given more
than 30 mg due to weakness.
This same patient deteriorated
on 20 mg diazepam also. 
1 non-ambulatory patient lost
the ability to stand on baclofen
due to weakness. 
Patients experienced greater
side-effects on diazepam than
on baclofen, especially
sedation.
12/16 patients preferred
baclofen to diazepam, 4/16
had no preference
3/5
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TABLE 3 Baclofen vs diazepam (cont’d)
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Roussan 
et al. (1985),
USA6
DB crossover
RCT
Baclofen 15–80 mg
(mean 47.3 mg).
Diazepam 6–40 mg
(mean 28 mg).
5 weeks on treatment,
3 weeks washout
N = 13.
7 had MS.
Duration and severity of
disease not stated
None Ad hoc global
assessment covering
spasm frequency, range
of motion, daily
activities, pain, by
patient and physician,
rated 0 to 3+.
NB: assessment
excluded the impact of
side-effects
Patient assessment: greater
improvement on diazepam in
3, baclofen in 2, equal in 1, 
no improvement on either
drug in 1. 
Physician assessment: greater
improvement on diazepam in
2, baclofen in 3, equal in 1, 
no improvement on either
drug in 1.
Drowsiness in 3 patients on
diazepam, 1 on baclofen, at
doses used. 1 patient suffered
loss of erection on both drugs.
Leg oedema in 1 patient on
baclofen
2/5
between 18 and 68 years. The duration of disease
was not reported in most studies, but where it was,
it was reported as between 3 and 30 years. Where
stated, all trials recruited both men and women.
The extent of spasticity is variably described,
either purely descriptively, using the Ashworth
scale or a variant of it, or an ad hoc scale.11 In two
studies12,13 which reported the baseline Ashworth
score it was 2.5 and 2.87. Another study14
reported that all patients had spasticity graded at
3–4 (out of 4). A fourth15 (using the Ashworth
scale in a different way) reported a baseline score
of 0.8. Details of the Ashworth and other outcome
scoring systems are given in Appendix 2. The
extent of disability also appears to have been
variable, with one trial12 recruiting inpatients who
could walk only short distances, if at all, and
another16 recruiting only patients who were
confined to bed or wheelchair. Others recruited
patients with lesser degrees of spasticity, or did not
include any details of the level of disability. One
study recruited only patients with a baseline
Expanded Disability Status Scale (EDSS) of less
than 5.5,17 and another reported that the median
EDSS was 5 at baseline.15
Interventions
Baclofen was administered orally in doses of
between 10 and 120 mg (the maximum daily
dosage is 100 mg). In the majority of studies the
dose was increased gradually to a maximum,
unless side-effects precluded this. In one,17 a fixed
dose of 20 mg was used. Where diazepam was
used as a comparator, the dose was between 6 and
40 mg daily. The duration of all studies was short,
with the length of treatment varying between 
11 days and 5 weeks.
Outcomes measured
A wide variety of outcome measures was used,
involving clinical assessment of spasticity and
frequency of spasms. One reported an objective
measure of quadriceps tonicity using a Cybex unit.
Five studies used the Ashworth scale. One used an
ad hoc measure of spasticity based on the speed
with which a passively flexed leg of a supine
patient fell to the bed. Another used a clinical
spasticity grading which appears to be very similar
to the Ashworth scale. In five of the nine
comparisons with placebo, improvement in
spasticity was reported as a dichotomous variable
(improved or not). Two14,15 reported the extent of
any improvement in spasticity, as measured by the
scale used (although as the Ashworth scale is an
ordinal, rather than an interval scale, the analysis
is possibly not valid).
Three measured spasm frequency. Four reported
the subjective preferences of patients and doctors.
Four reported functional ability measured in a
variety of different ways. One was primarily a
study of the effect of baclofen on gait,15 which was
analysed using a computerised treadmill and force
plate. One was primarily an electromyographic
(EMG) study,16 and was reported as such.
Validity of included studies
The DB design of the majority of the studies and
the broad range of severity of spasticity of
included patients ought to ensure that the results
are generalisable to MS patients. In crossover
studies of drugs against placebo where the drug
has marked therapeutic or side-effects, patients
may guess whether they are on active drug or
placebo, and may convey this to their physician.
Hence it is possible that the blinding was not
completely effective. In one crossover study
comparing baclofen with diazepam, the
comparison with placebo, or control, would not
have been blinded.13 As non-blinded studies tend
to overestimate treatment effects, the implication
is that the overall effect of baclofen may be
exaggerated.
The validity of the Ashworth scale as a measure of
spasticity is not clear. It is an ordinal, rather than
an interval scale, so that it is not appropriate to
analyse the data by comparing means. However, in
most of the studies here the analysis was
appropriate.
There was no mention of prior sample size
calculations in any of the studies. Their relatively
small size implies that they may not have had
sufficient power to detect small effect sizes, which
would have increased the chance of a Type II error.
Jadad scores were between two and four, with none
scoring five.
Summary of direction of effect
In three11,18,19 of the crossover studies comparing
baclofen with placebo, statistically significantly
more patients were reported to have had an
improvement in spasticity measured using the
Ashworth, or a similar, scale when on baclofen
than when on placebo treatment. In a fourth14 the
change in the Ashworth score was significantly
greater on baclofen than on placebo. The two
studies which used the lowest maximum dose of
baclofen were among the three that did not show a
statistically significant difference. One17 (which
used the lowest dose of baclofen, 20 mg) reported
an improvement in the Cybex score, but not in the
Results of the systematic review of treatments for spasticity in MS
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Ashworth score. One of the studies which reported
an improvement18 also reported that more
patients experienced an improvement in range of
motion and frequency of spasms on baclofen than
on placebo.
None of the comparisons between baclofen and
diazepam showed a significant difference in the
effect of the drugs on the Ashworth score. Nor did
the one study that reported on them detect any
difference in change in spasm frequency or clonus
between the two.12 Two studies12,13 reported an
improvement in the Ashworth score (for both
drugs) compared with control scores, but this
comparison would not have been blind.
In the study of gait,15 only one of 12 parameters
of gait showed an improvement with baclofen
treatment, and the p value for that comparison
was 0.04. Because of the multiple comparisons
being made, this would not normally be
considered statistically significant (usually one
would use a p value of 0.001), as it is likely to have
occurred by chance. The EMG study did show a
decrease in measures of muscle hypertonia on
baclofen as compared with placebo.
Preferred treatments
The studies comparing baclofen with placebo did
not report patient preferences. The comparisons
with diazepam did. In one,12 12 of 16 preferred
baclofen to diazepam, and four preferred
diazepam. In a second,13 19 of 37 patients
preferred baclofen, 15 prefered diazepam and
three expressed no preference. In the third,6
three of seven patients reported greater
improvement on diazepam, and two of seven 
on baclofen.
Impact on function
None of the comparisons with placebo was able to
demonstrate any effect of baclofen on functional
ability. In some cases, there was even a marked
deterioration in functional ability, and it was
commented that the spasticity may have been
necessary for some residual function. It should be
noted, however, that responses to baclofen were
variable, and although it may not have been
possible overall to demonstrate a consistent effect,
there were individual patients who did experience
benefit.
Side-effects
Side-effects with baclofen were common. Those
most commonly reported were drowsiness,
weakness, paraesthesiae and dry mouth. One
patient in a crossover study of baclofen and
diazepam suffered loss of erection on both drugs.
Side-effects do appear to limit the dose tolerated,
but are fewer, and more readily tolerated, than
those caused by diazepam.
Summary
The evidence that baclofen leads to an
improvement in clinical measures of spasticity in
MS as compared with placebo is limited. Objective
measures of muscle function (EMG and the Cybex
unit) do reveal an effect. However, in the blinded
comparisons it is not translated consistently into
an effect on subjective measures such as the
Ashworth score. There appears to be no difference
in the effectiveness of baclofen and diazepam,
although baclofen is better tolerated. None of the
studies demonstrated any improvement in
functional status, but there is some evidence of a
preference among patients for baclofen over
diazepam. 
Dantrolene (Dantrium)
Dantrolene acts directly on skeletal muscle to
inhibit contraction of muscle fibres, by inhibiting
the release of calcium from the sarcoplasmic
reticulum, which is necessary for muscle fibre
contraction. Thus, in addition to relieving
spasticity, it causes muscle weakness. The cost of
dantrolene is £12.32 for 100 25-mg tablets or
£43.07 for 100 100-mg tablets.23 The
recommended maximum daily dose is 100 mg
four times daily. At this dosage, the average daily
cost would be £1.72.
Quantity of research available
Ten papers on the effect of dantrolene on
spasticity were identified, of which one was a
review. Of the remaining nine, six were retained
for inclusion in this review. Three were excluded,
one because none of the patients had MS and the
other two because only 17/200 and 3/17 patients
in each study had MS, and their results could not
be separated out.
Details of the six studies included in this review
are summarised in Tables 4 and 5. Of these, one
was an open trial in which both MS and non-MS
patients were studied. The other five were all DB
RCTs, of which three recruited exclusively MS
patients. Four of these were crossover trials, and
one a parallel group study (which was reported 
as a letter). One of the crossover studies 
compared dantrolene with diazepam, whereas the
other five RCTs compared dantrolene with
placebo.
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TABLE 4 Dantrolene vs placebo
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Gelenberg
and
Poskanzer
(1973), UK26
DB crossover
RCT
Dantrolene 50–200 mg
q.d.s.
Placebo.
5 weeks treatment, 
3 weeks washout, then
5 weeks alternative
treatment
N = 20.
Age 37–67 y.
9 F, 11 M.
All had ‘clearly established’
MS.
Duration of disease not
stated.
14/20 were able to walk
with difficulty, 5 were
bedridden or wheelchair
bound and 1 was
quadriplegic
0 Clinical including
spasticity, strength,
clonus and tendon
reflexes.
Measures not specified
Dantrolene favoured by
patients and doctors for 6
patients. 1 additional patient
claimed a significant
improvement, but this could
not be measured objectively.
Remaining 13 felt that placebo
was better or same as
dantrolene, or the side-effects
of the treatment negated any
benefits.
Main side-effects reported
were weakness (15), light-
headedness (11), nausea (7),
dizziness (6) and diarrhoea (6)
2/5
Ladd et al.
(1974),
Sweden27
Open trial: 
5 patients
were
evaluated first
off drug, then
after 5–6 days
at the highest
dose. 
3 patients
evaluated in
reverse order:
first on drug,
then off drug
Dantrolene, 
25 increasing to 100 mg
q.d.s.
Duration of study not
clear
N = 18.
Age 21–54 y.
3 F, 5 M.
8 with ‘probable or
possible’ MS, 10 ‘normal
subjects’ as controls.
Kurtzke Disability status
3–8.
3/8 wheelchair bound
– Clinical evaluation of
spasticity and clinical
status.
EMG evaluation of
untreated ‘normal
subjects’ and patients on
and off treatment
Dantrolene reduced spasticity
in 6/8 patients and led to
clinical improvement or an
improvement in daily living
activity in 7/8 patients.
‘Marked improvement’ in
overall clinical condition in 
5/8 cases.
EMG evaluation suggested that
drug patients to increase
control over muscle activity as
measured by EMG.
Weakness was not reported in
any patients but some felt tired
and dizzy at first
0/5
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TABLE 4 Dantrolene vs placebo (cont’d)
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Tolosa et al.
(1975),
USA29
DB parallel
group RCT
Dantrolene 25–200 mg
q.d.s.
Placebo.
Treatment for 8 weeks,
evaluation at 0, 4 and 
8 weeks
N = 23.
Ages not stated.
Sex not stated.
All patients had MS.
Duration of disease not
stated.
Outpatient setting.
All patients had spasticity in
the lower extremities, 11
were severely disabled and
were wheelchair bound. 
12 on dantrolene and 11 on
placebo
2 (both in
dantrolene), 1 due to
profound weakness
Spasticity on a scale of
0–6 (0 = flaccid and 
6 = extreme resistance)
No clear difference.
Reduction in spasticity
occurred in 5/12 on
dantrolene and 3/11 on
placebo. In most cases this
improvement was only mild,
but was accompanied by an
improvement in functional
capacity.
Concluded that dantrolene
was of limited usefulness.
Side-effects were only noted in
the dantrolene group.
Objective weakness was found
in 50% of the dantrolene
group
3/5
Sheplan and
Ishmael
(1975),
USA28
DB crossover
RCT
Dantrolene 50–100 mg
q.d.s.
Placebo.
5 weeks treatment, 
2 weeks washout
N = 18.
8 with MS.
Basis of diagnosis not
stated.
MS patients aged 34–56 y.
Sexes not stated
0 Clinical evaluation of
clonus, rigidity and
hyperreflexia (no
evidence that these
scales are validated).
Electromechanical
evaluation of tendon
reflexes and response to
tibial nerve stimulation
Clonus reduced in 8/8,
abolished in 5/8.
Rigidity reduced in 7/7 where
present.
Hyperreflexia reduced in 8/8,
abolished in 6/8.
Mechanically measured
response to tendon tap and
tibial nerve stimulation
reduced in all 8/8, by a mean
of 45 and 39%, respectively
3/5
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TABLE 4 Dantrolene vs placebo (cont’d)
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Gambi et al.
(1983), Italy24
DB crossover
RCT
Dantrolene titrated up
to 350 mg/day, mean 
30 days. 
Placebo mean 31 days.
7 days washout
N = 24.
12 with MS.
Mean age of MS patients 
38 y.
5 M, 7 F.
Duration of spasticity, mean
7.2 y
N = 2 from MS
group, one with high
serum transaminases
on admission, one
non-evaluable
because spasticity
too severe
Spasticity, strength,
clonus, reflexes,
according to ad hoc
scales.
Physician final
assessment of
effectiveness
‘Dantrolene sodium reduced
spasticity of both lower limbs
(p < 0.05) in comparison with
placebo’.
Physician’s final judgement
gave significant difference in
benefit with dantrolene 
(p < 0.05).
Side-effects (total 13 of all 
24 patients): drowsiness (7),
nausea (4), gastric pain (4),
weakness (3), vomiting (1),
malaise (1)
4/5
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TABLE 5 Dantrolene vs diazepam
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Schmidt 
et al. (1976),
USA25,30
DB crossover
RCT.
The study had
6 evaluation
periods: 
2 control, and
low and high
doses of each
treatment
Dantrolene 50–300 mg
q.d.s.
Diazepam 4–20 mg
q.d.s.
Placebo.
Treatment for 4 weeks
with 2 week washout
periods between
treatments
N = 46.
Age, sex not stated.
All were MS outpatients
attending University Clinic.
Duration of disease not
stated.
Moderate – severe
spasticity.
Mainly ambulatory without
severe lower limb
weakness
Stable for 6 months
N = 4, due to side-
effects
Survey of symptoms.
Measures of 10 physical
functions, assessed by
neurologist blind to
drug, but not blind to
control/low/high dosage.
Patient preference.
Side-effects
No difference between drugs.
Both dantrolene and diazepam
reduced spasticity, clonus and
reflexes at low and high doses
compared with the control.
The effect of dantrolene was
more dose dependent than
with diazepam.
22 preferred dantrolene, 13
preferred diazepam and 7 had
no preference.
Dose reduced in 15/42
patients due to side-effects.
Diazepam decreased hand
coordination, reduced hand
speed and walking speed.
Dantrolene produced
weakness at low doses
whereas diazepam only
produced weakness at high
doses. Weakness caused by
dantrolene was severe
3/5
In two of the crossover studies comparing
dantrolene with placebo, active drug or placebo
was given for 5 weeks, followed by a washout (2
weeks in one study, 3 weeks in the other), followed
by the alternative. Drug dose was started at 50 mg
four times a day, and increased up to 100 or
200 mg four times a day. In the third, dantrolene
was titrated up to 350 mg daily, the duration of
treatment was a mean of 30 days (31 days for
placebo), with 1 week washout between treatments.
In the crossover study comparing dantrolene with
diazepam, patients were evaluated three times in
each study arm. The first evaluation was before
starting the drug, the second after 2 weeks of
increasing drug dosage (‘low dose’) and the third
after a further 2 weeks at higher dosage (‘high
dose’). Patients then had 2 weeks washout before
evaluation, following which the alternative drug
was administered in the same stepped regime. The
highest dose of dantrolene administered was
300 mg daily. There were therefore six evaluations
in all.
In the parallel group study, patients were
randomised to either dantrolene or placebo.
Dosage was started at 25 mg four times a day, and
increased up to a maximum of 800 mg daily.
Evaluation was undertaken at 4 and 8 weeks.
The open trial studied the clinical and EMG effect
of dantrolene on eight patients with MS, and
compared the EMG results with findings in 10
‘normal subjects’ (who were not given any drug
treatment). The duration of the study was not
stated. The dose of dantrolene used was 25,
increasing to 100 mg four times daily.
Populations examined
Three of the six studies recruited exclusively
patients with MS. One of the RCTs had 12 MS
patients out of a total of 24. Another had eight MS
patients out of 18, as did the open-label study.
One stated that the diagnosis was ‘clearly
established’, and one states that the patients had
‘probable or possible’ MS. The others do not state
the basis on which the diagnosis was made.
Duration of disease is stated in only one study,24 in
which spasticity had been present for a mean of
7.2 years. The severity of spasticity and extent of
disability were variable. In one study,25 patients
were mainly ambulatory without severe lower
extremity weakness. In another,26 five of the 20
patients were confined to a wheelchair or bed, and
one was completely paraplegic. Three studies
reported the age and sex of the patients: in one
RCT,26 there were 11 men and nine women, aged
39–67, with mean age 49 years; in another,24 of
the 12 patients with MS, there were five men and
seven women, with a mean age of 38 years; in the
open trial,27 there were five men and four women,
aged 21–58, mean 50 years.
Outcomes measured
The parallel group study used a ‘semi-quantitative
scale’ measuring spasticity from 0 to 6. One of the
crossover studies did not specify the outcome
measures used other than patient preference.26
One used clinical and mechanical tests of
musculoskeletal function although there is no
evidence that these were validated.28 Another used
ad hoc scales of spasticity, strength, clonus and
reflexes.24 The other crossover study25 used
clinical and ‘simple mechanical equipment’ to
assess 10 physical functions. As this was the study
which evaluated high and low doses of both
dantrolene and diazepam, and involved a control
evaluation (drug free), a total of 90 separate
comparisons were reported on, which must have
increased the chance of a Type I error. For this
reason, the authors only considered as ‘statistically
significant’ those comparisons in which the
difference is quoted as statistically significant with
p < 0.001. Further, in this study, neither patient
nor evaluating physician can have been blind to
whether the patient was taking a low or high dose
of drug. Hence the only comparisons for which
blinding was preserved were between drugs, not
between dosage levels of the drugs or between
drugs and ‘control’.
In three of the crossover studies, patients were
asked to express a preference for either dantrolene
or diazepam, or dantrolene or placebo.24,26
The open trial used an unspecified clinical
assessment of spasticity and overall clinical status,
and an EMG evaluation using four tests of the
patient’s ability to control muscular activity.27
Validity of included studies
Although there appears to have been some
variability between the study populations in terms
of the extent of disability and disease duration,
there is no reason to think that the populations
studied were not typical of MS patients. In
crossover studies of drugs against placebo where
the drug has marked therapeutic or side-effects,
patients may guess whether they are on active
treatment or placebo, and may convey this to the
evaluating physician. Thus, in addition to the
failure of blinding as to dose levels in one study,
mentioned above, there may have been a failure of
blinding in the crossover study which compared
dantrolene with placebo. Unblinded studies are
Results of the systematic review of treatments for spasticity in MS
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more likely than blinded studies to report positive
effects. The Jadad scores for the six studies are
low, with one score of 4, three scores of 3, one of 2
and one27 of zero.
There is no mention of sample size calculation in
any of the studies. The relatively small size of the
studies implies that they may not have had
sufficient power to detect small effect sizes, which
would increase the chance of a Type II error.
The open trial, being neither blinded nor
controlled, is of questionable validity.
Summary of direction of effect
One of the crossover comparisons with placebo
did not specify any objective outcomes. The others
reported benefit in both clinical and
electromechanical measures on dantrolene. In the
comparison with diazepam there was no consistent
effect of dantrolene other than an ‘improvement’
in ‘reflexes’ (it is impossible to determine the
clinical significance of the quantitative results
given with regard to this). Dantrolene at both low
and high doses is reported (at p < 0.001) to lead
to improved spasticity, reflexes, clonus and deltoid
strength compared with placebo but, as noted
above, neither patient nor physician would have
been blind for this comparison. In the parallel
study, a reduction in spasticity scores was observed
in five of 12 patients on dantrolene and in three of
11 on placebo. The improvement in spasticity was
said to be only mild except for one case.
The open trial reported an improvement in
clinical status in five of eight patients treated.
Preferred treatments
In one of the crossover comparisons against
placebo, seven of 20 patients expressed a
preference for dantrolene over placebo, four
preferred placebo (because of the avoidance of
side-effects) and nine had no preference. In the
crossover study of dantrolene compared with
diazepam, out of the 42 patients who completed
the study, 22 preferred dantrolene, 13 diazepam
and seven neither drug.25
Impact on function
Very little detail is given about any effect on
function. In both of the crossover studies against
placebo, some ambulatory patients were said have
improved gait and improved activities of daily
living. Four patients were confined to wheelchairs,
and relief of spasticity was said to have enabled
them to move around more, and to be beneficial
to their carers. In the parallel group study, the one
patient who was reported to have benefited
significantly from dantrolene was said to have had
an improvement in functional capacity, but further
details were not given. The open trial reports that
in two patients transfers were easier, and in three
gait was improved, although the extent of this was
not stated.
Side-effects
Eight out of the total of 115 patients recruited in
these studies dropped out because of the side-
effects experienced when taking dantrolene. The
main side-effect reported in all studies was
weakness. This affected more than 50% of patients
in all studies. The extent to which this was
disabling appears to have been variable. In one
study weakness produced even at low doses was so
severe that patients began to fall as their legs
buckled, and this side-effect stayed with them for
the duration of the treatment. Other commonly
reported side-effects included light-headedness,
dizziness, nausea and diarrhoea. In the one study
in which they were asked to express a preference,
four out of 20 patients expressed a preference for
placebo, because of the lack of side-effects.26
Summary
Dantrolene appears to have a moderate effect on
spasticity. However, its value is severely restricted
owing to the frequency of unwanted side-effects, in
particular weakness and gastrointestinal symptoms.
Tizanidine (Zanaflex, Sirdalud)
Tizanidine is a short-acting muscle relaxant which
acts on the 2-adrenergic receptors. It is indicated
for acute and intermittent management of
increased muscle tone associated with spasticity.
The cost of tizanidine is £89.70 for 120 4-mg
tablets.23 The maximum daily dosage is 36 mg
and the recommended daily dosage is 24 mg. At
this recommended dosage the average daily cost
would be £4.49.
Quantity of research available
Sixteen papers on the use of tizanidine in the
treatment of spasticity were identified. Of these,
one was a review, one was a letter and the third
was a very poor quality, selective meta-analysis.
These three were excluded, leaving 12 DB RCTs
and one randomised trial which was described as
‘partially blind’.31 Of these, two are studies of the
effect of single doses of the drug, compared with
placebo. The other 11 are studies of medium-term
use of the drug (5–15 weeks), three being
comparisons with placebo, one with diazepam, six
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with baclofen and one with both baclofen and
tetrazepam. Details of the studies included in this
review are given in Tables 6–9.
Study designs
Of the 12 DB RCTs included, nine were parallel
group studies and three were crossover studies
(two comparing tizanidine with baclofen, one with
placebo). The two single-dose studies involved 
142 and 17 patients. The larger one was a
dose–response study comparing the effects of
placebo and 8 and 16 mg of tizanidine. The
smaller one was a crossover study in which patients
were given placebo, 2, 4 and 8 mg of tizanidine on
four separate days, with a washout period in
between. There was one dropout in the smaller
study and two in the larger. In both cases muscle
tone was assessed using the Ashworth scale and
the pendulum test, although not in the same way.
Populations examined
All but one trial included involved only patients
with MS; one trial included 32 patients with MS
out of 36 subjects. Study sizes varied between 16
and 220 patients. In the majority of cases these
were ‘clinically diagnosed’, with or without
laboratory support. One study included patients
with ‘probable MS’. The mean age of patients in
the studies was between 42 and 54 years with, in
most cases, a majority of women over men. The
mean duration of disease was reported in five
studies, and varied from 7 to 15 years (within this,
there were wide variations for individual patients).
The duration of spasticity was reported in seven
studies, varying between ‘at least 2 months of
stable spasticity’ to between 6 and 8 years.
Four studies reported the severity of spasticity at
baseline, using the Ashworth score, two recruiting
only patients with a score of ≥ 2, one recruiting
patients with scores of 1–4 and another with scores
of 2–3. Three other studies described the baseline
spasticity as moderate or severe, one stated that
patients were ‘disabled by spasticity’ and two did
not characterise the severity at all. The extent of
overall disability varied substantially between the
populations studied. Three studies reported this in
terms of the EDSS (1.5–9.5 in one, 3.5–7 in
another, 4–7 in the third). Others reported the
level of disability in qualitative terms, ranging
from ‘interfering with activities of daily living’ to
‘seriously handicapped’. One included only
hospitalised patients.32
Intervention
The doses of tizanidine used in the single-dose
studies were between 2 and 16 mg. In the longer
term studies it was between 2 and 36 mg per day.
Comparator doses of diazepam were 15 mg per
day (mean), and of baclofen 15–80 mg per day. In
the trial of tizanidine against baclofen and
tetrazepam,33 the dose of each drug used was not
explicit.
Outcomes
In most of the studies the outcomes measured
included the Ashworth score, although it was not
used consistently in all studies. In some cases the
individual scores for single muscle groups were
reported. In others, the scores for a number of
muscle groups were aggregated to give an overall
score. Other outcomes measured included the
frequency of muscle spasms, muscle strength, the
pendulum test and measures of functional ability.
Validity of included studies
As far as can be ascertained, in all cases the
conduct of the studies was robust. The DB RCT
design ought to ensure internal validity. Although
there was no explicit consideration of sample size
in any of the studies, the sample sizes in the
studies of tizanidine were generally much larger
than those for the older drugs such as baclofen or
diazepam.
The summation and averaging of Ashworth scores
(an ordinal scale) which was done in some of the
studies34,35 was statistically inappropriate.
The Jadad scores for studies of tizanidine were
generally higher than those obtained for studies
based on other drugs in this review. The average
Jadad score for the 13 studies reviewed here is 3.5
with no single study scoring <3. The higher
quality of these studies may reflect the fact that
tizanidine is much newer to market than the other
drugs included in this review.
Summary of direction of effect
Both the single-dose studies showed a statistically
significant, dose-dependent improvement in the
result of the pendulum test. The larger study
showed a dose-dependent improvement in the
Ashworth score (up to four points, when the total
score is measured up to 16), but the improvement
in Ashworth score in the smaller study did not
appear to be statistically significantly different to
that seen with placebo. Neither study included any
functional assessment. The clinical effects appear
to last until 3 hours post-dose, but to have faded
by 6 hours.
The two longer-term studies comparing tizanidine
with placebo involved 187 and 220 patients, with
Results of the systematic review of treatments for spasticity in MS
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TABLE 6 Tizanidine vs placebo
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Lapierre 
et al. (1987),
Canada36
DB parallel
group RCT
Tizanidine titrated over
3 weeks to max. of 
32 mg/day, (mean 
18.4 mg/day) maintained
for 5 weeks, vs placebo
N = 66.
All with definite MS.
Mean age 47.6 y (T), 
43.8 y (P).
33 M, 33 F.
Mean disease duration 
15.2 y (T), 11.6 y (P).
Spasticity present for 
6–8 y, stable for at least 
2 months.
‘Generally moderate to
severe’
N = 7.
4 on tizanidine
due to lack of
effect or side-
effects, 1 due to
relapse of MS.
Two on placebo,
one due to
intercurrent
illness, one to
side-effects
Kurtzke score.
AMB.
Upper extremity index.
Limb tone.
Tendon reflexes.
Muscle strength.
Electrophysiological
parameters.
Overall assessment
made by investigators
based on patients’ own
impression and
objective findings.
Side-effects
Improved in three of each group,
deteriorated in five of placebo
group, but overall no change in
either group.
Small improvement in treated
group, not significantly different to
placebo. 
Small improvement in treated
group, not significantly different to
placebo.
‘Cumulative limb tone’ improved
more in the treated group than in
the placebo group.
Improved more in treated than
placebo group.
Mild improvement in both groups
overall, but one-third in each
group had increased weakness.
No change in either group in any
of the parameters measured.
Improvement in 69% of treated
group, 38% of placebo group.
Drowsiness and dry mouth
reported in 48%, 27% of
tizanidine patients, decreasing
with treatment
4/5
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TABLE 6 Tizanidine vs placebo (cont’d)
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
UK
Tizanidine
Trial Group
(1994), UK35
DB parallel
group RCT
Tizanidine 31 mg.
Placebo 35 mg.
3 weeks run-in.
9 weeks main stage
N = 187.
Mean age 47 y.
121 F, 65 M.
94 tizanidine, 93 placebo.
Clinically definite, lab.
supported or probable MS.
Mean duration of MS 13 y.
Mean duration of stable
spasticity 3 y.
Mostly mild–moderate
spasticity (Ashworth score
2–3).
EDSS scores from 1.5–9.5.
Some were bedridden,
most were ambulatory
N = 32.
19 tizanidine, 
13 placebo.
However, more
than this violated
the protocol
Muscle tone
(Ashworth score).
Muscle spasms and pain.
Muscle weakness (MRC
scale).
Walking.
EDSS.
Intermediate functions.
Subjective assessment of
efficacy
21% reduction muscle tone on
tizanidine (p = 0.004).
Differences not significant
No significant differences
No significant differences
No significant differences
There was a trend in favour of
tizanidine but this was not
statistically significant.
63% of patients on tizanidine
rated their treatment as effective
compared with 45% of those on
placebo
4/5
Smith et al.
(1994),
USA39
DB parallel
group RCT
Tizanidine 2–36 mg.
Placebo.
15 weeks
N = 220.
Mean ages 46 and 45 y in
tizanidine and placebo
groups.
125 F, 83 M.
111 tizanidine, 
109 placebo, 
159 completed.
Clinically definite MS.
Duration of MS 11 y
average (range 4 months –
40 y).
Duration of spasticity not
stated.
Ashworth score 1–4.
‘Significant discomfort or
functional impairment’
N = 61.
28 tizanidine, 
33 placebo
Muscle tone (Ashworth
score).
Spasms and clonus
(patient’s diary).
Muscle strength (MRC
scale)
No differences between groups.
Trend towards a reduction in
spasms and clonus with tizanidine
group. Post hoc non-parametric
analysis showed a reduction in
median response ratio 
(p = 0.028).
Strength maintained in both
groups
3/5
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TABLE 6 Tizanidine vs placebo (cont’d)
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Emre et al.
(1994),
Switzerland40
DB crossover
RCT
Tizanidine 2, 4, 8 mg.
Placebo.
Single dose only
N = 17.
Mean age 43 y (24–58).
13 F, 4 M.
Clinically definite MS.
Duration of MS not stated.
Duration of spasticity 
70 months (12–180
months)
Extensor spasticity had min
score of 2 on Ashworth
scale.
None were bedridden
N = 1, due to
baseline spasticity
declining below
minimum
Relaxation index (R2)
based on the
Wartenburg pendulum
test.
Muscle strength (MRC
scale).
Muscle tone using the
Ashworth scale
Dose-related response in R2 in
the tizanidine group.
No change.
There appears to be a moderate
change but the paper is not
explicit
5/5
Small 
Sample size
Nance et al.
(1997), USA
and Canada34
DB parallel
group RCT
dose –
response
study
Tizanidine 8 or 16 mg.
Placebo.
Single dose only
N = 142.
Ages not stated.
86 F, 56 M overall.
45 tizanidine 8 mg, 
49 tizanidine 16 mg, 
48 placebo.
Clinically definite MS.
Duration of disease not
stated.
Duration of spasticity not
stated.
Minimum score of 2 on
Ashworth scale for lower
extremity. Moderate/severe
disability.
EDSS scores 3.5–7
N = 2.
1 due to
hypotension after
tizanidine
Muscle tone using
Ashworth scale and the
pendulum test
In the tizanidine group the
Ashworth score decreased by an
average of 2 after 1 h and 1.6
after 3 h (p < 0.001).
Change in score correlated with a
change in plasma concentration.
Tizanidine produced a significant
improvement in the pendulum
test (p < 0.001).
Greater improvement in the 
16-mg group than with the 8-mg
group
3/5
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TABLE 7 Tizanidine vs diazepam
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Rinne (1980),
Finland41
DB parallel
group RCT
Tizanidine 18 mg.
Diazepam 22.5 mg
(maximum doses).
6 weeks
N = 30.
Age 42 (T), 40 (D) y
(mean).
19 F, 11 M.
15 in each group.
Basis of diagnosis not
stated.
Duration of disease 7 (T),
12 (D) y.
Duration of stable spasticity
at least 1 y.
Spasticity
‘moderate–severe’.
Extent of disability not
stated
N = 4.
All 4 were on
diazepam and had
to be withdrawn
owing to adverse
reactions
Ashworth scale 9 patients in each group showed
an improvement in spasticity and
there was no significant difference
between the two groups.
Overall the tolerability of
tizanidine was significantly greater
than diazepam
3/5
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TABLE 8 Tizanidine vs baclofen
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Smolenski 
et al. (1981),
Switzerland32
DB parallel
group RCT
Treatments titrated up
to an ‘optimal’ daily
dose. Baclofen 
10–80 mg/day.
Tizanidine 8–36 mg/day.
Treatment for 6 weeks.
Washout period 
3–5 days
N = 21.
Hospitalised MS patients.
10 M, 11 F.
Aged 42–73, mean 54 y
None Muscle tone and
spasms, and muscle
strength.
Subjective neurological
examination (Kurtzke
scoring) and functional
assessment (Pedersen).
Physician’s and patient’s
assessment of change.
Physician’s assessment
of clinical change.
Patient self-evaluation
No statistical analysis of efficacy
outcomes.
Most patients showed overall
improvement, similar between
treatment groups.
Little change evident.
Tendency for night-time spasms
and bladder function to show
more improvement in the
tizanidine group, otherwise little
difference between groups
3/5
Newman 
et al. (1982),
UK37
DB crossover
RCT
Dosage increased over
2 weeks to Baclofen 
40 mg, tizanidine 16 mg
daily, then maintained
for a further 1 month.
Washout 1 week
N = 36 (32 with MS).
‘Neurologically stable and
disabled by spasticity’.
26 patients assessed, 12 M,
14 F, mean age 45.9 y,
duration of disease 9 y
N = 10 (6 on
baclofen, 4 on
tizanidine), 8
because of side-
effects, two
because of
protocol violation
Neurological disability –
Kurtzke scale
Functional disability –
Pederson functional
assessment
Ashworth score
Subjective assessment
by patient and examiner
Neither drug led to any difference
in Kurtzke or Pederson scales.
No change in upper limb tone. 
In lower limb some improvement
in tone but no significant
difference between the two
drugs. When change in Ashworth
scores for all 4 lower limb joints
added, significant improvement
seen when on tizanidine, not on
baclofen.
Neither drug favoured in patients’
diaries
4/5
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TABLE 8 Tizanidine vs baclofen (cont’d)
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Stien et al.
(1987),
Norway42
DB parallel
group RCT
Tizanidine 23 mg.
Baclofen 59 mg.
6 weeks
N = 40.
Median ages 50 (T), 
45 (B) y.
21 F, 17 M.
Clinically definite MS.
Disease duration median 
14 (T), 13 (B) y.
Stable for >3 months.
Severity of spasticity not
explicitly stated.
Severely handicapped –
nearly all bed-ridden or in
wheelchairs
N = 2.
One in each arm
of the study
Clinical assessment:
Clonus activity.
Ashworth score.
Neurological disability –
Kurtzke scale.
Functional disability –
Pederson functional
assessment.
Neurologist estimate of
muscular resistance and
antispastic efficacy
No difference between drugs and
no overall reduction in clonus
activity ( 8 of the patients treated
with baclofen experienced an
increase in clonus activity.
No difference between drugs.
Neither drug led to any difference
in Kurtzke or Pederson scales.
Regardless of the treatment,
where spasticity did improve it
had no effect on functional
assessment or daily life activities.
Both drugs judged to have had an
antispastic effect in at least half
the patients
4/5
Eyssette 
et al. (1988),
France43
DB parallel
group RCT
Tizanidine 24 mg.
Baclofen 60 mg
(maximum doses).
2 weeks dose titration,
6 weeks stable dose 
(8 weeks total)
N = 100.
Mean age 47 (range 
23–79) y.
43 F, 57 M.
All MS, basis of diagnosis
not stated.
Duration of disease not
stated.
Duration of spasticity not
stated.
All with spasticity
symptoms, severity not
stated.
60 patients were bedridden
(33 T, 27 B)
N = 2.
1 patient in each
group withdrew
due to side-
effects
Overall assessment of
efficacy of treatment.
Locomotor function.
Patient’s state in bed
and in a chair.
Flexor spasms.
Muscle tone
No significant difference.
Tizanidine and baclofen improved
functional status in 80% and 76%
of cases, respectively.
In ambulatory patients there was
no change in walking distance.
At the end of the trial 31 in the
tizanidine group were bedridden
(a reduction of 2) and 29 baclofen
patients were bedridden (an
increase of 2)
3/5
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TABLE 8 Tizanidine vs baclofen (cont’d)
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Rice et al.
(1988),
Canada38,44
DB crossover
RCT
Tizanidine 6–32 mg
daily.
Baclofen 15–80 mg
daily.
3 weeks titration.
5 weeks max. dose on
each drug with washout
period in between
N = 66 entered.
Mean ages 50 (T–B), 
53 (B–T).
31 F, 31 M.
48 completed.
Clinically definite MS.
Duration of disease not
stated.
Both groups had spasticity
for 8 y, predominantly in
the legs, stable for 
>2 months.
All had moderately severe
spasticity.
Spasticity ‘interfered with
activities of daily living’
N = 18, 2 due to
non-compliance,
7 stopped taking
baclofen owing to
weakness, 4
stopped
tizanidine owing
to weakness, 
5 stopped
baclofen due to
nausea
Spasticity measured on
6-point ordinal scale.
Kurtzke functional scale.
Pederson functional
disability scale.
Overall evaluation of
efficacy by investigators,
physio therapists and
patients
No significant differences
between groups.
No change from baseline.
No change from baseline.
Patients, no difference.
Investigators and physiotherapists
both rated baclofen as more
effective overall (p = 0.05,
Fisher’s exact test).
Side-effects: more muscle
weakness experienced by those
on baclofen (statistically significant
at 0.01); patients reported no
difference in tolerability between
drugs, physicians and
physiotherapists reported
tizanidine better tolerated than
baclofen
3/5
Hoogstraten
et al. (1988),
The
Netherlands31
‘Partially blind’
randomised,
crossover
study
Dosage titrated over
2–3 weeks, then held
for 4 weeks. 
3 day washout.
Baclofen dose ranged
from 15 to 60 mg daily,
tizanidine from 12 to 
24 mg daily
N = 16.
All with MS.
All with spasticity for 
>2 months.
10 M, 6 F.
Scored 4–7 on EDSS
N = 5 Kurztke EDSS.
Incapacity status.
AMB.
Ashworth scale.
Patient-evaluated overall
spastic condition,
impairment of activities,
overall disability status,
etc.
‘Based on these … the
efficacy and tolerance of
the treatment were
evaluated …’
Overall, both drugs noted to be
effective, with no significant
difference between them.
Muscular weakness reported in 
6 patients on baclofen, none on
tizanidine.
Of the five withdrawals, one
started on baclofen and withdrew
because of falls due to weakness,
one started on tizanindine and
withdrew because of depression,
three started on tizanidine, then
withdrew in second treatment
period on baclofen because of falls
3/5
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TABLE 9 Tizanidine vs baclofen vs tetrazepam
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Pellkofer 
et al. (1989),
Germany33
DB parallel
group RCT
Tizanidine 2-mg
capsules, n = 15.
Baclofen 5-mg capsules,
n = 16.
Tetrazepam 25-mg
capsules, n = 16.
Number (dose) taken
not specified.
35 days treatment
N = 47.
All with MS >2 y duration,
stable for >2 months.
18 M, 29 F.
Aged 18–65 y
3 dropouts in the
baclofen and
tizanidine groups
due to
ineffectiveness!
Kurtzke scale. 
Pedersen scale. 
Ashworth score.
Zerlsen health status
scale.
Dotes scale
Spasticity reduced on all three
drugs, but no differences between
them in terms of effectiveness.
Side-effects: tizanidine 3
hypotonia, somnolence; baclofen,
1 weakness, somnolence,
dizziness; tetrazepam, 
3 weakness, dizziness,
somnolence
4/5
32 and 61 dropouts, respectively. Tizanidine was
given in doses up to 36 mg daily. In both cases the
primary outcome measure was a variant of the
Ashworth score (not measured in the same way in
both studies). In the larger study, the frequency of
muscle spasms and clonus was also used as a
primary outcome measure.
One study showed a reduction in muscle tone on
treatment that was significantly greater than
placebo, the other did not. In the former study,
the baseline muscle tone in the placebo group was
slightly lower than in the treated group. It should
be noted that the summation and averaging of the
Ashworth scores for individual muscle groups (the
basis on which efficacy was claimed) was
statistically inappropriate, as it is measured on an
ordinal scale. In the latter, the muscle tone was
slightly higher in the placebo group at baseline,
and the fall on placebo was greater than expected.
In this study, which assessed muscle spasm and
clonus as a primary outcome measure, there was a
greater reduction in spasms and clonus in the
treated than in the placebo group. A non-
significant trend towards this was reported in the
other study. Neither study demonstrated any
difference in functional status between the placebo
and treatment groups.
The third placebo-controlled RCT of prolonged
tizanidine use reported no significant difference
between active drug and placebo in Kurtzke EDSS
score, AMB, ‘upper extremity index’ muscle
strength or electrophysiological parameters.
However, there was significant improvement in
limb tone, tendon reflexes and in the overall
assessment made by the investigators in the drug-
treated as compared with the placebo group.36
Comparison with diazepam
One study compared tizanidine with diazepam in
MS patients. Thirty patients were treated with
tizanidine (mean dose 14.3 mg) or diazepam
(mean dose 15.0 mg) for 6 weeks. Clinical effect is
said to have been assessed using Ashworth score,
although how this was done is not explicit. Overall
there was no difference between the two drugs.
Comparison with baclofen
Six studies compared tizanidine with baclofen,
including the ‘partially blind’ study. The study
sizes varied from 16 to 100 patients, with between
0 and 18 dropouts. Tizanidine dosage was in the
range 6–36 mg daily, for a duration of 6–8 weeks.
Two were crossover studies. The severity of
spasticity of patients in these trials appears to have
been greater than in the placebo controlled trials,
with a high proportion moderately or severely
affected and in the largest trial the majority were
bedridden.
Outcome was assessed using a variety of measures,
including the Ashworth score, the Kurtzke and
Pedersen functional assessment scales, and
investigator, physiotherapist and patient
preference. Overall, there was no difference
between the two drugs on any of the outcomes
assessed, with the exception of one study37 which
reported a significant improvement in the
combined Ashworth score for four lower limb
joints on tizanidine but not on baclofen. Moreover,
in the three of the four studies which assessed
functional improvement using the Kurtzke and
Pedersen scales, neither drug produced any
improvement in functional status.
Comparison with baclofen and
tetrazepam
One study consisted of a three-way comparison
between tizanidine, baclofen and tetrazepam.33
Unfortunately, although the capsule strength is
stated, the number of capsules (and hence total
dose) taken by each patient is not explicit. There
were three dropouts (out of 16 and 15 patients) in
each of the baclofen and tizanidine groups due to
ineffectiveness of the treatment. Spasticity is
reported to have been reduced in each of the
three groups, but there was no difference between
them in terms of effectiveness.
Side-effects
Overall, tizanidine is well tolerated. The most
frequent side-effects mentioned are drowsiness
and a dry mouth. In general, a reduction in
spasticity was not achieved at the expense of
muscle strength. Tizanidine was better tolerated
than diazepam, but there appeared to be little
difference between it and baclofen in terms of
frequency and severity of side-effects. However, in
the only study where individual overall preferences
were assessed, patients, investigators and
physiotherapists preferred baclofen over
tizanidine.
Summary
Tizanidine is effective in both the short and
medium term, in comparison with placebo. When
compared with diazepam or baclofen, tizanidine
appears to be equally effective. Whilst tizanidine
has a significant effect on muscle tone, frequency
of spasms and clonus, it has not been shown to
have an effect in terms of functional ability.
However, in view of the relatively small sample
sizes of these studies, there may be a real
Health Technology Assessment 2003; Vol. 7: No. 40
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difference in effect that has been missed (Type II
error). Most of the studies show no difference
between tizanidine and its comparators in terms of
causing muscle weakness. Only two studies found
that tizanidine is less likely to cause muscle
weakness than alternative drug therapy.31,38
Diazepam
Diazepam reduces muscle tone by suppressing
sensory impulses from muscles and skin receptors,
potentiation of GABA action post-synaptically 
and inhibition of excitory descending pathways.
The cost of diazepam (Valium) is £8.58 for 100 
10-mg tablets.10 The maximum recommended
dosage is 60 mg per day. At this dosage the
average daily cost would be £0.52. A more 
typical dose of 20 mg per day would cost just
£0.17 per day.
Quantity of research available and
study characteristics
One single blind comparison of diazepam with
placebo was identified,45 together with six RCTs
comparing diazepam with other active drugs. Two
crossover studies compared diazepam with
baclofen and one with dantrolene, and one
parallel group study compared it with tizanidine.
All of these used diazepam as the comparator
rather than the main intervention, and so are
duplications of other sections of this report (hence
the results are only summarised here). Two studies
compared diazepam with ketazolam and placebo.
Details of the seven studies included in this review
are given in Tables 10–14.
Populations examined
The trial of diazepam against placebo included 21
patients, of whom only four had MS (although the
results for these patients were reported
separately). The disease was of 9–11 years’
duration, causing severe spasticity of the legs. The
age range was 49–62 years.
Of the two studies comparing diazepam with
baclofen, one recruited 40 patients, of whom 34
had definite and two probable MS. The Ashworth
score was 3 or 4 in at least one lower limb. The
other study recruited 17 patients with MS of on
average 17.5 years’ duration. There was one
dropout. Only two of the remaining 16 could walk.
The study comparing diazepam with dantrolene
recruited 46 MS patients from a university
outpatient clinic. They were said to be mainly
ambulatory, with moderate to severe spasticity, but
without severe lower limb weakness. Age, sex and
duration of disease were not stated. The study
comparing diazepam with tizanidine again
recruited only MS patients with mean disease
duration 9 years (basis of diagnosis not stated).
The mean age was 41 years, with 19 women and
11 men. Spasticity was described as ‘moderate to
severe’, but the extent of disability was not
otherwise stated.
Of the two trials comparing diazepam with
ketazolam, one recruited 50 patients, of whom 24
had MS, described as stable, severe and chronic.
Their ages ranged from 18 to 68 years. The other
recruited 17 patients, all of whom had ‘chronic MS
and severe spasticity’.
Outcome measures
The comparison with placebo reported only the
physician and patient overall assessment. Three of
the other studies used the Ashworth scale. In one
case12 this was supplemented by further clinical
evaluation. The comparison with dantrolene25
used measures of 10 physical functions, as assessed
by a neurologist, using clinical and ‘simple
mechanical’ measures. The comparisons with
ketazolam reported summary results of multiple
outcomes, including resistance to passive
stretching, range of motion, reflexes, clonus,
muscle power and pain.
Validity
Little weight can be put on the comparison with
placebo, as it was single blind only, and reported
only four patients with MS. With the exception of
the study in which diazepam was compared with
dantrolene,25 in which patients and evaluators
were not blind to drug dose level (although they
were to drug), the other study designs appear to
have been robust. A further criticism of that study
is that there were multiple outcome measures, 
and multiple comparisons, which must have
increased the chance of a Type I error. Two of the
studies reported four dropouts each, due to side-
effects. There was no explicit consideration of
sample size in any of the studies, and in most
cases they appear to have been a convenience
sample. Small sample sizes imply reduced power
and, thus, may increase the chance of a Type II
error.
Summary of the direction of effect
In both of the comparisons between baclofen and
diazepam, an improvement in the Ashworth score
on treatment with diazepam compared with
baseline was observed. However, no difference was
identified between the two drugs for any of the
measures used.
Results of the systematic review of treatments for spasticity in MS
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TABLE 10 Diazepam vs placebo
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Neill (1966),
UK45
Single-blind
placebo-
controlled
crossover
study
Diazepam 16 mg/day,
increasing after 1 week
to 24 mg/day, continued
for a further 1 week. 
Placebo. 
No mention of washout
between treatments
N = 21.
4 with MS, 9–11 y duration,
with severe spasticity of the
legs.
3 M, 1 F.
49–62 y
None Physician assessment 
(ad hoc scale).
Patient assessment
One patient improved a lot on
diazepam, two improved a little
on placebo, one deteriorated on
placebo.
3 of 4 patients said they felt they
had greater improvement of
spasms on diazepam
1/5
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TABLE 11 Diazepam vs baclofen
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
From and
Heltberg
(1975),
Denmark12
DB crossover
RCT
Baclofen 30–120 
(mean 61) mg/day.
Diazepam 10–40 
(mean 27) mg/day.
4 weeks on each drug
N = 17.
Age 38–68 y.
10 F, 6 M.
All MS.
Duration of disease 3–40 y
(mean 17.5).
All inpatients.
All had symptoms of
spasticity, predominantly in
the lower limbs. Mean
Ashworth score in lower
limbs 2.5.
Only 2 patients could walk,
the remaining 14 either
could not walk at all or
could only walk very short
distances
N = 1, due to
side-effects,
especially
sedation on
baclofen
Ashworth scale.
Change in flexor
spasms.
Clonus.
Walking ability.
Side-effects.
Subjective overall rating
No significant difference between
the two drugs.
No difference between the two
drugs.
No significant difference.
Of the 2 patients who could still
walk, both improved on baclofen,
but one of them deteriorated if
given more than 30 mg due to
weakness. The same patient
deteriorated on 20 mg of
diazepam also. One non-
ambulatory patient lost the ability
to stand on baclofen due to
weakness. 
Patients experienced greater side-
effects on diazepam than on
baclofen especially sedation.
12/16 patients preferred baclofen
to diazepam, 4/16 had no
preference
3/5
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TABLE 11 Diazepam vs baclofen (cont’d)
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Cartlidge 
et al. (1974),
UK13
DB crossover
RCT
Baclofen 30 or 60 mg.
Diazepam 15 or 30 mg.
2 weeks on each dose,
4 weeks total on each
drug
N = 40.
Aged 22–61 y.
19 F, 21 M.
34 had MS ‘in remission’, 
2 ‘probably’ had MS.
4 patients did not have MS.
All patients had a score of 3
or 4 on the Ashworth scale
in one lower limb at least,
but mean Ashworth score
2.87
N = 3, none
connected with
the treatment.
There were no
withdrawals
during low-dose
treatment.
During high-dose
treatment there
were 9 patients
withdrawn on
baclofen and 10
patients
withdrawn on
diazepam. These
patients were
included in the
data analysis
Ashworth scale,
assessed before, and
after low- and high-dose
treatment periods.
The assessed limb was
not specified.
Subjective impression of
patients and doctors
No significant difference between
the two treatments at low dose.
Both drugs produced an
improvement (cf. No treatment)
at both low and high dose, but
this comparison not blinded.
11 patients were unable to
tolerate high-dose baclofen, 
14 high-dose diazepam.
19/37 patients preferred baclofen,
15/37 diazepam.
Doctors preferred baclofen for
18/37 patients, cf. diazepam for
13/37.
Patients on diazepam experienced
more severe side-effects
especially weakness and sedation
4/5
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TABLE 12 Diazepam vs tizanidine
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Rinne
(1980),
Finland41
DB parallel
group RCT
Tizanidine 18 mg.
Diazepam 22.5 mg
(maximum doses).
6 weeks
N = 30.
Age 42 (T), 40 (D) y, mean.
19 F, 11 M.
15 in each group.
Basis of diagnosis not
stated.
Duration of disease 7 (T),
12 (D) y mean.
Duration of stable spasticity
at least 1 year.
Spasticity
‘moderate–severe’.
Extent of disability not
stated
N = 4.
All 4 were on
diazepam and had
to be withdrawn
owing to adverse
reactions
Ashworth scale 9 patients in each group showed
an improvement in spasticity and
there was no significant difference
between the 2 groups.
Overall the tolerability of
tizanidine was significantly greater
than that of diazepam
3/5
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TABLE 13 Diazepam vs dantrolene
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Schmidt
(1976),
USA25
DB crossover
RCT.
The study had
6 evaluation
periods – 2
control, and
low and high
doses of each
treatment
Dantrolene 50–300 mg
q.d.s.
Diazepam 4–20 mg
q.d.s.
Placebo.
Treatment for 4 weeks
with 2 week washout
periods between
treatments
N = 46.
Age, sex not stated.
All were MS outpatients
attending University Clinic.
Duration of disease not
stated.
Moderate – severe
spasticity.
Mainly ambulatory without
severe lower limb
weakness.
Stable for 6 months
N = 4, due to
side-effects
Survey of symptoms.
Measures of 10 physical
functions, assessed by
neurologist blind to
drug, but not blind to
control/low/high dosage.
Patient preference.
Side-effects
No difference between drugs.
Both dantrolene and diazepam
reduced spasticity, clonus and
reflexes at low and high doses
compared with the control. The
effect of dantrolene was more
dose dependent than with
diazepam.
22 preferred dantrolene, 
13 preferred diazepam and 7 had
no preference.
Dose reduced in 15/42 patients
due to side-effects. Diazepam
decreased hand coordination,
reduced hand speed and walking
speed. Dantrolene produced
weakness at low doses whereas
diazepam only produced
weakness at high doses. Weakness
caused by dantrolene was severe
3/5
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TABLE 14 Diazepam vs ketazolam
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Basmajian 
et al. (1984),
Canada46
DB crossover
RCT
Ketazolam (K) 
(3 × 10 mg/day for 
7 days increased to 
3 × 20 mg/day for 
7 days).
Diazepam (D) 
(3 × 5 mg/day for 7 days
increased to 3 × 10 mg
for 7 days).
Placebo (P) (dose
doubled after 7 days).
2 weeks treatment.
1 day washout period
N = 50, of whom 24 had
MS.
Age range 18–68 y (all
patients).
14 M, 10 F (MS only).
All MS patients ‘stable,
severe, chronic, stage.
Almost all patients having
had spasticity for 1 year
(MS patients
only.)
N = 4
Resistance to passive
stretching.
Range of motion.
Reflexes.
Clonus.
Muscle power.
Pain, motor status,
spasm and function
(subjective impression).
EMG
(MS patients only.)
(Summary results for all outcomes
reported only.)
K vs D = no significant difference.
K vs P = statistically significant
difference (p = 0.05) in favour of
K.
D vs P = statistically significant
difference (p = 0.05) in favour of
D.
4/5
Basmajian 
et al. (1986),
Canada47
DB crossover
RCT
Ketazolam (K) 
[1 × 10 mg + 2 × 10 mg
placebo (P)/day for 
7 days increased to 
1 × 20 mg + 2 × 20 mg
P/day for 7 days].
Diazepam (D) 
(3 × 5 mg/day for 7 days
increased to 3 × 10 mg
for 7 days).
Placebo (P) (dose
doubled after 7 days).
2 weeks treatment.
1 day washout period
N = 17.
All with ‘chronic MS and
severe spasticity’.
No further details reported
N = 3 Resistance to passive
stretching.
Range of motion.
Reflexes.
Clonus.
Muscle power.
Pain, motor status,
spasm and function
(subjective impression).
EMG
(Summary results for all outcomes
reported only).
K vs D = no significant difference.
K vs P = no significant difference.
D vs P = no significant difference
4/5
Similarly, in the comparisons with dantrolene and
tizanidine, a reduction in spasticity was observed
on treatment with diazepam, but the extent of this
reduction was no different to that seen with the
comparator drug.
In the comparison between diazepam and
ketazolam, no significant difference was reported
between the two active drugs. In the larger there
was a significant difference between both active
drugs and placebo in the overall effect on all
measured outcomes.
Preferred treatment
In both of the comparisons between diazepam and
baclofen, slightly more patients favoured baclofen
over diazepam than the other way round. This
does not appear to have been statistically
significant. In the comparison with dantrolene, 
22 patients preferred dantrolene and 13 preferred
diazepam.
Impact on function
No details are given of the impact of diazepam
treatment on patient functioning.
Side-effects
In the comparisons with baclofen, dantrolene and
tizanidine, diazepam caused significantly more side-
effects than the comparator drug. The commonest
reported side-effects were sedation and weakness.
Four patients in each of two trials25,41 had to
withdraw from the study because of the side-effects.
Summary
Diazepam appears to lead to a reduction in the
Ashworth score, but it is no more effective than
the four drugs with which it was compared, and
caused significantly more side-effects.
Gabapentin (Neurontin)
Gabapentin is an anticonvulsant drug licensed for
the treatment of partial seizures. It is structurally
similar to the neurotransmitter -aminobutyric
acid (GABA), but it does not bind to GABA
receptors, and the mechanism of action is
unknown. It is readily absorbed after oral
administration, and excreted unchanged in the
urine. The cost of treatment is £0.23, £0.53 and
£0.61 for 100-, 300- and 400-mg capsules,
respectively.23 A typical dose of 1.2 g daily would
therefore cost approximately £1.83.
Recently, the serendipitous observation that when
administered to patients with MS with paroxysmal
symptoms it led to an improvement in spasticity
has led to its effect on spasticity being explicitly
assessed.
Quantity of research available
Four studies were identified. One was an open-label
report of the effect of gabapentin on paroxysmal
symptoms in MS48 and another a report of two
cases.49 The other two were randomised, placebo-
controlled, crossover studies50,51 of its effect on
spasticity in MS. These latter two are analysed here
and are summarised in Table 15.
Populations examined
Both studies included only patients with definite
MS. One described the patients as having a
‘laboratory-supported’ diagnosis, the other as
having chronic progressive MS. The extent of
disability appears to have differed between the two
studies. In one, the mean duration of disease was
8.4 years, and the median EDSS score was 12 (pre-
gabapentin) or 13 (pre-placebo). [The EDSS
strictly runs from 0 to 10 (death), with intervals of
0.5. It appears that the authors of this paper have
reported it as running from 0 to 20, with intervals
of 1.0, although this is not explicit. It is likely,
therefore, that these EDSS scores ought to be
halved for comparison with other quoted scores.]
The other study recruited veterans (hence 20 men
to two women), whose EDSS scores were 6–9. The
overall age range was 31–67 years.
It is not possible to compare the degree of
spasticity at baseline. In one study,51 a modified
Ashworth score is used, but the way in which it has
been modified is not explicit, and the results given
are not interpretable in absolute terms. In the
other, the median Ashworth score at baseline was 2.
Interventions
Both trials were of short duration. In one,
gabapentin was administered at 400 mg three
times daily for 48 hours, with an 11-day washout.
In the other, the dose was 300 mg three times
daily for 2 days, then 600 mg three times daily for
2 days, then 900 mg three times daily for the final
2 days, a total of 6 days of treatment altogether,
with a 14-day washout. Both studies randomised
patients to receive gabapentin or placebo first.
Outcomes measured
The studies assessed a variety of outcomes. These
included clinical assessments (in both cases
including the Ashworth score, although in one of
these it had been modified in a way which was not
explicit),51 subject-reported assessments and the
Kurztke EDSS.
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TABLE 15 Gabapentin vs placebo
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Mueller et al.
(1997),
USA51
DB crossover
RCT
Gabapentin 400 mg
t.d.s.
Placebo.
48 h treatment.
11 day washout
N = 15.
Laboratory-
supported, definite
MS.
Mean age 42 y
(range 31–59).
Mean duration of
disease 8.4 y.
Median EDSS score
12 (pre-gabapentin),
13 (pre-placebo)
0 Ashworth scale
(modified; details not
explicit).
Clinical assessment of
clonus, reflexes,
response to noxious
stimuli.
Kurtzke EDSS.
Visual faces scale (pain)
Significant fall (p = 0.007).
No change.
Decrease in median score from 12 to 10 on
gabapentin, from 13 to 12.5 on placebo 
(p = 0.03)a
Decrease in median score from 2 to 1.5 on
gabapentin, no change on placebo 
(p = 0.008)
4/5
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TABLE 15 Gabapentin vs placebo (cont’d)
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Cutter et al.
(2000),
USA50
DB crossover
RCT
Gabapentin 300 mg
t.d.s. for 2 days, 
600 mg t.d.s for 
2 days, 900 mg t.d.s
for 2 days.
Placebo.
14 day washout
N = 22.
All had chronic
progressive MS.
Ages 34–67 y.
20 M, 2 F.
All veterans treated
at Denver VAMC.
Kurztke EDSS 6–9
1 (M), after 1 day
on gabapentin,
due to headache
Subject reported:
Spasm frequency scale.
Spasm severity scale.
Interference with
function scale.
Painful spasm scale.
Global assessment.
Physician reported:
Modified Ashworth
scale.
Clonus score.
Deep tendon reflexes.
Plantar stimulation
response.
Kurztke EDSS.
Digit span and digit
symbol portions of the
WAIS-R.
Fatigue impact scale.
Adjective generation
technique
Effect of gabapentin vs
baseline
Reduced (p = 0.0001)
Reduced (p = 0.0004)
Reduced (p = 0.002)
Reduced (p = 0.002)
Reduced (p = 0.0001)
Reduced (p = 0.0005)
Reduced (p = 0.002)
Reduced (p = 0.0001)
Reduced (p = 0.008)
Reducedb (p = 0.006)
Change on
gabapentin vs
change on placebo
Fall on G > fall on
P (p = 0.01)
Fall on G > fall on
P (p = 0.02)
Fall on G > fall on
P (p = 0.03)
Impact of G >
impact of P 
(p = 0.003)
Fall on G > fall on
P (p = 0.04)
Impact of G >
impact of P 
(p = 0.03)
4/5
a See the comment in brackets in the section Populations examined.
b Placebo administration also resulted in a reduction in the fatigue impact scale (p = 0.03) and the deep tendon reflexes (p = 0.04).
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Validity of included studies
Both studies were of relatively high quality, 
scoring four out of five on the Jadad scale. 
Both were randomised and double blinded.
Appropriate use was made of non-parametric
statistics. One used a p value of 0.05 as a 
threshold for statistical significance, despite a
multiplicity of comparisons,50 but does quote the 
p values for those comparisons which it reports as
statistically significant.
Summary of direction of effect
Both studies reported benefits, in terms of a
reduction in spasticity, on treatment with
gabapentin. The study which titrated up to the
higher dose of gabapentin50 reported a significant
effect on all the physician-assessed measures of
spasticity, and the other study also reported a fall
in the (modified) Ashworth score (but no effect on
clonus, reflexes or response to noxious stimuli).
Subject-reported outcomes (spasm frequency,
severity, interference with function, pain) were all
also reduced in the higher dose study.
Preferred treatments
The one study which recorded an overall subject
global assessment50 reported a clear preference for
gabapentin over placebo. A total of 71% of
patients reported spasticity as a little or a lot
better on gabapentin, compared with 24% on
placebo.
Impact on function
The Kurtzke EDSS score was improved from 12 to
10 (see the comment in brackets, in the section
Populations examined, above) in patients given
the lower dose for 48 hours, but did not alter in
the higher dose study. In that study, however,
‘anecdotally, subjects reported improved activities
of daily living (despite no change on the EDSS),
and improved sleep, mood, and appetite’. This
difference may be explained by the different
baseline levels of disability.
Side-effects
Gabapentin is reported to cause fatigue and
decreased concentration. The lower dose study
reported ‘no serious side-effects’. The other study
used four different psychological measures of
fatigue and concentration, and did not
demonstrate any adverse impact of gabapentin.
One patient, however, withdrew after 1 day on
gabapentin, because of a reported headache.
Summary
These two studies provide some evidence that
gabapentin is effective in alleviating clinical
measures of spasticity, at least in the short term.
The longer term effect of the drug on spasticity is
not established, but on the basis of these findings,
warrants further investigation. 
Progabide (halogabide)
Progabide is a GABA receptor agonist which was
formerly available as an anticonvulsant drug. It is
not currently marketed. 
Quantity of research available
One DB crossover RCT was identified.53 Details
are given in Table 16.
Populations examined
Seventeen patients were included in the study, of
whom 14 had MS, of between 2 and 33 years’
duration. The disease was said to have been stable
for at least 2 months. Five were women and nine
were men.
Interventions
Progabide, at a median dose of 1800 mg per day,
was given for 2 weeks, and placebo for 2 weeks in
a crossover trial.
Outcomes measured
The joint angle at which a stretch reflex appears,
the frequency of flexor spasms, muscle power and
the global therapeutic effect as assessed by the
investigator and patient were all reported as
outcomes. No evidence was given that any of the
scales used were validated.
Validity of included studies
The study scored four out of five on the Jadad
scale.
Summary of direction of effect
The joint angle at which the stretch reflex
appeared increased in 14 out of 16 patients (the
results for MS patients were not reported
separately), but the overall ‘evaluation of the reflex
response’ was not altered. Flexor spasm frequency
was reduced in nine out of 16 patients (p < 0.05).
Muscle power was not affected. 
Preferred treatments
Treatment was assessed as beneficial by the
investigator in 87% and by patients in 81% of
cases. The magnitude of the effect was judged as
‘medium’ or ‘important’ in seven cases each.
Impact on function
No details were reported on impact on function.
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TABLE 16 Progabide vs placebo
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Mondrup and
Pedersen
(1984),
Denmark53
DB crossover
RCT
Progabide, median dose
1800 mg/day, for 
2 weeks, placebo for 
2 weeks
N = 17.
Results reported in 16, 14
with MS, duration 2–33 y,
stationary phase of disease
for >2 months.
5 F, 9 M
N = 1, on
placebo, due to
urinary tract
infection
Measurement of joint
angle at which stretch
reflex appears, and
duration of response.
Evaluation of reflex
responses.
Frequency of flexor
spasms.
Flexor reflex of lower
limbs.
Voluntary muscle
power.
Global therapeutic
effect assessed by
investigator and patient
Angle at which stretch reflex
appeared increased in 14/16
patients.
Not significantly altered.
Reduced in 9/16 (p < 0.05).
Not significantly altered.
Not significantly altered.
Assessed as beneficial by
investigator in 87% and by patient
in 81% of cases. Magnitude of
effect judged as ‘medium’ or
‘important’ in 7 cases each.
No side-effects registered
4/5
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Side-effects
No side-effects were reported.
Summary
This single trial suggested that progabide may
have an antispastic effect in patients with MS.
However the study was small, of short duration
and did not report on functional outcomes. At best
it can be taken as an indicator that more research
is needed.
BT (Botox, Dysport)
BT A is one of seven neurotoxins produced by the
bacterium Clostridium botulinum. It causes the
clinical syndrome of botulism, a progressive flaccid
paralysis, following ingestion of the toxin.
Paralysis is caused through preventing the release
of acetylcholine from nerve endings, thus causing
a presynaptic neuromuscular block. Injection of
very small doses of the toxin produces local
paralysis, and individual muscles can, therefore, be
weakened. The duration and extent of the
paralysis depend on the dose administered.
BT is licensed for the treatment of blepharospasm,
spasmodic torticollis and hemifacial spasm in
adults, and dynamic equinus foot deformity due to
spasticity in ambulant paediatric cerebral palsy
patients. It is not currently licensed for treatment
of spasticity in MS in the UK.
The cost of one vial of Botox (100 units) is
£128.93 and that of Dysport (500 units) is
£164.74.23 Trials have used between 50 and 
400 units. The cost of treatment would also
include the cost of disposables (needles, syringes,
etc.) and the time of the clinician who administers
the injection(s). The units employed for the two
brands are not interchangeable and are not
equivalent. The total dosage of Botox should be
no more than 200 units and no more than 50
units at one site. The initial recommended dosage
of Dysport is 500 units per patient in total.
Depending on the clinical response, the dosage of
Dysport can range from 250 to 1000 units. It
should be noted that BT therapy would normally
be carried out in conjunction with a regime of
physiotherapy which would add to the total 
cost of treatment. A single treatment of BT 
should last for between 6 and 12 weeks. If one
assumes an average duration of a single treatment
to be 8 weeks, then the cost of treating two muscle
sites with Botox would be £2.30 per day. This
excludes other costs such as the syringe and
physiotherapy.
Quantity of research available
Twelve papers were identified, of which two were
reviews. Of the remaining 10 studies, only five
were retained for this review. One was excluded
because, although the study was on the treatment
of spasticity, it did not include patients with MS,54
and the other four were discarded because they
were either single case studies or a report of two
cases only.
Details of the five papers selected for inclusion in
this review are given in Table 17. Of the five
included, two were open-label studies of patients
administered the treatment, with longitudinal
follow-up.55,56 One of these was primarily
concerned with documenting the role of EMG in
determining the suitability of muscles for
treatment and monitoring toxin effect.55 The
other three were DB placebo-controlled crossover
RCTs, two of which recruited exclusively MS
patients whereas the other did not. In one study,
the second treatment was administered 3 months
after the first,57 whereas in another, the second
treatment was administered 2 weeks after the first,
or when any clinical effect of the first had worn
off. This indicates that clinical effects were
obvious, which calls into question the effectiveness
of the blinding (to both patient and physician).
Populations examined
All patients in the selected studies had chronic or
severe spasticity and in many cases were non-
ambulant. Two studies recruited only patients with
MS. One recruited nine women, one man, mean
age 40 years, from long-stay institutions, none of
whom were ambulant, and whose mean disease
duration was 18 years.57 The other recruited 74
patients (46 women, 28 men), with disease of
16–23 years’ duration.58 The other studies were
not restricted to MS patients. No information is
given about functional status, except for the two
patients in the case reports.59 In one of these the
main problem arising from the spasticity is said to
have been scissoring, which interfered with
walking between parallel bars. In the other, the
main problem was flexor spasms.
Intervention
BT was administered intramuscularly. One RCT
used a total of 400 mouse units (10 units = 4 ng)
in three different muscle groups.57 (One mouse
unit is the median lethal intraperitoneal dose for
mice.) A second RCT used 25–250 units of Botox
(titrated according to muscle bulk).60 The third
RCT was a dose-ranging study, using doses of 500,
1000 or 1500 units of Dysport to treat both legs
simultaneously on a single occasion.58 The other
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TABLE 17 BT studies
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Snow et al.
(1990),
Canada57
DB placebo-
controlled
crossover
RCT
BT (non-commercial
preparation).
160 ng (400 units)
administered
intramuscularly in 
3 muscle groups.
6 weeks
N = 10.
Mean age 40 y (23–61).
9 F, I M.
All had stable MS with a
mean duration of 18 y.
Non-ambulant. Recruited
from long-stay institutions
N = 1, 
on placebo
Scale adapted from the
Ashworth scale.
Spasm frequency score.
Hygiene score
BT showed significant reduction 
in spasticity over placebo 
(p = 0.009).
Frequency score in treatment
group decreased from mean 2.9
to 2.7, but this was not significant.
Statistically significant
improvement in treatment group
in hygiene score (p = 0.009). 
No change in placebo group.
The greatest benefit was found in
the most severely affected
patients.
No adverse effects were noted
5/5
Grazko et al.
(1995),
USA60
DB placebo-
controlled
crossover
RCT
BT (Botox).
25–250 units.
Placebo.
Treatment 2 given 
2 weeks after treatment
1, or when any clinical
effect had worn off
Total N = 20, of whom 12
had spasticity, and of these
5 had MS.
Basis of diagnosis not
stated.
3 F, 2 M.
Ages 40–66 y.
Baseline Ashworth score
3–4+
N = 0 Modified Ashworth
scale
Reduction of at least two grades
on the Ashworth score in all five
patients with MS, lasting 1–3
months.
‘Subjective improvements in
movement and posture’
3/5
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TABLE 17 BT studies (cont’d)
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Cava (1995),
USA56
Open trial.
Patients were
followed up
every 
2 weeks, but
the total
duration of
the study is
not clear.
The duration
of effect was
found to be
3–6 months
BT (Botox). 
Intramuscular dose per
muscle varied from 40
to 180 units.
Maximum dose range
270–300 units
N = 16, 10 of whom had
MS (MS patients who had
taken corticosteroids in
previous 6 months
excluded).
All aged >18 y.
All had dysfunctional limb
spasticity but no details of
functional status
N = 0 Modified Ashworth
scale.
Frequency of spasm
scale.
Pain scale
13/16 patients (8/10 MS patients)
showed significant improvements.
There was no change in 3 patients
(2/3 were MS patients).
Mean Ashworth score changed
from 2.6 to 1.3. This change was
statistically significant. Tone
improved 2–6 weeks after
treatment.
Spasm frequency also declined but
it was not statistically significant.
There was a large reduction in
pain particularly in the MS
patients.
Adverse effects were minimal,
mainly temporary bruising
0/5
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TABLE 17 BT studies (cont’d)
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Finsterer 
et al. (1997),
Austria55
Prospective,
open-label,
uncontrolled
longitudinal
with follow-up
after 17–57
days after
initial injection
BT (Dysport).
Mean intramuscular
dose per patient 276
units.
Mean dose per muscle
116 units.
3 of the patients had a
booster dose owing to
lack of response initially.
The number of muscles
treated was between
one and five. Muscles
were selected for
injection if their TAA
>150a
N = 9.
Mean age of MS patients =
52 y.
4 F and 1 M.
5 had severe spasticity, 
3 had right upper or lower
limb spasticity and 1 had
tetraspasticity.
The spasticity was due to
MS in 5 cases.
The average duration of
spasticity in MS cases was
16 y
N = 0 TAA (EMG measure)
ADL.
Pain.
Muscle tone
(Ashworth scale).
Range of motion
All outcome measures were
assessed on a 5-point scale by the
doctor, not the patient. The
duration of follow-up varied.
There is no evidence that this
scoring system has any validity.
All 5 MS patients showed an
improvement in TAA, mostly by at
least 2 points.
4/5 MS patients showed an
improvement of 1 point.
4/5 patients showed an
improvement in pain.
3/5 MS patients showed an
improvement.
3/4 MS patients showed an
improvement.
Scores for all patients improved at
a statistically significant level.
Improvement did not appear to
be dose dependent.
The injection was tolerated by all
patients without complaint and
there were no major side-effects
0/5
continued
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TABLE 17 BT studies (cont’d)
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Hyman et al.
(2000), UK58
DB placebo-
controlled,
dose-ranging
RCT
BT (Dysport) 
500 (n = 21), 
1000 (n = 20), 
1500 (n = 17) units or
placebo (n = 16).
Single treatment (both
legs) only
N = 74.
All with probable or
definite MS, with
disabling spasticity of hip
adductors, Kurtzke
Expanded Disability
Status (KEDS) ≥ 7,
stable for 6 months,
moderate pain or
difficulty in nursing,
hygiene score ≥ 2.
46 F, 28 M.
Mean duration of MS
16–23 y.
Mean ages 47–54 y.
Concomitant
medication continued
N = 2 prior to
week 4, N = 14
prior to end of
study at week 12,
due to need for
retreatment
Angles of active and
passive hip abduction.
Maximum distance
between knees on
passive hip abduction.
Modified Ashworth
score (muscle tone ×
spasm frequency).
Upper leg pain (4-point
scale).
Clinical global rating 
(4-point scale).
Perineal hygiene score
(6-point scale).
Overall investigator and
patient rating.
Time to retreatment.
Primary analysis was
performed on the
change from baseline at
week 4
Passive abduction increased in all groups,
no difference between groups.
Statistically greater increase in 1500-U
group than in placebo (p = 0.02).
Improved in all groups, no difference
between groups, although in placebo
group, unlike the treated groups, the
improvement was due to a reduction in
spasm frequency only, with no reduction
in tone.
Proportion pain free increased in all
groups, no difference between groups.
Median rating improved from severe to
moderate in all groups.
Median score unchanged in placebo and
500-U groups, improved from 2 (one
person able to clean/catheterise with
effort) to 1 (the same, with ease) in
1000- and 1500-U groups.
Similar in all groups.
Median time to retreatment 56, 99, 111,
119 days in placebo (n = 7), 500-U 
(n = 8), 1000-U (n = 10), 1500-U 
(n = 9) groups, respectively 
(p = 0.015).
Adverse events reported in 55% of
patients on active treatment, 63% on
placebo
5/5
a TAA, turn/amplitude analysis.
studies used between 50 and 400 units of each
preparation. The RCTs used a single dose only,
whilst in the other studies some patients received
booster injections.
Outcomes 
All three RCTs used the Ashworth scale, either as a
direct measure of spasticity60 or combining the
Ashworth score (muscle tone) with a score of
spasm frequency.57,58 One measured the angle of
active and passive hip abduction and the
maximum distance between the knees on passive
abduction.58 Two measured a hygiene score.57,58
One measured in addition a ‘clinical global
rating’, overall investigator and patient rating, and
the time to retreatment.58
One of the case series56 also reported on the
modified Ashworth scale and spasm frequency.
The other case series55 used a specifically
designed efficacy score, which incorporated
activities of daily living, pain, tone, passive range
of motion and turn/amplitude analysis count (an
EMG measure of muscle activity).
Validity
One of the RCTs which recruited exclusively MS
patients appears to have been conducted in an
exemplary fashion and, therefore, to be robust,
except that the authors appear to have used their
own adapted version of the Ashworth scale.57
Appropriate sample size calculations had been
undertaken. The evaluations were undertaken
‘blind’ by two separate neurologists, with a high
degree of correlation between them (correlation
coefficient 0.93 for spasticity score, 0.81 for
hygiene score). However, there is no evidence to
support the validity of the scales used. The
researchers claim to have based their assessment
of the degree of muscle tone on the Ashworth
scale, but the categories used in the study bear no
relationship to published versions of the scale.
The second RCT which recruited only MS patients
also scored 5/5 on the Jadad scale. Unfortunately,
there again is no evidence for the validity of the
rating scales used. That study was unable to recruit
the 80 patients required to gain 90% power to
detect a difference at the 5% level, and was
calculated to have only an 80% power.
In the other RCT the blinding is questionable,
which may have led to bias in reporting.
The validity of the other studies, being neither
randomised nor blinded, and of limited sample
size, must be questionable. However, the use of
small, open-label trials with this condition and
intervention is understandable. Because relatively
little evidence is available, their findings are
reported here.
Finsterer and colleagues55 claimed to be using the
modified Ashworth scale, but were in fact using
the earlier shorter version of the scale.61
Spasticity specific outcomes
In the RCTs, there was a significant reduction in
spasticity scores following treatment with BT,
which was not seen following placebo injection. In
one of the MS-only studies, the main contribution
to the decline in spasticity score was the decrease
in muscle tone (quoted as a decrease of 2.6 on a
five-point scale, but as it is a non-continuous scale
the appropriateness of this figure is questionable).
There was no statistically significant decrease in
spasm frequency. There was no evidence of any
carryover effect.57 In the second MS-only study,58
spasticity, as measured by the product of muscle
tone and spasm frequency improved in all groups
(including those treated with placebo), but in the
placebo-treated group this was due to a reduction
in spasm frequency only, not a reduction in muscle
tone. This study claims that there is a reduction in
hip adductor spasticity on treatment, although the
only significant changes observed were an increase
in the maximum distance between the knees on
passive abduction and an increased time to
retreatment in treated rather than placebo groups.
There does appear to have been a dose-response
effect.
In the case series, muscle tone was also observed
to fall (in eight of 10 MS patients in one study,56
and three of five in the other55), with a maximum
effect at 2–6 weeks post-treatment.
Preferred treatment
None of the studies reported patient preference.
Impact on function
In one of the MS-only RCTs, there was a
statistically significant improvement in hygiene
score following BT treatment (400 units), which
was not seen following placebo. The greatest
clinical benefits occurred in patients with the
highest initial scores. In two patients, one nurse
was able to perform care that had previously
required two. In another, a chronic perineal
excoriation became accessible to treatment and
healed. However, in four of the nine patients the
change in hygiene score was negligible or nil.57 In
the second MS-only RCT, hygiene improved in the
two groups of patients administered the higher
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doses (1000 or 1500 units), but not on placebo or
the lower dose (500 units).58 The validity of the
hygiene score is questionable. In the other RCT,
there were ‘subjective improvements in movement
and posture’.
In the case series which reported specifically on
the effect on activities of daily living (ADL), four
out of five MS patients were said to have had an
improved ADL score.55 The other case series, and
the case reports, also reported significant
functional improvement.
Side-effects
One of the RCTs reported adverse events in 55%
of patients on active treatment, compared with
63% of patients on placebo.58 The only other side-
effects reported were bruising of the injection site
in three patients in one of the case series.56 This
resolved within 24 hours. The potential for
overweakening muscles with high doses is noted.
Interestingly, the RCT which was not restricted to
MS patients, and which used a slightly lower dose,
reported that there was ‘no significant muscle
weakness’, which the authors attributed to titration
of dose against muscle bulk.
Summary
Although BT is not licensed in the UK for the
treatment of spasticity in MS, there is evidence
that it is effective. Because it has its effects
through causing paralysis, its role is restricted to
those cases in whom the relief of spasticity is of
greater functional benefit than retaining any
muscle strength. In practice, this is likely to be
only the most severely disabled patients. Much of
the benefit will come from allowing more effective
carer support.
Intrathecal baclofen
The site of the antispastic effect of baclofen (see
above) is the spinal cord. As the drug has poor
lipid solubility, it does not cross the blood–brain
barrier well, so relatively low concentrations are
found in the cerebrospinal fluid (CSF) in response
to an oral dose (unfortunately, it does cross into
the cerebral CSF in sufficient quantities to cause
side-effects). The administration of baclofen
directly into the spinal canal through a
programmable infusion pump allows a continuous
supply of drug to the site of action while
potentially avoiding side-effects. Costs, which
include the cost of the drug together with the cost
of administration, are referred to in the review of
economic evidence below.
Quantity of research available
Twenty studies evaluating the use of intrathecal
baclofen were identified. Five were excluded
because the number of patients with MS was less
than 50% of the total and the results for this
group of patients were not presented separately.
Fifteen studies are included in this review, details
of which are summarised in Table 18. Four
studies62–65 come from the same centre, and it is
not clear to what extent the patients were included
in more than one of them.
Of these, one66 was a DB RCT lasting 13 weeks.
Another was a short-term (3 days) crossover
RCT,63 whilst another study67 used a DB
randomised technique in the initial screening to
assess initial response to a bolus dose before
recruiting subjects into the open-label,
uncontrolled studies. The remaining 12 studies
were longitudinal, open-label, uncontrolled
designs or case series.
It is unfortunate, but understandable, given the
complex nature of this intervention, that there was
only one longer term DB RCT. Researchers may
be either unable or unwilling to randomise or
blind subjects. Many factors militate against the
use of a DB RCT design for this treatment in
patients with MS, including the invasive nature of
the intervention, possible ethical objections, the
need to titrate dosage over time and the large
number of treatment-related complications.
Despite the obvious potential for bias arising from
the design of the other studies, they have been
included in this review because of the lack of other
evidence. The duration of treatment in the studies
ranged from 4 months to 6 years.
Populations examined
None of the studies was restricted to patients with
MS. However, in all included studies 50% or more
of the subjects had MS, or the results for the MS
patients were shown separately. In all 15 studies all
patients had severe spasticity and in six studies the
subjects were stated explicitly to be unresponsive
to oral therapy. In most of the studies the subjects
were non-ambulatory and most had had their
condition for a long time.
The populations studied in these papers can be
regarded as broadly similar.
Intervention
All studies examined the effect of baclofen
administered intrathecally by programmable
continuous infusion pump. Most of the studies
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TABLE 18 Intrathecal baclofen studies
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured (MS patients only) quality
(Jadad)
Saltuari et al.
(1992),
Austria,
Italy72
Prospective,
longitudinal,
uncontrolled
Intrathecal baclofen.
Mean final dose for MS
patients 239 g/day.
Treatment duration
2–24 months
N = 11, of whom 6 had
MS. 
Ages 30–57 y.
5 F, 1 M.
Disease duration 6–27 y
None
documented
Ashworth scale.
Reflexes assessed on a
six-point scale.
Physician and
physiotherapist
assessment of motor
performance
Results in MS patients not
reported separately. Mean
Ashworth score for Knee flexion
reduced from 3.4 to 1.25, for
knee extension from 3.4 to 1.4.
Patellar reflex score reduced from
~3.9 to ~1.4.
One MS patient reported to be
able to use staircase.
4 catheter dislocations, one
catheter break, one catheter
torsion
N/A
Becker et al.
(1995),
Canada68
Prospective,
longitudinal,
uncontrolled
Intrathecal baclofen.
Mean dose at follow-up
for MS patients 
542 g/day.
Treatment duration 
13–34 months
N = 9, of whom 6 had MS.
Ages 34–56 y.
4 F, 2 M.
All were non-ambulatory
and many could not sit
properly owing to their
severe spasticity.
The MS patients were all
severely disabled, with little
or no leg function and
marked arm weakness.
6/9 were unable to live at
home.
Average duration of MS
16.5 y
None
documented
Nursing assessment of
transfers, pain control,
nursing care and skin
breakdown.
Self-reported
satisfaction survey of MS
patients (1–5 score).
Place of residence.
No. of days in hospital
There were major improvements
in transfers (5/6), pain control
(4/6), nursing care (5/6) and skin
breakdown (5/6).
All items showed major
improvements, in particular, the
ability to transfer, seating ability,
personal hygiene, sleeping ability
and pain control.
3 out of the 6 MS patients who
were previously hospitalised were
able to be discharged.
The average time spent in hospital
reduced from 108 to 28 days per
year.
There were a number of
significant complications, including:
surgical catheter revisions,
pseudomeningocele repair and
problems with pump refills
N/A
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TABLE 18 Intrathecal baclofen studies
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured (MS patients only) quality
(Jadad)
Broggi et al.
(1993), Italy69
Prospective,
longitudinal,
uncontrolled
Intrathecal baclofen. 
Mean dosage in MS
patients 178 mg/day.
Mean duration of
treatment 9 months
N = 12, of whom 4 had
MS.
2 F, 2 M.
Mean age 50 y.
Mean duration of disease
16 y.
Unresponsive to oral
therapy.
Mean Ashworth score 3.8.
All MS patients were
bedridden
None Ashworth scale.
Frequency of spasm
scale
Mean score before treatment was
3.8; this fell to 1.8 after
treatment.
Muscle spasms were abolished.
No reported side-effects in MS
patients. There were pump-
related complications in other
patients
N/A
Penn et al.
(1989),
USA63
DB crossover
RCT
Intrathecal baclofen. 
100–150 g/day or
saline administered for 
3 days in randomised
crossover trial.
Long-term follow-up for
mean of 19 months
(mean dose 
223 g/day)
N = 20, of whom 10 had
MS.
Ages 31–62 y.
7 F, 3 M.
One MS patient able to
walk a short distance with
crutches, the rest
wheelchair bound.
Mean Ashworth score 4.0
None
Ashworth scale, spasm
frequency (0–4),
laboratory analysis of
motor control,
neurological
examination by
neurosurgeon, patient
assessment of ‘on’ and
‘off’ periods
In MS patients:
No explicit results given for the
short-term crossover trial, but
period of baclofen infusion said to
have been correctly identified by
each assessment.
In long-term follow-up, mean
Ashworth score decreased from
4.01 to 1.05, mean spasm score
decreased from 2.9 to 0.2.
Of 20 patients, in 26 months
follow-up, 2 catheters dislodged,
one pump failure, one painful
implant site
3/5
Parke et al.
(1989),
USA64
Long-term
follow-up
Intrathecal baclofen. 
67–550 g/day.
3 and 6 months follow-
up
N = 8, of whom 4 had MS. 
May be same patients as
included in other studies
from the same centre62,63
None Ashworth scale.
Functional outcomes
using PECS (Patient
Evaluation Conference
System) scale
Ashworth score reduced from 4
or 5 to 1 in all 4 MS patients.
Bladder care score improved in all
4 patients (indwelling urinary
catheter removed in one patient),
dressing skills improved in 2 of 4
patients
N/A
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TABLE 18 Intrathecal baclofen studies
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured (MS patients only) quality
(Jadad)
Penn (1992),
USA65
Case series Intrathecal baclofen. 
Mean initial dose 
200 g/day
N = 66, of whom 33 had
MS. Presumably some of
the same patients as
included in other studies
from the same centre62–64
N = 2, because
they needed
extension rigidity
for standing
Ashworth scale.
Spasm scale (0–4)
For all patients:
Pre-implantation mean score
~3.7 falling to ~1.4 after
implantation, maintained for up to
81 months.
Pre-implantation mean score
~2.9 falling to ~0.8 after
implantation, maintained for up to
81 months.
Complications: 1 meningitis, 
1 pocket infection, 19 fungal
infection of pumps (no clinical
impact, all replaced), 9 pump
failures out of 91 pumps, 25
catheter complications (various), 
5 procedural complications.
Complications of baclofen:
drowsiness (22), dizziness(10),
blurred vision (10), slurred 
speech (6)
N/A
Broseta et al.
(1989),
Spain73
Prospective,
longitudinal,
uncontrolled
Intrathecal baclofen.
60–172 g/day.
Mean follow-up 
5 months
N = 8, of whom 4 had MS.
Ages 27–54 y.
3 F, 1 M.
All had severe spasticity
and were unresponsive to
oral treatments.
Ashworth score 2–4.
4 cases were either in a
wheelchair or bedbound
None Ashworth scale.
Frequency of spasm
score.
Functional assessment
All patients showed a reduction of
at least one point on the scale.
All patients showed a reduction in
frequency of spasms.
All 4 cases had increased walking
ability, transfers and daily activity.
The non-ambulatory patients
gained only in QoL and comfort
N/A
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TABLE 18 Intrathecal baclofen studies
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured (MS patients only) quality
(Jadad)
Coffey et al.
(1993),
USA67
Screening
protocol was
a DB RCT,
followed by
open-label
longitudinal
study
Intrathecal baclofen.
Mean starting dose 
171 g/day.
Mean dose at follow-up
320 g/day.
Placebo.
Patients followed-up
after a mean of 
19 months 
(5–41 months)
N = 93 patients screened,
of whom 31 had MS.
75 patients had a pump
implanted, of whom 27 had
MS.
53 of the 75 were male.
Average age 42 y.
All had severe chronic
spasticity and were
refractory to oral drugs
N = 1, due to
late surgical
complication
(pump pocket
infection)
Ashworth scale
(adapted slightly).
Frequency of spasm
score (0–5)
Mean score for MS patients with
intrathecal baclofen decreased
from 2.9 to 1.6.
Mean score for MS patients
reduced from 2.7 to 0.7.
One patient received an overdose
due to human error.
3 mechanical failures, 6 wound
complications, 22 catheter
complications out of the 75
implantations
0/5
Dressnandt
et al. (1995),
Germany74
Prospective,
longitudinal,
uncontrolled
Intrathecal baclofen for
mean of 61 months.
At end of 1st year, mean
dose was 189 g/day
N = 27, of whom 20 had
MS.
Ages 38–66 y.
16 F, 4 M.
Average age of MS patients
was 52 y.
All with severe
paraspasticity or
tetraspasticity
None
documented
Ashworth scale.
Frequency of spasm
scale
Decreased in all 20 MS patients.
Decreased in all 20 MS patients.
(N.B. The primary outcome
reported in this trial was the
ability to withdraw intrathecal
baclofen after prolonged
treatment. This was reported to
be possible in 5 MS patients)
N/A
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TABLE 18 Intrathecal baclofen studies
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured (MS patients only) quality
(Jadad)
Gianino et al.
(1998),
USA75
Prospective,
longitudinal,
uncontrolled
Intrathecal baclofen
(Synchromed).
Mean dose at 
12 months 298 g 
per day
N = 25, of whom 15 had
MS.
All had intractable spasticity
of spinal origin.
Most were paraparetic, 
6 were quadriparetic, 
1 hemiparetic and 
1 monoparetic.
Mean age 39 y.
15 F, 10 M
N = 9.
No reasons given
other than
questionnaire
fatigue
Ferrars and Powers
QoL Index.
SIP (0–100 scale).
Ashworth scale.
Frequency of spasm
score
No change between baseline and
2 months. It was felt that this lack
of change was due to the
emphasis of the QoL on non-
physical aspects.
SIP improved from 29.7 to 21.7 
(p = 0.8)
Physical sub-score went from 38.5
to 31 (p = 0.001)
Psychological subscore went from
20.8 to 13 (p = 0.025)
Significant decrease from 3.8 to
1.5 (p value not stated).
Significant decrease from 2.6 to
0.5 (p = 0.00001)
N/A
Lazorthes 
et al. (1990),
France70
Prospective,
longitudinal,
uncontrolled.
The mean
follow-up
period was 
18 months
(range 
4–43 months)
Intrathecal baclofen.
Individual doses in MS
patients ranged from
100 to 250 g per day
N = 18, of whom 6 had
MS.
MS patients ages 40–56 y.
5 F, 1 M.
All patients had severe,
debilitating spasticity and
were unresponsive to oral
treatment
None Ashworth scale.
Modified Davis and Gray
scale for the evaluation
of motor performance.
Painful muscular spasms.
Functional assessment
2–4 point improvement in all 
6 patients.
1/6: large improvement
1/6: moderate improvement
4/6: no improvement in function.
Abolition of painful spasms in 5/6.
Significant functional improvement
was noted in 1 MS patient.
Functional improvement was
much greater in those with
traumatic lesions as opposed to
those with MS.
Two MS patients had serious
complications (overdose,
meningitis)
N/A
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TABLE 18 Intrathecal baclofen studies
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured (MS patients only) quality
(Jadad)
Middel et al.
(1997), The
Netherlands66
The cost
analysis of this
study is
covered in
the paper by
Postma et al.
(see Table 21)
DB RCT for
13 weeks,
followed by a
longitudinal
observational
study for 
52 weeks
Intrathecal baclofen.
75–150 g per day
Placebo
N = 22, of whom 12 had
MS.
Aged 19–70 y.
55% women (all patients).
Baclofen N = 12.
Placebo N = 10.
All 22 received intrathecal
baclofen in the
observational study.
All patients had chronic,
disabling spasticity and
were not responding to
oral medication
None Ashworth scale (claims
to be modified version
but is standard version).
Frequency of spasm
score.
Self-reported pain.
QoL measured by the
SIP.
Hopkins symptoms
checklist (HSCL)
Significantly greater fall in
Ashworth, spasm and pain scores
in treated cf. placebo groups at 
3 months. Effect sizes 0.2, 1.4 and
0.94, p < 0.05, <0.01, <0.05,
respectively. No significant
differences in change in SIP or
HSCL.
Significant fall in Ashworth, spasm
and pain score on treatment at 3
(not for pain) and 12 months
Significant improvement in SIP,
HSCL on treatment at 3 and 
12 months
5/5
Ochs and
Tonn (1996),
Germany76
Prospective,
longitudinal,
uncontrolled
Intrathecal baclofen.
Mean dose 199 g/day
at 1 year.
Study duration up to 
5 years
N = 70, of whom 59 had
MS.
Ages 35–69 y.
Sexes not stated.
All patients suffered from
spinal lesions resulting in
severe spasticity.
Mean Ashworth score 4.1
N = 2, both with
MS.
Two MS patients
died during the
study, but this
was thought to
be unrelated to
their treatment
Ashworth scale.
Spasm score.
Changes in mobility.
Subjective evaluation
Significant reduction in muscle
tone at on average 2 points below
the initial baseline score. This
reduction was sustained over 
5 years in 12 patients.
Spontaneous spasms also reduced
but less reliably than muscle tone.
At baseline 54% (38/70) were
bedridden. After 6 months 22 of
the 38 could leave bed and use a
wheelchair. Initially, 14 patients
were wheelchair bound. After
treatment 4 of these were able to
stand.
After 6 months 19/22 patients and
20/22 physicians rated the
outcome as good or excellent
N/A
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TABLE 18 Intrathecal baclofen studies
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured (MS patients only) quality
(Jadad)
Patterson 
et al. (1994),
UK71
Prospective,
longitudinal,
uncontrolled
Intrathecal baclofen.
Initial mean dose 
223 g/day.
Effective mean dose 
485 g/day.
Treatment duration
varied from 9 to 
79 months
N = 21, of whom 15 had
MS. Mean age 46 y (range
24–67).
Sexes not stated.
All patients had severe
spasticity and were
unresponsive to oral
treatment.
None was ambulant
7 patients died
but this was
thought to be
unrelated to the
treatment.
Complications in
9 patients led to
the pump being
removed. This
included
infections leading
to meningitis in 5
patients
Ashworth scale.
Frequency of spasm
score.
Barthel index
‘Complete and sustained’ fall in
score in 16/21 patients. In 4 other
patients there was short-term
benefit.
18/21 patients showed a complete
absence of spasms. 15/15 MS
patients showed a complete
absence of spasms.
No change in any patients,
possibly due to inappropriateness
of this measure.
16/21 patients showed sustained
improvements but the 2 patients
who showed the greatest
improvements in terms of
mobility and ability to drive did
not have MS
N/A
Penn and
Kroin (1985),
USA62
Prospective,
longitudinal,
uncontrolled
Intrathecal baclofen.
Initially 12–200, later
12–400 g/day for 
7 months
N = 6.
3 with MS.
All had severe rigidity in
lower limbs (Ashworth
score 4–5) and 5/6 had
frequent spasms.
5/6 non-mobile, 
1/6 partially mobile. 
All female, with an average
age of 36 y (range 19–54)
N = 1 Ashworth scale All patients showed an immediate
and long-lasting return from a
score of 4–5 to 1 (normal tone).
Spasms were controlled in all
patients and stretch reflexes were
reduced in half.
None of the patients had any of
the central side-effects which they
had with oral baclofen.
Functional improvement in ADL
reported
N/A
involved an initial screening stage, in which
baclofen was administered as a bolus dose to test
the responsiveness of the patient. If this was
successful, a pump and catheter were then inserted
for the administration of the baclofen on a long-
term basis. The long-term dosage used in these
selected studies ranged from 21 to 648 g per day.
Outcomes measured
A number of different outcome measures were
employed, the main ones being the Ashworth scale
and various spasm frequency scales. Other
miscellaneous outcome measures such as Ferrars
and Powers Quality of Life Index and the Sickness
Impact Profile (SIP) were also used.
Validity of included studies
Only three studies were DB RCTs and, of these,
only one was a longer term study, which scored 5/5
on the Jadad scale. However, despite the weaker
methodological design of some of the other
studies, there is a need to include these in the
review for the reasons given above. Most of these
studies are uncontrolled and open-label, for which
a Jadad score is inappropriate. It is important to
be aware of the inherent biases produced by
studies of this design. 
In unblinded assessments, subjective outcome
measures are more likely to be reported as having
been affected by the intervention than objective
measures. Therefore, it is possible to attach more
credence to some outcome measures than others.
For example, a change in status from wheelchair
bound to an ability to stand may have more
credence than a change in the Ashworth score.
The longitudinal studies and case series relied on
the observation of the patients’ condition prior to
implantation of the pumps as controls against
which to assess the impact of the intervention.
This is not ideal, as it does not allow for any
change in the condition of the patients, which
could have occurred spontaneously. However,
although MS can be a relapsing and remitting
disease, it appears that in the majority of these
cases the disease was stable, so that one can be
reasonably confident that the condition of the
patient would not have altered significantly
without the intervention.
It is also important to consider sample size. The
sample sizes of the 11 studies ranged from 6 to 93,
with many at the lower end. Some of the studies
may not have had adequate levels of statistical
power and most did not attempt to justify their
sample size.
Generally, there was an absence of data analysis
using statistics in the included studies, with many
of the studies resorting to just describing the
findings.
Effect on spasticity
The selected studies show an overall positive
outcome for patients treated with intrathecal
baclofen. All 15 trials reported positive findings.
In those that reported the Ashworth score, it fell
almost universally by 2–3 points, typically from
3–4 pre-implantation to 1 on treatment. Similarly,
there was a near-universal abolition of spasms,
which was reflected in spasm frequency scores.
Impact on function
Becker and colleagues68 attempted to measure
various aspects of nursing need, such as ease of
transfer, pain control, nursing care and skin
breakdown, in addition to assessing patient
satisfaction. In both cases the study found major
improvements. Five studies attempted to measure
functional ability. Broggi and colleagues69 found
that the less severe cases gained the greatest
improvements in terms of mobility and daily
activity. The non-ambulatory patients gained only
in terms of QoL and comfort. Lazorthes and
colleagues70 reported similar findings. On 
the other hand, Patterson and colleagues71 found
no change in the Barthel index, despite
substantial improvements in the Ashworth and
spasm scores.
Complications and side-effects
Complications are not infrequent, relating
primarily to problems with the pump and catheter.
In particular, kinking and dislodging of the
catheter and breaks in the catheter are not
infrequent. Pump failure, particularly with earlier
models, is also reported. In contrast, side-effects
from the drug itself are uncommon, with the most
commonly reported being drowsiness, dizziness,
blurred vision and slurred speech. Erectile
dysfunction is also reported in one patient.72
Acute accidental overdose as a result of pump
malfunction65 and human error67 is also reported.
One of these resulted in coma, from which the
patient recovered.
Summary of systematic review of
intrathecal baclofen
The studies indicate that patients with severe
spasticity are likely to benefit from treatment with
intrathecal baclofen in terms of a reduction in
spasticity, improved ability to sit in a wheelchair,
possibly to stand and improved nursing care.
Patients with less severe disability may also benefit
Results of the systematic review of treatments for spasticity in MS
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from improvements in care with ability to transfer
and painful spasms being likely to be reduced
considerably. There is some evidence that
bedridden patients with very severe forms of MS
are unlikely to benefit in terms of improved
functionality or mobility but may benefit from
generally improved care and hygiene. In spite of
the weaknesses of the study designs, one can
conclude from the striking benefits seen in these
studies that intrathecal baclofen has a positive
outcome for MS patients with severe spasticity.
Phenol
Phenol injection into or around a nerve produces
a temporary block that may last for months. It has
been used as a neurolytic agent for over 60 years.
Initially it was used to produce a sympathectomy
in the treatment of peripheral vascular disease.
Subsequently it has been used to treat intractable
cancer pain and to control muscle spasticity. This
may be achieved either through injection at the
level of the spinal cord, or at the level of a
peripheral nerve, or at the motor end plate.77
Aqueous 5% phenol is produced in ampoules in
packs of 10 for a cost of £21.30. A single ampoule
containing 5 ml of phenol would therefore cost
£2.13. As the duration of the effect is not clear, it
has not been possible to calculate a cost per day.
There would also be a moderate cost of
disposables and clinician time associated with its
use.
Quantity of research available and
study characteristics
We were not able to identify any controlled studies
of the effect of phenol injection on spasticity,
either in MS or when due to other causes. One
controlled study was identified which compared
the effect of two different approaches to obturator
nerve block in patients with adductor spasticity
(30% of whom had MS),78 but this was small, and
used (apparently) unvalidated outcome scales. Its
greatest value is probably therefore as a case series
documenting the effect of obturator blockade,
irrespective of approach used. Four other case
series were identified which included patients with
MS (although sometimes the number with MS was
not specified). Because of the lack of higher grade
evidence, the study inclusion criteria have been
relaxed to include these. Details of the studies
included are given in Table 19.
Populations examined
Few details are given about the patients included
in the studies, or how they were selected, other
than that they suffered from spasticity, with the
exception of one report of two cases of patients
with painful spasms due to longstanding MS.79
Two of the case series do include case examples,80,81
but there is no indication that these are typical of
all the cases. 
Outcome measures
The case series all simply reported the overall
effect of the injection in general terms. The
comparative study of the two different approaches
to obturator block used what appear to be ad hoc
scales for spasticity, hygiene and gait, in addition
to reporting overall success rate and patient
acceptability.
Validity and generalisability
The validity of the observations made in
uncontrolled case series can always be called into
question because of the lack of information about
the condition the patients would have been in
without treatment. Nevertheless, where natural
history of a condition is that it is stable or 
steadily deteriorating, and intervention is 
followed by a prompt improvement in the
condition, we can take it that this is likely to be
due to the intervention. The one controlled 
study was small, used ad hoc outcome scales for
which no evidence of validity was cited and did
not include any discussion of sample size.
Conclusions with regard to the differences 
between the two groups (two different approaches
to obturator block) can therefore only at best be
seen as tentative.
Although we may assume that the observations in
the case series are valid, there is insufficient
information about patient characteristics and
selection to enable judgement to be made about
the generalisability of the results.
Summary of the direction of effect and
impact on function
All of these case series reported relief of spasticity
in a high proportion of cases. In the one study
which used more explicit outcome measures78
there appears to have been a marked reduction in
adductor spasticity, improved hygiene and
improved gait. In the case series of two,79 one
patient was rendered able to sit in a wheelchair
(previously unable to) with improved hygiene,
while the other was also enabled to sit in a
wheelchair, albeit only for 1–2 hours at a time.
One case example is cited of a woman who was
able to resume sexual relationships after obturator
blockade.81
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TABLE 19 Phenol
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Cain (1965),
USA80
Case series Phenol in glycerine
solution. Variable
concentration, 3–10%.
Dose 0.5–0.6 ml.
Subarachnoid injection
43 patients treated overall,
of whom 8 had MS. 33
were treated for spasticity,
19 for pain
None Observed relief of
spasticity
Of the 33 patients treated for
spasticity, 28 (85%) said to have
had good or excellent relief
Not
applicable
Copp et al.
(1970), UK82
Case series Phenol in aqueous
solution: 3% for nerve
blocks, 5% for motor
point blocks. Volume
1–4 ml. Injection site
located using nerve
stimulator
50 blocks performed on 
33 patients including an
unspecified number with
MS
None Observed relief of
spasticity
‘A useful reduction of spasticity for
up to 13 months’
Not
applicable
Awad (1972),
USA81
Case series Phenol in aqueous
solution, 5%. Volume
0.1–0.2 ml. Obturator
or lumbar plexus block
Obturator blocks: 
56 patients, 28 with MS.
Lumbar plexus block: 
13 patients, 5 with MS
None Observed relief of
spasticity
Not explicitly stated, though
effects reported to last from 3 to
14 months (slightly longer for
lumbar blocks). Overall reported
to lead to improved gait, transfer,
dressing, hygiene, bladder and
general nursing care
Not
applicable
Browne and
Catton
(1975),
Canada79
Two cases Phenol in glycerine: 
1 ml 10% in one case;
1.5 ml 5%, followed by
1.5 ml 20%, then 2 ml
20%, in the other.
Intrathecal injection
2 patients with MS and
painful spasms
None Observed relief of
spasticity
Relief of painful spasms in one
case, with improved extension of
hips and knees. Relief of painful
spasms on right, but not left, in
second case
Not
applicable
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TABLE 19 Phenol (cont’d)
Study Design Drugs and dose Patients Withdrawals Outcomes Results Trial 
measured quality
(Jadad)
Wassef
(1993), USA78
Comparison
of two
approaches to
obturator
block
Phenol in glycerine: 
5 ml 6% solution
administered by
traditional or
interadductor approach
to obturator nerve
10 patients in each group,
of whom 3 (in each group)
had MS
None Percentage of block
success.
Muscle spasm score 
(ad hoc scale from 1 
to 4).
Hygiene score (ad hoc
scale from 1 to 4).
Gait score (ad hoc scale
from 1 to 3).
Patient satisfaction
Successful block reported in
81.4% of cases following
interadductor approach, 60.5% of
cases following traditional
approach.
Reduced from 3.3 to 1.3 following
interadductor approach, from 3.2
to 1.7 following traditional
approach.
Reduced from 3.3 to 1.1 following
interadductor approach, from 3.3
to 1.8 following traditional
approach.
Reduced from 3.0 to 1.3 following
interadductor approach, from 3.0
to 1.5 following traditional
approach.
8/10 completely satisfied or minor
reservation in interadductor
group, 4/10 in traditional group
Not
applicable
Results of the systematic review of treatments for spasticity in MS
64
Side-effects
Few side-effects are reported in these case series.
Complications which are reported include ‘further
muscle weakness’, sensory loss and genitourinary
dysfunction following subarachnoid block.80
Peripheral nerve blockade other than the obturator
nerve (which supplies a very small area of skin,
and that is partially supplied by other nerves) is
reported to result in anaesthetic skin and
sometimes persistent severe pain.81 Arachnoiditis
and sphincter dysfunction following intrathecal
injection are also referred to.82
Summary
The only evidence which we were able to identify
with regard to the effectiveness of phenol blockade
in treating spasticity was of low grade, being
essentially only case series. Nevertheless, in the
light of the stable or deteriorating nature of
spasticity, and the prompt relief observed in a high
proportion of cases, it is reasonable to conclude
that phenol injections do relieve spasticity, with a
duration of action of some months. There is
insufficient evidence to draw firm conclusions
about the functional impact of this relief of
spasticity, although it is likely that in some cases
significant advantage may be gained. Peripheral
nerve or motor point blockade is likely to lead to
fewer complications than intrathecal block.
Threonine
Threonine is an amino acid. It is not licensed as a
prescription drug in the UK. Two studies of its use
for the treatment of spasticity in patients with MS
were identified. Both were DB, crossover RCTs.
The study design, outcome measures and results
are detailed in Table 20. Both were of a high
quality, achieving a Jaded score of 5/5.83 No data
are available on the cost of threonine, although it
is thought to be inexpensive.
In the first study,83 of the various outcome
measures used, only one showed a difference, with
p = 0.036. It is possible that with the multiple
testing involved this represents a Type I error.
Furthermore, as the paper did not include a
power calculation, and in view of its small size, it is
possible that the study was underpowered.
As the postulated mechanism of action of
threonine is to increase spinal glycine levels, the
finding that the CSF glycine concentration was not
altered (although plasma and CSF threonine levels
were), indicates that threonine, at least at the
dosage used, is ineffective.
In the second study,84 a sequential analysis was
undertaken. Patients were assessed using the
Ashworth scale, with the six highest of 10 passive
movements summed to give a ‘spasticity score’ and
a 10% reduction in this score taken to be a
response to treatment. The study was stopped
after 33 patients were recruited because of a
statistically significant benefit from threonine.
Both spasticity score and spasm score (frequency ×
severity) were reduced more on threonine than on
placebo, but there was no change in the Barthel
index or the Kurtzke disability status scale (DSS).
The plasma threonine level was significantly
higher in the treatment than placebo arm (498
versus 184 mol/l). There was no significant
change in plasma glycine. The correlation between
plasma threonine levels and spasticity reduction or
spasm score was poor.
Vigabatrin
One review of pharmacodynamic and
pharmacokinetic properties of vigabatrin was
identified. This indicated that there was some
early phase trial work which showed that
vigabatrin ameliorated spasms and improved 
some parameters of spasticity to a small or
moderate extent, including reducing the frequency
of spasms and the associated pain. Some of this
work was carried out on patients with MS, but it is
not possible to describe the findings in more
detail since these data are on file with Marion
Merrell Dow. The cost of vigabatrin is £44.85 for
100 500-mg tablets. The maximum dose is 3 g per
day. At this dosage, the cost per day would be
£2.69. It is an anticonvulsant, and as such is not
licensed specifically for use in the treatment of
spasticity.
Clonidine
Two studies of clonidine in the treatment of
spasticity were identified from the scoping review.
Both were excluded, the first because the study did
not include patients with MS and the second
because it took the form of a letter with anecdotal
evidence on three case histories.
Methylprednisolone
Compston and Swingler suggest that intravenous
methylprednisolone is a treatment for spasticity,
but do not cite any evidence to support this.4
Neither did there appear to be any evidence of
current clinical usage to this end. Intravenous
methylprednisolone is used to reduce the length
of episodes of relapse, and its effect reduces with
increased use. No research studies were identified
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TABLE 20 Threonine vs placebo
Study Design Drugs and dose Patients Withdrawals Method of Outcomes Trial 
assessment quality
(Jadad)
Hauser et al.
(1992), USA83
DB crossover
RCT
Threonine 2.5 g t.d.s. 
Placebo.
2 × 8-week treatment
periods separated by a
2-week wash-out
N = 26.
All had clinically definite
MS.
Mean age 41 y.
15 F, 11 M.
Mean disease duration
12 y.
Mean EDSS score 4.7.
Ambulatory patients
with inactive or slowly
progressive MS
N = 5, 2 during the
1st treatment
period, 3 during the
2nd treatment
period.
One case due to
additional
antispasticity
medication being
initiated, the others
apparently unrelated
EDSS.
AMB.
Ashworth scale.
Clinician spasticity scale.
Patient spasticity scale.
Clinician global assessment.
Patient global assessment.
EMG measures.
CSF glycine
Not stated.
Not stated.
No difference.
11 patients improved on
threonine vs 5 on placebo 
(p = 0.036).
No difference.
No difference.
No difference.
No difference.
No difference
5/5
Data analysis
is correctly
based on
only those
that
completed
both arms of
the
crossover
Lee and
Patterson
(1993), UK84
DB cross-over
sequential
analysis RCT
L-Threonine 6 g/day.
Placebo.
4-week baseline, 
2-week treatment, 
2-week washout, 
2-week treatment
N = 33.
23 had MS.
11 F, 12 M.
Ages 35–66 y.
DSS 6–9.
N = 4 in baseline
period because of
excessive variability
in spasticity
Ashworth scale – six
highest of 10 passive
movements summed to
give ‘spasticity score’. A
10% reduction in score is
defined as response to
treatment.
Spasm score (frequency ×
severity).
Barthel index.
Kurtzke DSS
Study stopped after 33
patients because of significant
benefit from L-threonine. 
16 responded to L-threonine,
3 to placebo, 8 to neither, 2 to
both.
Mean (?29 patients) spasticity
score reduced from 21.5 to
18.9 on L-threonine, 21.5 to
20.6 on placebo.
Reduced from 3.8 to 2.6 on 
L-threonine, 3.4 to 3.0 on
placebo.
No change.
No change.
1 patient reported indigestion
and 1 diarrhoea on threonine
5/5
which include methylprednisolone in the
treatment of spasticity.
Cyproheptadine
One report of the use of cyproheptadine, a
serotonergic antagonist, in the treatment of
spasticity was identified.85 Six patients, four of
whom had MS, were given cyproheptadine in
doses up to 24 mg/day over periods varying from
4 to 24 months. It was an open study, without any
controls. Cyproheptadine was reported as
significantly decreasing ankle clonus and
spontaneous spasms. Walking was said to improve
in four of the patients (two with MS).
Magnesium
A single case report of the effect of magnesium
glycerophosphate on spasticity in a 35-year-old
woman with MS was identified.86 At a dose of 
1000 mg/day, there was a reduction in the mean
Ashworth score for 10 lower limb movements of
0.7 points (from 4.9 to 4.2). Nursing care was said
to have been facilitated.
Clinical effectiveness of treatments for
spasticity – summary
On the basis of the evidence reviewed above, drug
treatments for spasticity may be categorised into
three groups. Baclofen, dantrolene, diazepam and
tizanidine are all oral treatments. They all differ in
the pharmacological mode of action, but all
appear to be moderately effective in reducing
spasticity (as measured using the Ashworth scale or
other clinical measure). The evidence of
effectiveness is stronger for tizanidine than for the
other three, possibly reflecting its more recent
development, at a time of more stringent
requirements for establishing effectiveness. Very
little evidence is available as to the effect of these
drugs on functional ability in patients with
spasticity, and what there is does not suggest any
effect. There is no evidence that any one drug is
more effective than any other, but side-effects
appear to be most common with diazepam and
dantrolene and least common with tizanidine.
BT (administered intramuscularly), intrathecal
baclofen and phenol injections are effective in
reducing spasticity (although the evidence base for
phenol is less good than for the other two drugs).
All three are invasive treatments, have a longer
term effect and are more costly than oral
treatment. BT has its effect by causing paralysis of
the treated muscle, so is only appropriate when
the loss of muscle tone is of greater functional
benefit than maintaining spasticity and power.
Intrathecal baclofen requires the insertion of a
permanent indwelling intrathecal catheter and
pump, which gives rise to the risk of infection and
other serious side-effects. In practice, these
considerations mean that these treatments are
only appropriate for patients with severe spasticity,
in whom functional ability and QoL are severely
impaired.
Other possible drug treatments for spasticity
include threonine, vigabatrin, clonidine,
methylprednisolone, cyprohepladine and
magnesium. The authors were not able to identify
any good evidence to establish the effectiveness or
otherwise of these treatments.
Economic evidence
The results of the searches described in Chapter 3
were used to identify economic evidence relating
to treatments for pain and spasticity in MS.
Despite a broad search strategy on economic
studies, no formal cost-effectiveness analyses for
any of the included indications were found.
Although literature was found on treatment
effectiveness, implying potential economic benefits
through the improved management of patients,
none of these papers attempted to calculate
formal cost-effectiveness ratios, estimates of utility
or overall treatment costs.
The four studies which most closely approximated
to formal health economic evaluations dealt with
the use of CIBI in the treatment of MS-related
spasticity and its impact on hospitalisation rates.
This economic review is, therefore, restricted to
those studies. No formal economic review has
been undertaken of the other treatments for
spasticity, or treatments for pain.
Patients with severe spasticity frequently require
hospitalisation for the treatment of related
problems. These include the management of
bedsores due to long-term immobility and respite
care. Hospital stays may last as long as several
months. The impact on hospitalisation
requirements following CIBI have been reported
for the USA,87 Canada68,88 and The
Netherlands.89 These four studies are summarised
in Table 21.
The cause of spasticity in these studies is not
always MS. Causes include cerebral damage and
spinal cord injury (SCI). Generalisation of the
results specifically to MS patients may not,
therefore, be valid. The studies were also
Results of the systematic review of treatments for spasticity in MS
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TABLE 21 Economic studies of intrathecal bacolofen
Study Patients’ Method Results Savings and comments
characteristics 
Nance et al.
(1995)88
6 patients.
SCI or MS
Comparison of
hospital admissions,
causally related to
spasticity, 2 years
prior to treatment, 
2 years post
treatment
Prior 2 years: 376 in patient hospital days (range:
0–186, average 63 days). 
Post 2 years: 136 inpatient days (range: 11–36,
average 23 days), none of which was due to
spasticity. 
All admissions post-CIBI were related to
screening, implantation, treatment of problems
related to the intrathecal drug delivery devices
and problems related to marked reduction in
muscle tone
The authors report average net savings of Can$25,250 per patient,
taking account of the cost of pump and hospital days (average cost per
inpatient day Can$813). The authors consider the treatment to be cost-
effective.
Using UK costs of £211 per inpatient day, there would be savings of
£8440 over 2 years in reductions of hospital days. This would balance
the cost of the pump.
The number of days used within the post-CIBI years may be
overestimated owing to use of placebo days in the screening phase. 
2 patients reported ability to decrease personal attendant services and 1
patient obtained employment following CIBI. 2 patients had skin ulcers
which healed following CIBI
Postma 
et al.
(1999)89
18 patients
undergoing CIBI
(11 MS, 7 SCI).
15 matched
patients of similar
age, sex and
diagnosis (9 MS, 6
SCI)
Comparison of the
number of days in
hospital between
groups 1 year prior
to implantation and 
1 year following
implantation
Average number of hospital days in year of
implant in treated group was 31.5; 9.9 in the test
phase, 12.3 for the implantation phase and 8.4
resulting from complications.
Average number of hospital days 18.7 for the
matched patients. 
In the year following implantation no significant
difference was found
A calculation of the average direct costs that would be likely to occur in
a non-experimental situation was made in this study. For this analysis
only 2 days were allocated to the test phase, 10.3 days for the
implantation phase and, again, 8.4 days for complications. If this had
been the case, the average number of days for the treated group would
have been 20.7, i.e. only 2 additional days in comparison to the matched
group.
For the non-experimental situation, the total average cost of selection,
testing, implantation and medical follow-up amounted to US$28,473 per
patient for the first year. Full breakdown given in the paper.
continued
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TABLE 21 Economic studies of intrathecal bacolofen (cont’d)
Study Patients’ Method Results Savings and comments
characteristics 
Becker et al.
(1995)68
9 patients.
6 MS, 2 cervical
SCI and 1 head
injury
Hospitalisation costs
1 year prior and one
year post-
implantation
Prior to implantation: 755 acute hospital days
(range: 0–319, average 84 days).
Year of implantation: 259 days (range: 10–48,
average 29 days)
Based on cost of hospital stay of Can$570 per day, reductions in hospital
days give average saving of Can$31,000 per patient (excluding pump and
implant).
Using UK costs of £211 per inpatient day, there would be savings of
£11,660 within the first year in reductions of hospital days. This would
balance the cost of the pump.
At time of implantation, 6 of the 9 patients were institutionalised in
either chronic or acute care hospitals owing to problems managing their
spasticity. Following CIBI, 3 patients were discharged after prolonged
hospitalisation, 2 to their own home and 1 to a group home. 
Savings are likely to be underestimated as 2 patients were in chronic
care institutions prior to implantation and, thus, would not have required
acute care.
Authors conclude CIBI to be beneficial in terms of nursing assessment,
patient satisfaction and cost-effectiveness
Ordia et al.
(1996)87
10 patients.
Spasticity of
spinal cord origin,
MS or SCI.
59 patients in
total had pump
implant, but only
the first 10 were
included in the
cost study
Number of bed days
used for 1 year prior
and 1 year following
implantation.
Hospitalisations
were all cause and
not specifically
related to spasticity
Prior to implantation: 95 bed days.
Post-implantation: 68 bed days, i.e. 2.7 days per
patient saved for general hospitalisations in 
1 year.
Also 58 days used for screening and
implantation, i.e. 5.8 days used per patient for
the screening and implantation
This study does not report the proportion of days that are related to
spasticity, and, thus, may include admissions for unrelated causes.
Similarly, there is no information as to the number of post-implant bed
days that are due to complications from the procedure.
The number of bed days reported is low as patients who received acute
rehabilitation less than 1 year prior to surgery were excluded from cost
study.
Authors concluded CIBI to be a cost-effective method for treatment of
severe intractable spinal spasticity. However, this was based upon an
average cost of US$2500 per day.
conducted in relatively small numbers of patients
which again may undermine validity.
The savings reported by Nance and colleagues88
and Becker and colleagues68 refer only to
hospitalisation days related to spasticity. The
former reported an average reduction of 40 days
in the number of bed days used over 2 years,
whereas the latter reported a reduction of 55 bed
days used over 1 year. The difference in numbers
could be due to a greater degree of disability in
the population reported by Becker and colleagues,
as there were patients suffering skin breakdown
who had considerable resource requirements.
The savings reported by Ordia and colleagues87
do not relate specifically to spasticity and no
reasons are given for hospitalisation prior to or
post-CIBI. These results cannot be used in this
analysis without further information.
Postma and colleagues89 provide a detailed
analysis of the costs and savings of CIBI in The
Netherlands. The study showed no significant
difference between patients and controls in the
number of hospital days in the year following
CIBI. For the implantation year there were 18.7
days used on average by the control group
compared with an estimated average of 20.7 days
related to the CIBI procedure and no further days
related to spasticity for the CIBI group. 
These papers provide three separate estimates of
bed days used for patients without or prior to
CIBI: 19 days,89 32 days (63 days over 2 years)88
and 84 days.68 The differences are almost certainly
due to differences in patient selection and care
settings. Assuming an average UK cost per
inpatient day of £211,90 this represents costs of
£4000, £6800 and £17,700, respectively.
The number of bed days used during the year of
implantation ranges from 21 days89 to 29 days.68
This corresponds to costs of £4400–6100 for the
hospitalisation related to the CIBI procedure.
Overall, these studies imply the likelihood of
significant cost off-sets and patient benefits from
avoided hospitalisations post-treatment, but they
do not attempt to go further in combining this
with any form of cost of treatment and overall
utility gain per patient.
Estimates of cost utility for CIBI
A recently completed health technology
assessment has attempted to estimate a cost per
life year gained from the use of CIBI.91
The cost of CIBI was estimated at around £11,700
for the initial assessment, test procedure,
implantation procedure and equipment. This
includes a cost of £6770 for the pump. In
addition, costs of £870 per annum were indicated
for the general maintenance, drug refill and
follow-up of patients. An assumption was made
that treatment would last for up to 7 years,
depending on the type of pump used, although it
was noted that life expectancy may be less than
this in these MS patients. This equated to a total
cost of around £15,900 for a 5-year period and
£17,600 for a 7-year period. Discounting costs at a
rate of 6% gave a total current value of £15,400
for a 5-year period and £16,700 for a 7-year
period.
In the absence of studies reporting upon QoL
utilities for CIBI, the report used a generic QoL,
the Index of Health Related Quality of Life
measure (IHQL), to construct a range of utility
estimates. 
It was initially assumed that a patient pre-CIBI
would be confined to bed (state D7), have severe
pain (state P3) and be moderately distressed
(anxious and depressed most of the time, but
happy and relaxed some of the time) (state E3).
Given these scores across the three domains, the
average patient was associated with a utility of
0.449.
The post-CIBI patient was assumed to have the
same distress and disability, but a reduction in
pain to slight pain. This resulted in a revised
utility score of 0.675 equating to a utility gain of
0.226. When the initial pain level was judged as
only moderate, the QALY utility gain reduced
further to 0.149. An improvement in pain to
moderate pain levels, with the patient also
experiencing a reduction in disability to state D6
(confined to a chair, only able to get out with
assistance, very limited ability to perform role
functions), resulted in a utility gain of 0.199.
The authors clearly recognised that using a
generic scale in this way was not sufficient to
provide conclusive economic evidence of cost-
effectiveness. However, they did suggest that
assuming 5 years’ worth of health benefit are
obtained from the pump implantation, then an
average annual QoL utility gain of around 0.16
would result in a cost–utility ratio of £20,000. The
authors argue that this level of shift in utility
scores was possible, from the indicative health
benefits as calculated in their own estimated QoL
analysis, described above.
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Summary of economic evaluation
Although effectively no published information
related to the economic impact of treatments for
pain and spasticity was found, it is useful to recap
on the likely areas of cost impact of treatment.
These are the areas in which cost offsets could be
achieved, in addition to health benefits provided
to the patient.
Pressure sores/ulcers
Pressure sores are a considerable risk for patients
who are bed-bound owing to spasticity. The cost of
treating pressure sores is substantial, as they
require either long periods of hospitalisation or
intensive community nursing care. For example, a
full thickened sacral ulcer extends hospital stay by
over 25 weeks at a cost of £26,000 including extra
staffing, drugs, dressings and hospital overheads.92
Costs for pressure ulcers differ depending on the
ulcer stage, and also vary depending on care
setting. Local estimates of costs for treating
pressure sores are around £17,000 for a grade 4
pressure sore and £5000 for grade 3/4
(McClelland MR, personal communication, 1999).
Research is lacking in many areas of pressure ulcer
prevention and treatments with regards to cost-
effectiveness. It is estimated that the total national
cost in the UK for the treatment of pressure sores
is approximately £755 million per year.92
Orthopaedic surgery
Treatments may defer the onset of muscle
contractures and hip dislocations and potentially
delay or inhibit the onset of scoliosis. Although it
is not clear whether these procedures have been
avoided or merely delayed, there is clearly
potential for cost savings.
Reductions in oral treatments or other
interventions
The cost of CIBI should be offset by reductions in
oral treatments. The use of CIBI may also reduce
the need for interventions such as therapeutic
nerve blocks.
Aids and adaptations
Improved management of spasticity may lead to a
reduction in the need for seating aids,
wheelchairs, spinal jackets and orthoses.
Reductions in spasticity have also been reported to
decrease the need for specially designed
wheelchairs designed to accommodate extended
legs, and thus allow patients to switch to less
expensive compact models. The compact
wheelchair means that there is no need for
remodelling of the home, and fewer adaptations
are required.
There are currently no data available to quantify
these potential savings, although anecdotal
evidence suggests that the savings will be realised.
Examples of potential cost savings from the
reduced need for home adaptations are as follows:
 redesign bathroom: £1925 (median)
 redesign kitchen: £2282 (median).90
Reductions in care resources
One area of potentially significant savings is the
reduction in carers’ time and the need for nursing
home care following a reduction in spasticity.
Owing to the intensity of care required for patients
with severe spasticity, any reductions in care
requirements will lead to considerable cost savings.
Improved sleep may lead to reductions in night
care and patients will be able to be seated and
dressed more easily, sometimes reducing the
number of carers required. Although reductions in
the caregiving time required and greater ease of
care are frequently reported in effectiveness
studies, there is no quantification of the savings
which may be realised.
Discussion and conclusions
The literature reviewed suggests that there is
limited evidence of the effectiveness of four oral
drugs for spasticity – baclofen, dantrolene,
diazepam and tizanidine – when used orally for
the treatment of spasticity. All appear to be
approximately equally effective when assessed
clinically, though in no case is there any good
evidence of functional benefit. 
Baclofen
 For oral baclofen, 16 studies were identified and
12 included. All were DB controlled trials and
11 of the 12 were randomised. They achieved
Jadad scores of between 2 and 4.
 Patients preferred baclofen over diazepam
owing to fewer side-effects. 
 None of the comparisons with placebo was able
to show any improvement in functional ability.
 The Cochrane review of pharmacological
interventions for spasticity following spinal cord
injury published in 2002 noted that there is
some evidence that oral baclofen is effective
against placebo, but the outcome measures used
are of limited clinical relevance.93
Dantrolene
 Ten papers were identified and six included.
Five were DB RCTs and the fifth was an open
study. Five studies were against placebo and one
against diazepam. The Jadad scores were low,
ranging from 0 to 4.
 Dantrolene appeared to have a moderate effect
in reducing spasticity, but this was undermined
by the number of patients experiencing side-
effects, weakness in particular.
Diazepam
 Seven studies including diazepam were
identified. Only one of these was placebo
controlled. The other six were comparative
studies against active drugs where diazepam was
the comparator.
 Diazepam is effective in reducing the Ashworth
score but was no more effective in comparison
with other drugs.
 Diazepam has considerable side-effects which
patients do not like, predominantly sedation
and weakness.
Tizanidine
 Sixteen studies were identified and 12 were
included. These were all DB controlled trials.
Five of these were comparisons against placebo.
 Tizanidine appears more effective against
placebo in the two single-dose trials, but there is
little evidence of increased effectiveness over
and above placebo in the trials of longer
treatment. Only one out of three studies
comparing tizanidine with placebo showed a
statically significant difference in the Ashworth
score and in this study there was no difference
from placebo in terms of muscle spasms. 
 Tizanidine appears only equally effective as
baclofen or dantrolene. Tizanidine shows
effectiveness in improving muscle tone and
frequency of spasms, but this is not translated
into improvements in functional ability. 
 In terms of tolerability, only two of the studies
showed tizanidine caused less muscle weakness
than other drugs.
 The Cochrane review of pharmacological
interventions for spasticity following SCI noted
that tizanidine produced a large number of
adverse events, notably drowsiness and dry
mouth, in some cases causing withdrawal from
the studies.94
 Tizanidine is far more expensive than other
oral therapies. At the recommended dosage the
average daily cost of tizanidine is £4.49 per day
compared with a daily cost of £2.58 for oral
baclofen at its maximum daily dosage.
There is no good evidence of effectiveness for
gabapentin, threonine, vigabatrin,
methylprednisolone, cyprohepladine and
magnesium. The Cochrane review of antispasticity
agents for MS published in 2002 included just 13
studies and found that the test drugs only
produced statistically significant results in three
out of six placebo controlled trials.8 They included
seven comparative studies with other drugs and
found that there were no statistically significant
differences between the drugs in any of the seven
studies. They concluded that as a result of lack of
evidence, no prescribing recommendations could
be made. 
This report has been less restrictive than the
Cochrane review in terms of the studies included
in the analysis. Some of the studies included here
have very low Jadad scores and even though some
studies had higher Jadad scores, there are still
limitations to some of these studies. The Jadad
scoring system has been criticised as being an
appraisal of the quality of reporting rather than
the quality of the trial itself. For instance, the
Jadad score takes account of whether or not
withdrawals are reported but not how many
withdrawals there were, or their reasons for
withdrawing. The Jadad score also takes no
account of the sample size and whether the study
has adequate power.
In terms of the more invasive drug treatments for
spasticity, there appears to be limited evidence for
the effectiveness of BT and much more evidence
(but not all of good quality) that intrathecal
baclofen is effective in the treatment of patients
with severe spasticity. The evidence that phenol
injections are effective is anecdotal.
BT
 12 studies were identified and five were
included. Three were DB placebo-controlled
trials and two were open studies. The two open
studies had Jadad scores of 0 whereas the three
RCTs had Jadad scores of 5.
 The evidence for effectiveness was very limited.
Most studies showed an improvement in the
Ashworth score, but this does not always
translate into functional improvement. Only
one RCT showed a statistically significant
improvement in the hygiene score. 
 A Cochrane review of BT A in the treatment of
lower limb spasticity in cerebral palsy 
published in 2002 found only three eligible
studies and concluded that there is no strong
evidence to support the role of BT in treating
spasticity.94
 BT eliminates spasticity through causing
paralysis. This can cause unwanted muscle
weakening and means that BT is best suited for
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patients with the most severe spasticity and
where muscle strength is no longer required.
Intrathecal baclofen
 20 studies were identified and 15 included in
this review. Only two of these studies took the
form of DB RCTs, the remainder being open-
label studies. Only one study obtained a Jadad
score of 5. The sample sizes also tended to be
small.
 There is evidence that intrathecal baclofen is
effective in reducing spasticity in terms of both
muscle tone and frequency of spasms. The
studies indicate that patients have an improved
ability to sit in a wheelchair and ability to stand
and easier transfers. Improvements were also
noted in SIP and ADL scores.
 Intrathecal baclofen requires the installation of
a pump, depot and intrathecal catheter. Their
use is, thus, most appropriately restricted to
people with severe disabling spasticity.
 With regard to more severe spasticity, the
numbers quoted as receiving a pump implant
for intrathecal baclofen seem very low
compared with the potential number of patients
with spasticity severe enough to benefit from
this technique. 
 Although intrathecal baclofen exposes the
patient to certain risks and complications, there
is clear evidence that it is an effective treatment.
Carers and nursing staff are also in a position to
benefit from the use of intrathecal baclofen as
the patient becomes easier to nurse and
hygiene can be maintained.
 Economic evaluation of intrathecal baclofen
suggests that although expensive, its use may be
associated with significant savings in
hospitalisation costs. Further research is
required to establish reliably its cost-
effectiveness. 
 Other reviews of pharmacological interventions
for spasticity from other causes have also
identified intrathecal baclofen as an effective
treatment. Creedon and colleagues carried out
a meta-analysis of intrathecal baclofen for
severe spasticity including studies published
prior to June 1996.9 They found statistically
significant changes in both the Ashworth score
and the spasm score before and after treatment
in all patients, but particularly in patients with
MS, and spinal cord injuries. The results for
those with cerebral palsy were not statistically
significant but did show a trend towards
improvement. This may have been due to the
low numbers of patients with cerebral palsy
included in the meta-analysis. It should also be
noted that the Creedon study showed that 92%
of those who had a pump installed were still
using the pump at 1 year of follow-up, which
indicates that problems experienced with the
pump and catheter may be minor.
 The Trent Institute for Health Services Research
carried out a review of the effectiveness of
intrathecal baclofen in the management of
patients with severe spasticity and building on
the Creedon review went on to look at
functional outcome measures. They found that
intrathecal baclofen led to functional
improvements including improvements in the
ability to sit up in bed or to sit more
comfortably in a wheelchair, improved nursing
care and moderate improvements in ADL.91
 The Cochrane review of pharmacological
interventions for spasticity following SCI, last
updated in 2000, covered nine studies, of which
three involved intrathecal baclofen. The
reviewers concluded that two of the studies
showed that intrathecal baclofen had a
significant effect in reducing spasticity
compared with placebo. However, they noted
that use of intrathecal baclofen is an expensive,
demanding process and that its use should be
restricted only to true non-responders,
identified through a careful assessment of the
extent of non-response.93
Non-drug therapies for spasticity
There are a number of possible non-drug
therapies which are employed to assist with
spasticity in MS:
 Neurotomy – there is anecdotal evidence that
selective neurotomy can be helpful in reducing
spasticity, but it is really only suitable when the
spasticity affects just a single joint.
 Myelotomy – myelotomy has anecdotally a good
success rate according to Shetter,95 but it is not
reversible. There appears to be little or no
evidence in patients with MS.
 Chronic cerebellar stimulation (CCS) – a review
of CCS, which is used to reduce spasticity
caused by cerebral palsy, found that CCS
resulted in an 85% reduction in spasticity. How
the change in spasticity was measured is not
clear.96
 Microsurgical DREZ-otomy (surgical sectioning
of nerves in the dorsal root entry zone) – there
is some evidence of DREZ for the treatment of
spasticity and pain in MS.97
Conclusions
Overall, there is limited evidence for the
effectiveness of oral therapies for moderate
spasticity. Diazepam is particularly disliked by
Results of the systematic review of treatments for spasticity in MS
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patients because of its side-effects. There is little
evidence that tizanidine, despite its extra cost, is
any more effective than other oral therapies such
as baclofen and dantrolene. The findings of this
review are supported by reviews of the same
treatments for spasticity derived from other
aetiologies. It is debatable whether or not the
effectiveness of treatments for spasticity of
aetiologies other than MS, such as SCI or stroke,
can be compared. Nevertheless, the evidence from
other reviews suggests that the effectiveness of oral
antispasticity agents is very weak, despite their
widespread usage. 
The evidence for intrathecal drug treatment for
severe spasticity is stronger, particularly in relation
to intrathecal baclofen. It is believed that the
appropriate use of intrathecal baclofen could
result in significant savings in hospitalisation costs
in relation to bed-bound patients who are at risk
of developing pressure sores. 
There is a great need for more research into the
clinical and cost-effectiveness of treatments for
spasticity, in MS including the development of
better outcome measures which relate to
functional ability and patients’ QoL.
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Scope of review
This review addresses the questions of what the
treatments currently available for the management
of pain in MS are and what the effectiveness (and
cost-effectiveness) of those treatments is. It
concentrates in particular on medical
(pharmacological) treatments, and does not
explicitly look at the effectiveness of surgery,
psychological or complementary therapies.
Although there is a strong belief among many
patients with MS that cannabis provides effective
relief for pain (and spasticity) in the condition, it
is not included in this review. If clinical trials of
good quality are completed looking at the
effectiveness of cannabis, or its derivatives or
constituents, we may be in the ironic position of
having better evidence of its effectiveness than any
of the currently used drugs.
Prevalence
For some decades, the received wisdom appears to
have been that MS did not cause, or only rarely
caused, pain. This is now recognised to be far
from the case. Observational studies of patients
attending neurology clinics have reported
prevalence of pain between 28.8 and 86% (see
Table 22). Differences in prevalence may be due to
a variety of factors, including the selection of
patients, definition of pain syndromes, means by
which the information is collected (notes review
versus questionnaire) and inclusion or exclusion of
pain thought not to be directly caused by MS. The
results of studies are summarised in Table 22.
It is clear, therefore, that pain is a common
problem for patients with the disease. Because of
its often chronic nature, and the particularly
unpleasant character it can sometimes have, it
may be a very major cause of impaired QoL.
Further, because it is essentially subjective, and
because the treatment offered may be very variable
(see below), some patients may feel that they are
not being taken seriously by clinicians, which in
itself exacerbates the problems.
The authors were not able to identify any studies
which looked explicitly at the impact of pain on
the QoL of patients with MS, or any which sought
to correlate pain symptoms with prognosis. A
number of surveys of patients with MS which
sought to identify the prevalence of pain as a
symptom also examined whether there was any
association between pain and disability.
Brochet and colleagues98 reported a correlation
between pain and higher levels of disability, as
measured by the DSS. Archibald and colleagues99
found no difference between the pain and no-pain
groups in the Kurtze EDSS, but did find that those
with pain had a significantly lower score on the
Mental Health Inventory (MHI) (mean 159.2, SD.
28.4, versus mean 170.4, SD. 25.8, p < 0.05).
Indaco and colleagues100 did not identify any
difference between patients reporting pain and
those who did not in terms of the DSS, Hamilton
Rating Depression Scale or Beck Self Depression
Inventory. 
Three studies give some information as to the
overall impact of pain on daily life. Warnell101
reported that 49% of patients stated that pain
compromised their ability to work (although pain-
free patients were not more likely to be employed
than those reporting pain); 44% said pain
interfered with sleep patterns, and 34% said that it
interfered with relationships with family and
friends. Rae-Grant and colleagues102 reported that
5% of respondents identified pain as the worst
symptom of their disease. The MS Society survey3
asked responders to identify the three symptoms
which caused them the most difficulty or distress;
18% of responders identified pain as one of the
three ‘worst’ symptoms.
Types of pain syndromes 
(and difficulties in defining and
dissociating them)
The manifestations of pain in MS are protean. Pain
may either be due directly to nerve damage as part
of the underlying pathological process, or it may
be secondary to paralysis and immobilisation. Pain
syndromes are often categorised as acute or chronic.
Acute pain syndromes (other than optic neuritis)
are probably due to ectopic excitation at the sites
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TABLE 22 Observational studies of the prevalence of pain in MS patients
Lead Year No. of patients Patient selection Information Overall Notes
author (included/ collection prevalence 
eligible) (%)
Clifford103 1984 317/317 All patients who had Notes review 29 Increased prevalence with age and duration of disease
attended outpatient clinic
Vermote104 1986 83/83 Patients with MS hospitalised McGill pain 54 Musculoskeletal pain increased in frequency with 
for rehabilitation questionnaire increasing disability, neurogenic pain did not
Kassirer105 1987 28/? Long-standing MS patients (duration Specific questionnaire 75 Patients with long-standing disease, 84% wheelchair 
29 y) at outpatient clinic bound
Moulin106,107 1989 159/? Excluded patients in nursing homes Specific questionnaire 55 Increased prevalence with age: up to 73% in 60+ y
age group
Rolak108 1990 104/104 Consecutive patients at private Interviewer took 52 Survey of headache only: optic neuritis and trigeminal 
and public clinic detailed headache (headache only) neuralgia excluded. Prevalence in control groups 14 
history and 18%
Warnell101 1991 258/364 All patients attending outpatient clinic Specific questionnaire 64 Increased prevalence in the older age groups (81% in 
60+ y). No difference in prevalence in different types
of MS. 49% of patients stated that pain compromised
their ability to work, 44% said pain interfered with
sleep patterns and 34% said that it interfered with
relationships with family and friends
Stenager109 1991 117/124 Random sample of hospitalised Specific questionnaire, 65 Increased pain frequency with age and duration of 
patients aged 25–55 y structured interview, disease
neurological examination
Stenager110 1995 49/63 Follow-up after 5 y of younger Examination by the 86 Increased frequency of both chronic and acute pain 
patients in study above same physician as syndromes. Frequency of pain in this subgroup of 
previously individuals in the previous study had been 53%
Brochet98 1992 108/? All patients attending outpatient clinic Specific questionnaire 41 Patients with pain slightly older, had disease of longer
duration and more likely to have progressive MS.
Correlation between pain and higher levels of
disability, as measured by the DSS
Archibald99 1994 85/94 Patients referred to outpatient clinic Structured interview, 53 Pain prevalence not correlated with age or disease 
MHI type. No difference between the pain and no-pain 
groups in the EDSS. MHI score lower for patients with
pain than those without
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TABLE 22 Observational studies of the prevalence of pain in MS patients (cont’d)
Lead Year No. of patients Patient selection Information Overall Notes
author (included/ collection prevalence 
eligible) (%)
Indaco100 1994 122/? Patients admitted to the clinic with Structured interview 57 21% of patients had pain at the onset of their disease. 
MS. Patients with headache and those Most common pain syndromes were chronic.
whose pain was relieved by analgesics No difference between patients reporting pain and 
excluded those who did not in terms of the DSS, Hamilton
Rating Depression Scale or Beck Self Depression
Inventory
MS Society3 1997 223/275 MS Society members who had Specific questionnaire 54 54% of responders were currently suffering from pain. 
attended recent meetings 18% of responders rated it as one of the worst 3
symptoms. Of the 74% of responders who had
spasticity, 77% reported that it was associated with
some pain
Rae-Grant102 1999 224/387 Patients identified through practices Specific questionnaire 67 Overall 67% reported having had pain (same as 
of local neurologists who were able to controls), but 44% reported active pain (22% of 
complete questionnaire, plus controls). No increase with duration of disease. 5% 
100 controls said pain was the worst symptom of the disease
of demyelination. Sometimes, as with Lhermitte’s
sign, it is a purely subjective matter as to whether
or not the symptom can be described as painful.
Acute pain syndromes include:
 Trigeminal neuralgia; clinically indistinguishable
from idiopathic trigeminal neuralgia. May be
the first manifestation of MS. Bilateral trigeminal
neuralgia is said by some to be pathognomonic
of MS. Glossopharyngeal neuralgia is less
common, but also seen.
 Lhermitte’s sign; an electrical sensation passing
down the back to the legs on flexion of the
neck.
 Acute radicular pain; may be the presenting
symptom of MS.
 Tic-like extremity pain.
 Dysaesthetic limb pain.
 Painful tonic seizures; painful tonic seizures may
be associated with paroxysms of tic-like or
dysaesthetic pain.
 Optic neuritis; aching retro-orbital pain
exacerbated by eye movement, probably caused
by inflammation of the meninges surrounding
the optic nerve.
 Painful bladder spasms.
 Headache; there are conflicting reports as to
whether headache is more common in patients
with MS and, if so, what the association is.111,112
Chronic pain syndromes may be due to neuronal
damage to the spinothalamic pain pathways. In
general, they appear to be more common in older
people and people who have longer duration of
disease (see above). Chronic pain syndromes
include:
 Dysaesthetic extremity pain; commonest pain
syndrome in MS. Continuous burning, aching
or throbbing pain, particularly in the legs and
feet, is common. Although the pathophysiology
is unclear, it is frequently associated with
spinothalamic sensory loss.
 Painful spasticity; spasticity is common in
advanced MS, and is often painful. Often
precipitated by tactile stimulation.
 Visceral pain.
Many patients develop secondary pain as a result
of MS-related disability. The most common
manifestation is back pain, particularly in patients
confined to wheelchairs. Spastic weakness
produces abnormal stress on the paravertebral
musculature, and can accelerate degenerative disc
and facet joint disease. Abnormal gait may also
contribute to spinal stress. Spinal disease may also
be exacerbated by vertebral compression fractures
as a result of steroid-induced osteoporosis.
Immobilisation may also lead to pressure sores.
Secondary visceral pain may also arise as a result
of constipation.
Individual patients may suffer more than one type
of MS-related pain during the course of their
illnesses.
Current clinical practice
We were not able to identify any formal review of
current clinical practice regarding the treatment of
pain in MS. There is evidence, however, that despite
the high prevalence of pain as a symptom in MS,
very few patients are referred to pain specialists –
fewer than 2% in the MS Society survey.3
Access to specialist pain services appears to be
very variable, and to depend to a large extent on
the interests and availability of neurologists,
specialist nurses and anaesthetists. The extent to
which patients with MS have access to neurologists
appears to be variable. The extent to which
neurologists have an interest in pain relief, or have
access to pain clinics, specialists nurses,
anaesthetists and supporting services
(physiotherapy, wheelchairs, etc.) appears variable.
The approaches taken by different pain specialists
also varies. Overall, therefore, the experience of
individual patients with pain related to MS will be
very variable indeed.
Clinicians (neurologists and specialist nurses) who
have an interest in the treatment of pain in MS
emphasise that identifying the nature of the pain
is important – in particular distinguishing between
pain which is caused by the MS pathology itself,
and that which is secondary to MS-related
disability. In most cases, pain is a long-standing
symptom, which will, therefore, require chronic
treatment. The psychological management of the
problem is also seen as important, whether simply
in terms of the one to one relationship between
clinician and patient, or more formally in terms of
pain management programmes.
Where pain is secondary to MS-related disability,
such as inappropriate choice or use of wheelchairs,
or abnormal gait, adequate support from the
appropriate service is important. In these
circumstances, many patients do not wish to take
more medication, and transcutaneous electrical
nerve stimulation (TENS) treatment, or trigger-
point injections with local anaesthetic or steroid,
may be more acceptable.
Pain in MS
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Certain treatments for pain in MS appear to be
commonly used and may, therefore, be called
standard. Trigeminal neuralgia is routinely treated
with carbamazepine, with phenytoin often used as
a second choice (or adjunct) if it is not effective.
Gabapentin is also increasingly used as first-line
treatment, most particularly since its licensing for
neuropathic pain.
Dysaesthetic limb pains are often treated initially
with tricyclic antidepressants, with anticonvulsants
(carbamazepine or phenytoin) often used as
second-line treatment. Beyond this, we do not
have adequate information from which to
generalise.
There is anecdotal evidence based on clinical
experience for a wide variety of non-
pharmacological approaches to pain control being
used and found to be of value. These include
aromatherapy, acupuncture, reflexology,
relaxation, electroacupuncture and TENS. In some
cases these treatments can be self-applied or
applied by patients’ partners. Surgical treatment,
such as microvascular decompression for
trigeminal neuralgia, is another therapeutic
option, although uptake is very variable.
One service model, which appears to be of
considerable value even if unusual, is to have a
specialist pain nurse working within an MS clinic.
In this way, expertise with regard to the
management of pain is made available not only to
the patients, but also to the MS clinic staff. It is,
therefore, likely to lead to an increase in the
availability of effective pain relief.
It is noteworthy that most of the drugs used to
treat pain in MS are being used out of licence.
Carbamazepine is licensed for use in trigeminal
neuralgia (aetiology unspecified) and phenytoin as
second-line treatment for the same condition.
Otherwise, none of the drugs discussed below is
licensed for pain relief in MS in the UK.
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Formal scoping review
The aim of the search was to identify treatments
for inclusion in the review, and to locate relevant
RCTs, reviews and cost-effectiveness studies. The
search methods were based on the methods used
for the review of treatments for spasticity
described in Chapter 3.
Initial scoping searches were conducted to identify
references relating to MS and pain. The main
aims of the initial searches were twofold: to
identify interventions to contribute to the
framework of treatments considered in the review;
and to identify search terms to inform the
development of further, comprehensive search
strategies. Therefore, search strategies, at this
stage, were designed to optimise the specificity of
the search results. The searches were undertaken
in July 2000 on MEDLINE, EMBASE and the
Science Citation Index. Search results were not
limited by date, language or by study or
publication type.
Comprehensive search strategies were then
constructed to identify papers relating to MS and
the individual treatments for pain and to MS and
individual pain types. Search results were not
restricted by date, but were restricted to English
language only. Filters to limit search results to
RCTs, reviews or cost-effectiveness studies were
applied. Searches were undertaken in July and
August 2000 on the following databases:
 MEDLINE
 EMBASE
 Science Citation Index
 CDSR (Cochrane Database of Systematic
Reviews)
 CENTRAL/CCTR (Cochrane Controlled Trials
Register)
 PubMED
 HealthSTAR
 Best Evidence
 CINAHL (Cumulative Index of Nursing and
Allied Health Literature)
 AMED (Allied and Complementary Medicine)
 NHS CRD DARE (Database of Abstracts of
Reviews of Effectiveness)
 NHS CRD NHS EED (NHS Economic
Evaluation Database)
 NHS CRD HTA (Health Technology
Assessment).
Search strategies for MEDLINE are given in
Appendix 3. Search strategies for other databases
are available from the authors.
In addition to searches of electronic bibliographic
databases, sources were consulted to identify
studies not retrieved through database searching,
current research and grey literature. The National
Research Register (NRR), MRC Clinical Trials
Register and the US NIH Clinical Trials Register
were searched. The publication lists and current
research registers of health technology assessment
and guideline-producing agencies and funding
and regulatory bodies were consulted.
Searches were repeated in March 2002.
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Chapter 6
Review of the treatment of pain in MS: methods
Scope and quality of research
evidence
There is a glaring dissociation between the
published evidence regarding the effectiveness of
treatments for pain and what appears to be
current clinical practice. This does not, of course,
mean that treatments currently being used are not
evidence-based, still less that they are ineffective.
What it does mean is that the evidence on which
they are based is largely clinical experience, the
teaching of others and anecdote. It also militates
against effective treatments being consistently used
throughout the NHS.
Although the authors were able to identify a large
number of papers which related to pain in MS and
its treatment, most of these were review articles, or
small case series or individual case reports. It was
not possible to identify any RCTs whose prime
purpose was to examine the treatment of pain
specifically in patients with MS. We identified two
which looked at the effect of a drug on spasticity
in patients with MS, and reported on the effect on
pain,50,51 and one further one which looked
specifically at the effect of intrathecal baclofen on
pain,113 but not exclusively in MS patients. 
Drugs considered
The drug most frequently mentioned in review
articles was carbamazepine, in particular in the
context of the treatment of trigeminal neuralgia.
Other drugs which were mentioned in numerous
articles were steroids (particularly for optic neuritis),
baclofen (oral and intrathecal), gabapentin and
phenytoin. A number of drugs are mentioned only
in single papers describing case series (misoprostol,
octreotide, acetazolamide). Remarkably, there do
not appear to be any studies which specifically
examined the efficacy of tricyclic antidepressants,
which may be considered ‘standard’ treatment for
dysaesthetic limb pain (see above).
Outcome measures
There is no consistency regarding the outcome
measures used to gauge effectiveness. In many
cases, case reports or short series recorded only
that pain had or had not been relieved. Only one
study, an open uncontrolled study of
gabapentin,114 appears to have used a validated
instrument to assess pain, and hence effectiveness.
(It should be noted, however, that this instrument
was designed for, and validated in, cancer
patients.) No study of the effectiveness of
treatment used the McGill pain questionnaire,
thought by some to be the definitive instrument
for pain measurement. Where attempts were made
to quantify the effect of treatment, it was usually
done by using pain scales from 0 to 3 or from 1 to
10. It was very rare for reports to give any detail of
the effect of treatment on patient functioning.
However, concern about outcome measures may
be academic in view of the paucity of evidence
available for review.
The published research evidence is, therefore,
clearly very restricted both in scope and in quality.
There is a great need for sound research in this
area.
Given the almost complete absence of formal
research, of any quality, in this area, what follows is
a brief summary of information from reviews and
case series and reports. Details are also
summarised in Table 23.
Specific drug treatments
Carbamazepine
Carbamazepine is an anticonvulsant used for the
treatment of generalised tonic–clonic and partial
seizures. It is also specifically licensed for use in
the treatment of trigeminal neuralgia.
Although a mainstay for treatment of trigeminal
neuralgia,115,116 and also used for the treatment of
glossopharyngeal neuralgia117 and other
paroxysmal pain,118 no RCTs have been identified
which specifically examined the effect of this drug
in patients with MS. Trials of its use in idiopathic
trigeminal neuralgia have demonstrated clear
superiority over placebo, and effectiveness in
relieving pain in 70–84% of cases. Indeed, response
to carbamazepine is seen by some as a diagnostic
test for the condition. A similar degree of efficacy
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TABLE 23 Drug treatments for pain syndromes in MS
Treatment General Trigeminal (and Lhermitte’s Paroxysmal Optic neuritis Dysaesthetic Thalamic pain Painful spasms
glossopharyngeal) sign limb pain limb pain
neuralgia (TGN)
Carbamazepine Licensed for use
in the treatment
of TGN. Dose
400–600 mg daily,
occasionally up to
1200 mg
Demonstrated to be
effective in the
treatment of
idiopathic
TGN,116,149 and
observed to be as
effective in MS-
related TGN119
Reported as being
effective123
Reported as being
effective in
controlling
‘painful tonic
seizures’120–122
Reported as being
effective in
controlling
‘painful tonic
seizures’120
Phenytoin Licensed for use
as second-line
treatment for
TGN. Common
dose 300 mg daily
Reviews115,116
suggest it is not as
effective as
carbamazepine at
treating TGN, but
can be useful as
second-line
treatment
Reported as being
effective in
controlling
‘painful tonic
seizures’120
Reported as being
effective in
controlling
‘painful tonic
seizures’120
Gabapentin Open-label study
included 6 patients
with TGN in all of
whom it was
effective.48
Case series of 7
patients reports
relief in 6.127
Addition to
lamotrigine or
carbamazepine
reported as bringing
relief and allowing
reduction of
previous drug dose
and amelioration of
adverse effects128
Open-label study
suggests
effectiveness in
wide variety of pain
syndromes,
especially
‘dysaesthetic
pain’.114 Further
report states that it
is effective in
relieving refractory
pain129
Open-label study
included 11
patients with
painful spasms in
10 of whom it
was effective.48
2 RCTs have
shown it to be
effective in
reducing spasms
and associated
pain50,51
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TABLE 23 Drug treatments for pain syndromes in MS (cont’d)
Treatment General Trigeminal (and Lhermitte’s Paroxysmal Optic neuritis Dysaesthetic Thalamic pain Painful spasms
glossopharyngeal) sign limb pain limb pain
neuralgia (TGN)
Lamotrigine 100 Two cases report
that relief was
obtained in 5/5 and
16/18 patients132,133
Case series
reported benefit
in patients with
paroxysmal limb
pain and burning
pains130
Case series
reported benefit in
patients with
paroxysmal limb
pain and burning
pains130
Tricyclic
antidepressants
Reported in a
number of
reviews to be
effective.103,134,135
No research
studies specifically
addressing this
issue identified
Steroids Reviews report
that pain
associated with
optic neuritis
respond to
steroid
treatment.103,135
Effect of steroids
on pain not
reported in the
optic neuritis
treatment trial137
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TABLE 23 Drug treatments for pain syndromes in MS (cont’d)
Treatment General Trigeminal (and Lhermitte’s Paroxysmal Optic neuritis Dysaesthetic Thalamic pain Painful spasms
glossopharyngeal) sign limb pain limb pain
neuralgia (TGN)
Baclofen DB RCT of use in
idiopathic TGN
reported it to be
effective.138 Also
reported to have
been used in MS-
related TGN, but
outcome not
stated119
Effective in the
treatment of
spasticity, thus
reducing pain22
Intrathecal baclofen Small RCT113 and
single case
report139 showed
it to be effective
in suppressing
dysaesthetic pain
and spasticity
Effective
treatment for
spasticity, and
hence spasticity
related pain
Amantadine 4 out of 5
patients with
‘chronic pain’
(undefined)
obtained relief
from
amantadine140
Misoprostol Case series of 
7 patients with
refractory MS-
related TGN
reported relief in
6141
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TABLE 23 Drug treatments for pain syndromes in MS (cont’d)
Treatment General Trigeminal (and Lhermitte’s Paroxysmal Optic neuritis Dysaesthetic Thalamic pain Painful spasms
glossopharyngeal) sign limb pain limb pain
neuralgia (TGN)
Octreotide 1 patient with MS
reported as having
pain relieved by
intrathecal
octreotide
Acetazolamide Case series of 
9 patients
describes it as
being effective in
reducing painful
spasms144
Reported to have
reduced painful
spasms in 3
patients145
Mexiletine Partial relief only
in 2/12, no relief
in 10/10
patients147
Complete relief
in 7/7 patients147
Case series of 
9 patients with
thalamic pain
reported benefit
– but the single
patient with MS
had no relief148
Complete relief
in 10/10
patients147
Lidocaine Complete relief
in 10/12
patients147
Complete relief
in 7/7 patients147
Complete relief
in 10/10
patients147
Bupivacaine Single case report
of effective
treatment143
in patients with MS induced trigeminal neuralgia
has been observed.119 The drug has also been
reported as being effective at controlling pain in
three patients with glossopharyngeal neuralgia
secondary to MS, and patients with ‘painful tonic
seizures’120 and other paroxysmal pain
syndromes.121,122 It has also been reported as
being effective in suppressing Lhermitte’s sign.123
The dose used is usually 400–600 mg daily,
although sometimes up to 1200 mg daily.
The use of this drug is often limited by side-
effects.119 Further, it has been reported as being
ineffective in some patients with pain associated
with MS,124 and as leading to worsening of other
symptoms of MS.125,126
Phenytoin
Phenytoin is an anticonvulsant licensed for control
of tonic–clonic seizures (grand mal epilepsy),
partial seizures (focal including temporal lobe) or
a combination of these, and the prevention and
treatment of seizures occurring during or
following neurosurgery and/or severe head injury.
It is recommended for the treatment of trigeminal
neuralgia only as second-line therapy if
carbamazepine is ineffective or patients are
intolerant to carbamazepine.
Phenytoin is referred to as an alternative or adjunct
to carbamazepine for the treatment of paroxysmal
pain in MS. Again, no RCTs have been identified
which have examined its effectiveness. Reviews115,116
suggest that it is not as consistently effective at
suppressing (idiopathic) trigeminal neuralgia as is
carbamazepine. There are case reports suggesting
that it is effective in the treatment of painful tonic
seizures120 and non-specific limb pain.103 Common
dosage is 300 mg daily. Again, treatment may be
limited by side-effects.
Gabapentin
Gabapentin is an antiepileptic drug indicated as
add-on therapy for partial seizures and partial
seizures with secondary generalisation in patients
who have not achieved satisfactory control with, or
who are intolerant to, standard anticonvulsants
used alone or in combination.
Two open-label, uncontrolled studies suggest that
gabapentin is effective in treating a wide variety of
pain syndromes in MS.48,114 One reports its use, in
doses up to 1.2 g daily, in 21 MS patients with
paroxysmal symptoms.48 Of these, six had
trigeminal neuralgia (in whom treatment with
carbamazepine or phenytoin had been tried and
abandoned), and 11 had painful tonic spasms. In
all but one patient with painful spasms who
dropped out, there was significant relief of
symptoms. In the second,114 25 MS patients with
both acute and chronic pain syndromes were
treated with gabapentin at doses up to 2.4 g per
day (average 600 mg). ‘Excellent’ to ‘moderate’
relief of pain was reported in 15 patients, and it
was observed to be more likely to be effective in
those in whom the pain was described as
throbbing or cramping, or pins and needles. 
A case series of seven patients with trigeminal
neuralgia associated with MS which was
unresponsive to carbamazepine reports that six of
the seven had complete, and the seventh partial,
relief of pain with gabapentin.127
A single paper128 reports two small case series in
which gabapentin was added to either
carbamazepine or lamotrigine (see below) when
the use of these drugs in the treatment of
trigeminal neuralgia associated with MS was
limited by adverse effects. In five of six patients
treated with a carbamazepine–gabapentin
combination there was complete amelioration of
the pain, and a reduction in adverse effects
following reduction in carbamazepine dosage. In
five patients treated with lamotrigine–gabapentin
combination there was complete pain relief, and
adverse effects resolved in four of the five with
reduction in lamotrigine dosage.
Two RCTs of gabapentin for the treatment of
spasticity in patients with MS have shown it to be
effective at reducing the frequency of painful
spasms.50,51 A single case report describes it as
ameliorating refractory dysaesthetic limb pain in
MS.129 Doses used were usually 900–1200 mg
daily, occasionally up to 2400 mg daily.
Lamotrigine
Lamotrigine is an anticonvulsant licensed for use
in mono- or add-on therapy for simple and
complex partial seizures, and primary or
secondarily generalised tonic–clonic seizures.
A case series of 21 patients with painful phenomena
in MS reported that eight out of 15 patients with
paroxysmal limb pain or burning pain experienced
a sustained reduction in pain when treated with
lamotrigine. In the same report, five of eight
patients with painful spasms also reported benefit.130
There is another case report of the effectiveness of
lamotrigine in the treatment of burning pain.131
There are two reports (both unblinded case series)
of the use of lamotrigine in the treatment of
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trigeminal neuralgia secondary to MS. In one, all
of five patients achieved complete relief with
lamotrigine which lasted for at least 3 months.132
In the second, pain relief was achieved in 16 out
of 18 patients.133 Typically, doses used were up to
400 mg daily. (These two reports are from the
same authors, so there may be overlap in the
patients included.)
Tricyclic antidepressants
Tricyclic antidepressants, particularly amitryptyline,
are reported in a number of reviews to be effective
in the treatment of dysaesthetic limb pain,103,134,135
although not invariably so.136 No reports of trials,
or even case series, were identified which reported
specifically on their effectiveness, although one is
said to have been conducted.
Steroids and adrenocorticotrophin
(ACTH)
Both ACTH and steroids are widely used to treat
exacerbations of MS, including episodes of optic
neuritis. Optic neuritis is associated with pain in
the majority of cases. Reviews103,135 report that
pain associated with optic neuritis, and a variety of
other pain syndromes in MS, respond to steroid
treatment.
The optic neuritis treatment trial137 examined the
effect of oral prednisolone, intravenous
methylprednisolone and placebo on acute
episodes of optic neuritis; 92% of patients had
ocular pain at baseline. Patients treated with
intravenous methylprednisolone had more rapid
recovery of visual function (improved function at 
2 weeks, but not maintained at 6 months) than
either oral prednisolone or placebo. The effect on
ocular pain is not reported.
Baclofen and intrathecal baclofen
Baclofen (both oral and intrathecal) is primarily
used in MS as a treatment for spasticity (see
above). Effective treatment of the spasticity will
relieve any associated pain.22 Baclofen is reported
to have been used in the treatment of trigeminal
neuralgia in MS119 (though the outcome was not
reported). A DB trial of its use in idiopathic
trigeminal neuralgia (dose: 60–80 mg daily)
reported it to be effective in reducing the number
of painful paroxysms in seven out of 10 patients.138
Intrathecal baclofen provides effective relief of
spasticity with a reduced risk of side-effects as
compared with oral baclofen. Again, the effective
relief of spasticity will reduce associated pain. One
small (seven patients, four of whom had MS) DB
controlled trial of the effect of baclofen intrathecally
(bolus doses of 50 g) has shown it to suppress
both dysaesthetic pain and spasm-related pain.113
A single case report describes intrathecal baclofen
as being effective in providing complete relief of
dysaesthetic leg pain in a woman with MS that had
previously been unresponsive to carbamazepine,
amitryptyline, clonidine, mexiletine, haloperidol
and oral morphine.139
Amantidine
Amantadine is a drug used for the prophylaxis
and treatment of signs and symptoms of infection
caused by influenza A virus. It has dopaminergic
properties and is also used in the treatment of
Parkinson’s disease and for the treatment of
fatigue in MS.
One letter140 reports that five out of seven patients
with MS who had chronic pain (nature undefined)
had relief when treated with amantadine, at a dose
of 2–300 mg daily. No correlation was observed
between the efficacy for relief of pain (and fatigue)
and the nature of the pain.
Misoprostol
Misoprostol (Cytotec) is indicated for the healing
of duodenal ulcer, and gastric ulcer including
those induced by non-steroidal anti-inflammatory
drugs (NSAIDs) in arthritic patients at risk, whilst
continuing their NSAID therapy.
A case series of seven patients with trigeminal
neuralgia associated with MS who had had
unsatisfactory pain relief with conventional
therapy (including surgery) were treated with
misoprostol.141 Complete pain relief was reported
to have occurred in four, and partial relief in two
others, using up to 200 g four times daily.
Octreotide (intrathecal)
Octreotide is a somatostatin analogue which is
used (orally) for the relief of symptoms associated
with gastroenteropancreatic endocrine tumours,
including carcinoid tumours with features of
carcinoid syndrome, VIPomas and glucagonomas.
It is also used for symptomatic control and
reduction of growth hormone and somatomedin C
plasma levels in patients with acromegaly.
A single report of two cases of chronic pain treated
with intrathecal octreotide included one with
MS.142 The patient suffered burning and tingling
pains in the legs, which had not been relieved by a
variety of treatments. Intrathecal octreotide, at a
dose of 20 g/hour, was associated with relief of
pain, reduced supplemental opioid intake and
increased activity.
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Bupivacaine (intrathecal)
Bupivacaine is a local anaesthetic used for pain
relief.
There is a single case report of the use of
intrathecal bupivacaine in the treatment of
‘refractory’ pain and spasticity in a woman with
MS.143 The pains were described as stabbing,
cutting, cramping and unbearable. A variety of
treatments had been tried previously. With
treatment at up to 95 mg/day, pain was almost
completely relieved, as was spasticity, so that it was
possible for the patient to sit in a wheelchair.
Acetazolamide
Acetazolamide is a carbonic anhydrase inhibitor. It
is indicated in the treatment of glaucoma, fluid
retention (it has diuretic properties) and epilepsy,
in conjunction with other anticonvulsants.
Acetazolamide has been reported to be effective in
suppressing paroxysmal pain in MS. An
uncontrolled case series reports it to have been
effective in suppressing paroxysmal disturbances
in nine patients, and details of five of them are
given.144 Of these, three had a painful element to
the spasms. Relief from the spasms (and pain) is
reported to have occurred in all three when
treated with acetazolamide 750 mg daily. Another
study also reported it to have abolished painful
spasms in three patients.145
Morphine (intrathecal)
One woman with MS and ‘severe leg spasms and
leg pain’ is included in a case series of 43 patients
with intractable pain treated with intrathecal
morphine. An ‘excellent’ response to treatment is
reported.146
Lidocaine and mexiletine
Lidocaine and mexiletine are anti-arrhythmic drugs
used in the treatment of ventricular arrhythmias. A
single-blind, placebo-controlled study of the use of
intravenous lidocaine (Xylocaine) and oral
mexiletine in patients with MS reported lidocaine
to be effective in the treatment of painful tonic
seizures (10 of 10 patients), Lhermitte’s sign (10 of
12 patients) and paroxysmal pain and itching (10
of 10 patients). Mexiletine was reportedly effective
in the treatment of painful tonic seizures and
paroxysmal pain, but not Lhermitte’s sign.147
On the other hand, in an open-label trial in
patients with the thalamic pain syndrome (nine
patients, of whom one had thalamic pain
secondary to MS), although six of the nine were
reported as having ‘dramatic relief of pain’ on 
300 mg/day of the drug, and two ‘near complete
relief ’, the one patient with MS had no relief.148
Other treatments for pain in MS
A variety of non-pharmacological approaches to
the treatment of pain in MS have been reported in
the literature. There is in particular a substantial
body of literature on the benefit of microvascular
decompression in trigeminal neuralgia, neurolysis,
spinal cord stimulation, TENS and thalamotomy.
Non-surgical approaches which have been
reported include electromagnetic field stimulation,
hypnosis and other psychological treatments.
These are not within the scope of this review. 
Discussion
Pain has a variety of manifestations in MS. It is
clearly a common symptom, with reported
prevalence of between 29 and 86% of patients. In
a substantial proportion of these, it is a significant
problem, being described as one of the worst of
their symptoms, and interfering to a large degree
with daily living.
Despite this, there is a lack of research evidence
on the effectiveness of drugs to treat pain in MS.
Although this review identified 14 different drugs,
or groups of drugs, which have been used to treat
pain in MS, some of which are well established in
clinical use, it was not possible to identify a single
RCT which looked specifically at the effectiveness
of a drug in the treatment of pain in this
condition. The majority of studies identified were
either case reports or case series.
The lack of good-quality research into the
treatment of pain in MS should not be taken to
imply that there are not effective treatments
available. Indeed, it may be the case that research
into the well established treatments (carbamazepine
for trigeminal neuralgia, for example) would be
considered unnecessary or unethical by clinicians
because they are not in a state of ‘equipoise’
regarding its effectiveness. However, where there
are established treatments, there is scope for
comparative studies. Further, unless trials are
conducted of the newer treatments above while
there is still clinical equipoise about their
effectiveness, the opportunity to define their place
in treatment will have been missed.
It is unlikely that effective interventions will be
applied consistently in the absence of robust
research-based data to support them. This is
evidenced by the report from the MS Society
survey,3 and anecdotal information, to the effect
that only a very small minority of MS patients with
pain are able to access specialist treatment. It is
then unsurprising that many patients seek
alternative ‘complementary’ therapies, often at
their own expense.
Conclusions
There is a great need for robust research to be
undertaken into the effectiveness, and
comparative effectiveness, of different drug
treatments in the treatment of pain in MS.
Although some drugs are well established in
current clinical use, it is not possible to be
confident that they are the best that are available.
There is anecdotal evidence to the effect that
access to specialist treatment for pain is variable. It
is very likely, therefore, that many patients are not
receiving treatment which might be of benefit to
them. 
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Many of the studies included in this review areof poor quality, some achieving Jadad scores
of ≤ 2. A number of the studies are based on very
small sample sizes in single sites, and are often
uncontrolled. It has been common for these
studies not to use blinding, leaving them open to
bias. A wide variety of outcome measures have
been used and even where researchers have
purported to use the same instrument there have
been inconsistencies in the way in which they have
been used and analysed. This has made a meta-
analysis impossible. More research is needed into
the definition of standard outcome measures for
classifying levels of spasticity in order to support
comparisons between studies, and to allow
definition of the different roles of the different
available treatments.
Clearly, there is an urgent need for adequately
powered, probably multi-centre, DB RCTs in the
treatment of spasticity. This would be feasible to
achieve with oral medications but it may be more
difficult in relation to invasive treatments, such as
intrathecal baclofen. Placebo arms may be
regarded as unethical and even where placebos are
used they can be easy to detect owing to the
distinctive side-effects associated with some of the
treatments. One way forward may be to
commission more crossover studies which would
allow all participants to access the intervention
arm and have the added benefit of requiring fewer
patients than a parallel design. This would make
the introduction of a placebo arm slightly more
acceptable.
The duration of some of the studies has been too
short and there is a need to ensure that any future
studies are of sufficient duration. 
These requirements for future research are echoed
by the recent Cochrane review of anti-spasticity
agents for MS.8 Shakespeare and colleagues8
suggest that there are serious problems in
understanding and measuring spasticity and that
the wide variety of approaches taken to measure it
reflect this confusion. The Ashworth scale is
interpreted in a variety of ways and this makes
comparison between studies problematic. Likewise,
there are problems with the definition of weakness
which may have different meanings in different
studies. There is a requirement to develop more
meaningful instruments to measure spasticity
which have some correlation with the patient’s
experience and QoL.
There is a remarkable lack of good-quality
research into the effectiveness of drugs to treat
pain in MS. The majority of studies identified
were either case reports or case series. Although
this does not mean that the various treatments
currently in common use are not effective, it does
make it unlikely that effective treatments will be in
uniform use throughout the NHS (and there is
evidence that they are not). It also means that the
relative effectiveness of the available drugs in
different circumstances is not established.
Finally, there is lack of evidence for the role of
non-drug therapy for spasticity and pain in MS
and this also needs to be addressed by the
development of large-scale, pragmatic RCTs.
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Chapter 8
Implications for future research
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The criteria included in the Jadad scale are as follows:
1. Was the study described as randomised (this includes the use of words such as randomly, random and
randomisation)?
2. Was the study described as double blind?
3. Was there a description of the withdrawals and dropouts?
Give a score of one point for each ‘yes’ or no points for ‘no’.
Give one additional point if the method to generate the sequence of randomisation was described and
was appropriate (table of random numbers, computer-generated, etc.). Deduct one point if this method
was inappropriate (patients allocated alternately, according to date of birth, hospital number, etc.). 
Give one point if the study was described as double blind, but the method of blinding was appropriate
(identical placebo, active placebo, dummy, etc.). Deduct one point if the study was described as double
blind but the method of blinding was inappropriate (e.g. comparison of tablet versus injection with no
double dummy).
Participants who were included in the study, but did not complete the observation period or who were not
included in the analysis, must be described. The number and reasons for each withdrawal must be stated.
If there were no withdrawals, it should also be stated in the article. If there is no statement on
withdrawals, this item must be given no points.
Appendix 1
Jadad scale for assessing the quality of 
published research
Ashworth scale
The Ashworth scale (Table 24) is an ordinal scale
which usually ranges from 0 to 4. However, some
of the papers in this review use the same
categories ranging from 1 to 5. There seems to be
some confusion amongst researchers as to the
difference between the Ashworth scale and the
modified version and it would appear that some
researchers use the two terms interchangeably.
Both the original scale and the modified version
have been shown to have good inter-rater
reliability.151,152
As the Ashworth scale is an ordinal scale, rather
than a ratio or interval scale, it is inappropriate to
summate and calculate the mean of Ashworth
scores in different muscle groups or different
patients (as most investigators do). Rather, non-
parametric statistical methods should be used to
analyse results.
The main problem with the Ashworth scale is that
a change in the score does not necessarily correlate
with a change in the patient’s function or QoL.
British Medical Research 
Council for Muscle Strength
(BMRC scale)
5 = normal muscle strength
4.5 = voluntary movement against major
resistance applied by examiner but not
normal
4 = voluntary movement against moderate
resistance applied by examiner
3.5 = voluntary movement against mild
resistance applied by examiner
3 = voluntary movement present, but not able
to overcome gravity
1 = contraction of muscle visible or detected
by palpation, but without effect in the
limb
0 = absence of any voluntary movement
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Appendix 2
Outcome measures and rating scales
TABLE 24 Ashworth scale for assessment of muscle tone (hypertonia scale)
Ashworth scale61 Modified Ashworth scale150
Score Meaning Score Meaning
0 No increase in tone 0 No increase in tone
1 Slight increase in tone giving a ‘catch’ when the 1 Slight increase in muscle tone, manifested by a 
limb is moved in flexion or extension catch and release or by minimal resistance at the
end of the range of motion when the affected
part(s) is moved in flexion or extension
– – 2 Slight increase in muscle tone, manifested by a
catch and release or by minimal resistance
throughout the remainder (less than half) of the
range of motion
2 More marked increase in tone but limb easily 3 More marked increase in muscle tone through 
flexed most of the range of motion, but affected part(s)
easily flexed
3 Considerable increase in tone, passive 4 Considerable increase in tone, passive 
movement difficult movement difficult
4 Limb rigid in flexion or extension 5 Affected part(s) rigid in flexion or extension
Penn Frequency of Spasm scale
Oxford Scale for muscle strength
Wartenburg pendulum test
(amplitude of first knee-swing)
The pendulum test was developed in 1951 by
Wartenburg as a measure of change in resting
muscle tone.
QoL measures
Sickness Impact Profile (SIP)
The SIP is a general health status measure which
consists of 12 categories.153 The SIP produces a
score for each of the physical and psychosocial
dimensions and also an overall score. A low score
represents minimal impairment and a high score
represents increasing disability.
Kurtzke Expanded Disability Status
Scale (EDSS)
The EDSS is a 20-point scale proposed in 1983 by
Kurtzke and is based on the Disability Status Scale
(DSS), a 10-point scale by the same author.154 It
has been widely used as a tool to measure
disability and overall function in MS. The global
rating scores range from 0 to 10; moving from a
normal score of 0 through various signs and
symptoms and ending in death with a score of 10.
The EDSS divides the DSS between break points
1–9 (inclusive) into half points. The EDSS has
been substantially criticised; in particular, there is
concern that a change in score does not
necessarily reflect a clinically significant change.
The EDSS focuses mainly on mobility and neglects
other types of impairment, such as blindness or
dementia.
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Grade Clinical condition
0 None
1 No spontaneous spasms/spasms induced by
stimulation
2 Occasional spontaneous spasms and easily
induced spasms
3 >1, but <10, spontaneous spasms per hour
4 >10 spontaneous spasms per hour
Grade Clinical condition
1 Normal
2 Movement against slight resistance
3 Movement against gravity
4 Slight movement against gravity
5 Isometric contractions only
6 Paralysis
Scoping review
MEDLINE search strategies (OVID
BIOMED 1966–)
Initial scoping search
1 Multiple sclerosis/
2 exp Pain/
3 Pain measurement/
4 Muscle spasticity/
5 Spasm/
6 2 or 3 or 4 or 5
7 1 and 6
Multiple sclerosis and pain
1 exp multiple sclerosis/
2 "multiple sclerosis".tw.
3 "disseminated sclerosis".tw.
4 or/1-3
5 exp pain/
6 pain$.tw.
7 or/4-6
8 exp Thalamic diseases/
9 exp Thalamus/
10 thalam$.tw.
11 or/8-10
12 7 and 11
13 4 and 12
14 limit 13 to english language
15 exp Optic neuritis/
16 (optic or eye).tw.
17 or/15-16
18 7 and 17
19 4 and 18
20 limit 19 to english language
21 exp Trigeminal neuralgia/
22 7 and 21
23 4 and 22
24 limit 23 to english language
25 ((dysaesthe$ or dysesthe$) adj5 limb$).tw.
26 (dysaesthesia or dysesthesia).tw.
27 or/25-26
28 7 and 27
29 4 and 28
30 limit 29 to english language
31 (paroxysmal$ adj5 limb$).tw.
32 7 and 31
33 4 and 32
34 limit 33 to english language/
35 exp Spinal nerve roots/
36 ((nerve$ or neuron$) adj5 root$).tw.
37 or/35-36
38 7 and 37
39 4 and 38
40 limit 39 to english language
41 "lhermitte$ sign".tw.
42 7 and 41
43 4 and 42
44 limit 43 to english language
45 exp Musculoskeletal physiology/
46 postur$.tw.
47 or/45-46
48 7 and 47
49 4 and 48
50 limit 49 to english language
51 meta-analysis/
52 exp review literature/
53 (meta-analy$ or meta analy$ or
metaanaly$).tw.
54 meta analysis.pt.
55 review academic.pt.
56 review literature.pt.
57 letter.pt.
58 review of reported cases.pt.
59 historical article.pt.
60 review multicase.pt.
61 or/51-56
62 or/57-60
63 61 not 62
64 19 and 63
65 limit 64 to english language
66 49 and 63
67 limit 66 to english language
68 randomized controlled trial.pt.
69 controlled clinical trial.pt.
70 randomized controlled trials/
71 random allocation/
72 double blind method/
73 single blind method/
74 or/68-73
75 clinical trial.pt.
76 exp clinical trials/
77 (clin$ adj25 trial$).ti,ab.
78 ((singl$ or doubl$ or trebl$ or tripl$) adj25
(blind$ or mask$)).ti,ab.
79 placebos/
80 placebos.ti,ab.
81 random.ti,ab.
82 research design/
83 or/75-82
84 comparative study/
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Search strategies
85 exp evaluation studies/
86 follow up studies/ 
87 (control$ or prospectiv$ or
volunteer$).ti,ab. 
88 prospective studies/ 
89 or/84-88
90 74 or 83 or 89
91 19 and 90
92 limit 91 to english language
93 49 and 90
94 limit 93 to english language
Multiple sclerosis and pain treatments
1 exp multiple sclerosis/
2 "multiple sclerosis".tw.
3 "disseminated sclerosis".tw.
4 or/1-3
5 exp pain/
6 pain$.tw.
7 or/4-6
8 exp Thalamic diseases/
9 exp Thalamus/
10 thalam$.tw.
11 or/8-10
12 7 and 11
13 4 and 12
14 limit 13 to english language
15 exp Optic neuritis/
16 (optic or eye).tw.
17 or/15-16
18 7 and 17
19 4 and 18
20 limit 19 to english language
21 exp Trigeminal neuralgia/
22 7 and 21
23 4 and 22
24 limit 23 to english language
25 ((dysaesthe$ or dysesthe$) adj5 limb$).tw.
26 (dysaesthesia or dysesthesia).tw.
27 or/25-26
28 7 and 27
29 4 and 28
30 limit 29 to english language
31 (paroxysmal$ adj5 limb$).tw.
32 7 and 31
33 4 and 32
34 limit 33 to english language
35 exp Spinal nerve roots/
36 ((nerve$ or neuron$) adj5 root$).tw.
37 or/35-36
38 7 and 37
39 4 and 38
40 limit 39 to english language
41 "lhermitte$ sign".tw.
42 7 and 41
43 4 and 42
44 limit 43 to english language
45 exp Musculoskeletal physiology/
46 postur$.tw.
47 or/45-46
48 7 and 47
49 4 and 48
50 limit 49 to english language
51 meta-analysis/
52 exp review literature/
53 (meta-analy$ or meta analy$ or
metaanaly$).tw.
54 meta analysis.pt.
55 review academic.pt.
56 review literature.pt.
57 letter.pt.
58 review of reported cases.pt.
59 historical article.pt.
60 review multicase.pt.
61 or/51-56
62 or/57-60
63 61 not 62
64 19 and 63
65 limit 64 to english language
66 49 and 63
67 limit 66 to english language
68 randomized controlled trial.pt.
69 controlled clinical trial.pt.
70 randomized controlled trials/
71 random allocation/
72 double blind method/
73 single blind method/
74 or/68-73
75 clinical trial.pt.
76 exp clinical trials/
77 (clin$ adj25 trial$).ti,ab.
78 ((singl$ or doubl$ or trebl$ or tripl$) adj25
(blind$ or mask$)).ti,ab.
79 placebos/
80 placebos.ti,ab.
81 random.ti,ab.
82 research design/
83 or/75-82
84 comparative study/
85 exp evaluation studies/
86 follow up studies/
87 (control$ or prospectiv$ or
volunteer$).ti,ab.
88 prospective studies/
89 or/84-88
90 74 or 83 or 89
91 19 and 90
92 limit 91 to english language
93 49 and 90
94 limit 93 to english language
95 12 or 18 or 22 or 28 or 32 or 38 or 42 or
48
96 exp Antidepressive agents, tricyclic/
97 exp Anticonvulsants/
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98 carbamazepine.tw.
99 carbamazepine.rn.
100 carbamazepine.rw.
101 carbamazepine/
102 or/97-101
103 exp Phenytoin/
104 phenytoin.tw.
105 phenytoin.rn.
106 phenytoin.rw.
107 or/103-106
108 exp baclofen/
109 baclofen.tw.
110 baclofen.rn.
111 baclofen.rw.
112 or/108-111
113 exp Misoprostol/
114 misoprostol.tw.
115 misoprostol.rn.
116 misoprostol.rw.
117 or/113-116
118 exp Analgesics/
119 Steroids/
120 gabapentin.tw.
121 gabapentin.rn.
122 gabapentin.rw.
123 or/120-122
124 exp Transcutaneous electric nerve
stimulation/
125 (("spinal cord$" or "dorsal column$") adj5
stimulat$).tw.
126 96 or 102 or 107 or 112 or 117 or 118 or
119 or 123 or 124 or 125
127 lamotrigine.tw.
128 lamictal.tw.
129 lamiktal.tw.
130 lamotrigine.rn.
131 lamotrigine.rw.
132 or/127-131
133 96 or 102 or 107 or 112 or 117 or 118 or
119 or 123 or 124 or 125 or 132
134 95 and 133
135 4 and 134
136 limit 135 to english language
Multiple sclerosis and treatments for spasticity
(two strategies)
1 exp Multiple sclerosis/
2 multiple sclerosis.tw.
3 multiple sclerosis.in.
4 (disseminat$ adj3 sclerosis).tw.
5 multiple sclerosis.jw.
6 multiple sclerotic.tw.
7 or/1-6
8 exp Botulinum toxins/
9 botulinum toxin$.tw.
10 botulinum toxin$.rw.
11 botox.tw.
12 dysport.tw.
13 or/8-12
14 exp diazepam/
15 diazepam.tw.
16 diazepam.rw.
17 439 14 5.rn.
18 or/14-17
19 dantrolene/
20 dantrolene.tw.
21 dantrolene.rw.
22 dantrium.tw.
23 7261 97 4.rn.
24 or/19-23
25 tizanidine.tw.
26 zanaflex.tw.
27 tizanidine.rw.
28 51322 75 9.rn.
29 or/25-28
30 baclofen/
31 baclofen.tw.
32 "1134 47 0".rn.
33 baclofen.rw.
34 or/30-33
35 exp Methylprednisolone/
36 methylprednisolone.tw.
37 methylprednisolone.rw.
38 83 43 2.rn.
39 solumedrone.tw.
40 depomedrone.tw.
41 or/35-40
42 exp Threonine/
43 threonine.rw.
44 threonine.tw.
45 72 19 5.rn.
46 or/42-45
47 Vigabatrin/
48 vigabatrin.tw.
49 vigabatrin.rw.
50 60643 86 9.rn.
51 sabril.tw.
52 or/47-51
53 Clonidine/
54 clonidine.tw.
55 clonidine.rw.
56 4205 90 7.rn.
57 catapres.tw.
58 dixarit.tw.
59 or/53-58
60 Mexiletine/
61 mexiletine.tw.
62 mexiletine.rw.
63 31828 71 4.rn.
64 mexitil.tw.
65 or/60-64
66 13 or 18 or 24 or 29 or 34 or 41 or 46 or
52 or 59 or 65
67 7 and 66
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68 randomized controlled trial.pt.
69 controlled clinical trial.pt.
70 Randomized controlled trials/
71 Random allocation/
72 Double-blind method/
73 Single-blind method/
74 or/68-73
75 clinical trial.pt.
76 exp Clinical trials/
77 (clin$ adj25 trial$).tw.
78 ((singl$ or doubl$ or trebl$ or tripl$) adj25
(blind$ or mask$)).tw.
79 Placebos/
80 placebo$.tw.
81 random$.tw.
82 Research design/
83 or/75-82
84 "comparative study"/
85 exp evaluation studies/
86 Follow-up studies/
87 Prospective studies/
88 (control$ or prospectiv$ or 
volunteer$).tw.
89 or/84-88
90 74 or 83 or 89
91 "animal"/
92 "human"/
93 91 not 92
94 90 not 93
95 Meta-analysis/
96 exp review literature/
97 (meta analy$ or metaanaly$).tw.
98 meta analysis.pt.
99 review academic.pt.
100 review literature.pt.
101 letter.pt.
102 review of reported cases.pt.
103 historical article.pt.
104 review multicase.pt.
105 or/95-100
106 or/101-104
107 105 not 106
108 "human"/
109 "animal"/
110 109 not 108
111 107 not 110
112 107 not 111
113 Economics/
114 exp "Costs and cost analysis"/
115 Economic value of life/
116 exp Economics, hospital/
117 exp Economics, medical/
118 Economics, nursing/
119 exp models, economic/
120 Economics, pharmaceutical/
121 exp "Fees and charges"/
122 exp Budgets/
123 ec.fs.
124 (cost or costs or costed or costly or
costing$).tw.
125 (economic$ or pharmacoeconomic$ or
price$ or pricing).tw.
126 Quality-adjusted life years/
127 or/113-126
128 67 and 94
129 67 and 111
130 67 and 127
131 128 or 129 or 130
1 exp Benzodiazepines/
2 benzodiazepine$.tw,rw.
3 benzodiazepinone$.tw,rw.
4 alprazolam.tw,rw.
5 chlordiazepoxide.tw,rw.
6 clorazepate dipotassium.tw,rw.
7 estazolam.tw,rw.
8 medazepam.tw,rw.
9 midazolam.rw,tw.
10 triazolam.tw,rw.
11 anthramycin.tw,rw.
12 bromazepam.tw,rw.
13 clonazepam.tw,rw.
14 devazepide.tw,rw.
15 flumazenil.tw,rw.
16 flunitrazepam.tw,rw.
17 flurazepam.tw,rw.
18 lorazepam.tw,rw.
19 nitrazepam.tw,rw.
20 oxazepam.tw,rw.
21 pirenzepine.tw,rw.
22 prazepam.tw,rw.
23 temazepam.tw,rw.
24 28981 97 7.rn.
25 58 25 3.rn.
26 57109 90 7.rn.
27 29975 16 4.rn.
28 2898 12 6.rn.
29 59467 70 8.rn.
30 "28911 01 5".rn.
31 4803 27 4.rn.
32 1812 30 2.rn.
33 1622 61 3.rn.
34 103420 77 5.rn.
35 78755 81 4.rn.
36 1622 62 4.rn.
37 17617 23 1.rn.
38 846 49 1.rn.
39 146 22 5.rn.
40 604 75 1.rn.
41 28797 61 7.rn.
42 2955 38 6.rn.
43 846 50 4.rn.
44 hypnovel.tw.
45 rohypnol.tw.
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46 dalmane.tw.
47 loprazolam.tw.
48 lormetazepam.tw.
49 or/1-48
50 exp Multiple sclerosis/
51 multiple sclerosis.tw.
52 multiple sclerosis.in.
53 (disseminat$ adj3 sclerosis).tw.
54 multiple sclerosis.jw.
55 multiple sclerotic.tw.
56 or/50-55
57 49 and 56
58 exp diazepam/
59 diazepam.tw.
60 diazepam.rw.
61 439 14 5.rn.
62 or/58-61
63 57 not 62
64 randomized controlled trial.pt.
65 controlled clinical trial.pt.
66 Randomized controlled trials/
67 Random allocation/
68 Double-blind method/
69 Single-blind method/
70 or/64-69
71 clinical trial.pt.
72 exp Clinical trials/
73 (clin$ adj25 trial$).tw.
74 ((singl$ or doubl$ or trebl$ or tripl$) adj25
(blind$ or mask$)).tw.
75 Placebos/
76 placebo$.tw.
77 random$.tw.
78 Research design/
79 or/71-78
80 "comparative study"/
81 exp evaluation studies/
82 Follow-up studies/
83 Prospective studies/
84 (control$ or prospectiv$ or volunteer$).tw.
85 or/80-84
86 70 or 79 or 85
87 "animal"/
88 "human"/
89 87 not 88
90 86 not 89
91 Meta-analysis/
92 exp review literature/
93 (meta analy$ or metaanaly$).tw.
94 meta analysis.pt.
95 review academic.pt.
96 review literature.pt.
97 letter.pt.
98 review of reported cases.pt.
99 historical article.pt.
100 review multicase.pt.
101 or/91-96
102 or/97-100
103 101 not 102
104 "human"/
105 "animal"/
106 105 not 104
107 103 not 106
108 Economics/
109 exp "Costs and cost analysis"/
110 Economic value of life/
111 exp Economics, hospital/
112 exp Economics, medical/
113 Economics, nursing/
114 exp models, economic/
115 Economics, pharmaceutical/
116 exp "Fees and charges"/
117 exp Budgets/
118 ec.fs.
119 (cost or costs or costed or costly or
costing$).tw.
120 (economic$ or pharmacoeconomic$ or
price$ or pricing).tw.
121 Quality-adjusted life years/
122 or/108-121
123 63 and 90
124 63 and 107
125 63 and 122
126 123 or 124 or 125
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